P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1A P H A S E [ADDRESS_81890] u d y I nter ve nti o n N u m ber : P F -[ADDRESS_81891] u d y I nter ve nti o n N a me: N/ A 
U S I N D N u m ber: [ADDRESS_81892] a C T N u m ber: N/ A 
Cli nic al Tri als. g o v I D:   N C T 0 5 3 7 5 9 5 5 
Pr ot oc ol N u m ber: C 3 9 4 1 0 0 5
P h ase: 2 b 
Brief Title: A P hase [ADDRESS_81893] u d y wit h M ulti ple D ose 
Le vels of P F -0 7 0 3 8 1 2 4 Oi nt me nt i n Partici pa nts 1 2 Years a n d Ol der a n d Wit h Mil d t o M o derate At o pic 
D er m atitis or Mil d t o Se vere Pla q ue Ps oriasis 
T his d oc u me nt a n d acc o m pa n yi n g materials c o ntai n c o nfi de ntial i nf or mati o n bel o n gi n g t o [COMPANY_007]. E xce pt 
as ot her wise a gree d t o i n w riti n g, b y acce pti n g or re vie wi n g t hese d o c u me nt s, y o u  a gree t o h ol d t his 
i nf or mati o n i n c o nfi de nce a n d n ot c o p y or discl ose it t o ot hers (e xce pt w here re q uire d b y a p plica ble la w ) 
or use it f or u na ut h orize d p ur p oses. I n t he e ve nt of a n y act ual or s us pecte d breac h of t his o bli gati o n, [COMPANY_007] 
m ust be pr o m ptl y n otifie d. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 2D oc u me nt Hist or y 
D oc u me nt Versi o n D ate 
A me n d me nt [ADDRESS_81894] of c o u ntr y  healt h a ut h orities a n d I R Bs/ E Cs a n d a n y pr ot oc ol a d mi nistrati ve c ha n ge 
letter(s) .
Pr ot oc ol A me n d me nt S u m m ar y of C h a n ges T a ble 
A m e n d me nt 1 ( 0 2 N o ve m ber 2 0 2 2) 
O ver all R ati o n ale f or t he A me n d me nt: T he a me n d me nt is m a ki n g a s u bst a nti al c h a n ge 
i n per mitte d c o ntr ace pti o n met h o ds of fe m ale p artici p a nts .
Secti o n # 
a n d N a me Descri pti o n of C h a n ge Brief R ati o n ale S u bst a nti al or 
N o ns u bst a nti al 
Secti o n 
[ADDRESS_81895] of hi g hl y  
effecti ve c o ntrace pti o n 
met h o d sb y  a d di n g 
“ + barrier” t o met h o ds 
w hic h were user 
de pe n de nt . 
2. Hi g hli g hte d acce pta ble 
use of barrier met h o ds. 
3. Delete d list of met h o ds 
( # 9 - # 1 2) t o a v oi d 
t h ose bei n g c o nsi dere d 
as hi g hl y effecti ve , 
w he n n ot use d i n 
c o nj u ncti o n wit h ot her 
met h o ds. C o nc urre nt use of a 
barrier met h o d of 
c o ntrace pti o n pr o vi des 
a d diti o nal pr otecti o n wit h 
hi g hl y effecti ve user 
de pe n de nt met h o ds. S u bsta ntial 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 3Secti o n # 
a n d N a me Descri pti o n of C h a n ge Brief R ati o n ale S u bst a nti al or 
N o ns u bst a nti al 
Title Pa ge A d de d cli nicaltrials. g o v 
I D A vaila bilit y  of I D  as trial 
is re gistere d o n 
cli nicaltrials. g o v .N o ns u bsta ntial 
Secti o n 1. 3. 1 
At o pic 
Der matitis, 
F o ot n ote ‘j’ 
Secti o n 1. 3. 2. 
Pla q ue 
Ps oriasis 
F o ot n ote ‘i’ U p date d f o ot n otes i n S o A 
ta bles t o clarif y  t hat if a 
partici pa nt has n’t 
wit h dra w n c o nse nt fr o m 
partici pati o n fr o m t he 
st u d y , e- diar y  ma y  be 
c ollecte d at E T or E O S 
visits .Clarificati o n pr o vi des 
sites wit h o pti o n of n ot 
c ollecti n g e -diar y  if 
st ora ge s pace at t he site is 
li mite d, t here b y  re d uci n g 
b ur de n. N o ns u bsta ntial 
Secti o n 1. 3. 1 
At o pic 
Der matitis, 
F o ot n ote ‘ k’ 
Secti o n 1. 3. 2. 
Pla q ue 
Ps oriasis, 
F o ot n ote ‘j’ U p date d f o ot n otes i n S o A 
ta bles t o clarif y  i nsta nce 
w he n l ocal t olera bilit y  
assess me nt is n ot re q uire d. Local t olera bilit y  
assess me nt perf or me d 
i m m e diatel y  after 
a p plicati o n of t he I P o n 
n o n -lesi o nal s ki n a n d 
pri or t o a p plicati o n o n 
lesi o nal s ki n. T heref ore, if 
I P a p plicati o n is n ot 
pla n ne d, l ocal t olera bilit y  
assess me nt is n ot re q uire d. N o ns u bsta ntial 
Secti o n 
[ADDRESS_81896] -me n o pa usal 
stat u s usi n g F S H le vels. N o ns u bsta ntial 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 4T A B L E O F C O N T E N T S 
LI S T O F T A B L E S ................................ ................................ ................................ ................... [ADDRESS_81897] u d y  Rati o nale ................................ ................................ ....................................... 2 5 
2. 2. Bac k gr o u n d ................................ ................................ ............................................. 2 5 
2. 2. 1. Cli ni cal O ver vie w ................................ ....................................................... 2 8 
2. 3. Be nefit/ Ris k Assess me nt ................................ ......................................................... 3 0 
................................ ......................................................... 3 1 
2. 3. 2. Be nefit Assess me nt ................................ ..................................................... 3 3 
2. 3. 3. O verall Be nefit/ Ris k C o ncl usi o n ................................ ................................ [ADDRESS_81898] u d y  P o p ulati o n ................................ .................................... 4 1 
4. 2. 2. C h oice of C o ntrace pti o n/ Barrier Re q uire me nts ......................................... [ADDRESS_81899] u d y  Defi niti o n ................................ .......................................................... 4 4 
5. S T U D Y P O P U L A T I O N................................ ................................ ...................................... 4 4 
5. 1. I ncl usi o n C riteria ................................ ................................ ..................................... 4 4 
5. 1. 1. Ge neral I ncl usi o n Criteria A p plica ble f or b ot h A D a n d Ps O ..................... 4 4 
5. 1. 2. Disease -S pecific I ncl usi o n Criteria: ........................................................... 4 5 
5. 1. 2. 1. A D S pecific I ncl usi o n Criteria .................................................. 4 5 
5. 1. 2. 2. Ps O S pecific I ncl usi o n Criteria ................................................. 4 5 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 55. 2. E xcl usi o n Criteria ................................ ................................ ................................ .... [ADDRESS_81900] y le C o nsi derati o ns ................................ ................................ .......................... 4 7 
5. 3. 1. C o ntrace pti o n ................................ ................................ .............................. 4 7 
5. 3. 2. Dietar y  S u p ple me nts ................................ ................................ ................... 4 8 
5. 3. 3. Me dicati o ns/ Treat me nts Disc o nti n uati o n, N o n -Me dicate d E m ollie nts ..... [ADDRESS_81901] yl e Re q uire me nts..................................................................... 4 9 
5. 4. Scree n Fail ures ................................ ................................ ................................ ........ 5 0 
6. S T U D Y I N T E R V E N TI O N( S) A N D C O N C O MI T A N T T H E R A P Y ................................ .[ADDRESS_81902] u d y  I nter ve nti o n(s) A d mi nistere d ................................ ................................ ........ [ADDRESS_81903] u d y  I nter ve nti o n S u p plies ................................ ................ 5 5 
6. 3. Meas ures t o Mi ni mize Bias: Ra n d o mizati o n a n d Bli n di n g ................................ ..... [ADDRESS_81904] u d y ...................... 5 7 
6. 7. Treat me nt of O ver d ose................................ ................................ ............................ 5 7 
6. 8. C o nc o mita nt T hera p y ................................ ................................ .............................. 5 8 
6. 8. 1. Resc ue Me dici ne ................................ ................................ ......................... 5 8 
7. DI S C O N TI N U A TI O N O F S T U D Y I N T E R V E N TI O N A N D P A R TI CI P A N T 
DI S C O N TI N U A TI O N/ WI T H D R A W A L ................................ ................................ ........... [ADDRESS_81905] u d y  I nter ve nti o n ................................ ................................ .... 5 8 
7. 1. 1. L i ver I nj ur y ................................ ................................ ................................ .5 9 
7. 1. 2. E C G C ha n ges ................................ ................................ .............................. 5 9 
7. 1. 3. Pre g na nc y ................................ ................................ ................................ ... 5 9 
7. 1. 4. L ocal T olera bilit y ................................ ................................ ....................... 5 9 
7. 1. 5. A Es ................................ ................................ ................................ ............. 6 0 
7. 1. 6. Te m p orar y  Disc o nti n uati o n ................................ ................................ ........ 6 0 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 67. 2. Partici pa nt Disc o nti n uati o n/ Wit h dra wal Fr o m t he St u d y ....................................... [ADDRESS_81906] or y ................................ ................................ 6 8 
8. 2. 2. P h y sical E xa mi nati o ns (I ncl u di n g Hei g ht a n d Wei g ht) ............................. 6 9 
8. 2. 3. Electr ocar di o gra ms ................................ ..................................................... 6 9 
8. 2. 4. Vital Si g ns ................................ ................................ .................................. 7 0 
8. 2. 5. Cli nical Safet y  L a b orat or y  Assess me nts .................................................... 7 1 
8. 2. 6. S uici dal I deati o n a n d Be ha vi or Ris k M o nit ori n g - C- S S R S ...................... 7 1 
8. 2. 7. L ocal T olera bilit y  Assess me nt ................................ ................................... 7 2 
8. 2. 8. Pre g na nc y  Testi n g ................................ ...................................................... 7 2 
8. 3. A d verse E ve nts, Seri o us A d verse E ve nts, a n d Ot her Safet y Re p orti n g ................. 7 2 
8. 3. 1. Ti me Peri o d a n d F re q ue nc y  f or C ollecti n g A E a n d S A E I nf or mati o n ....... 7 3 
8. 3. 1. 1. Re p orti n g S A Es t o [COMPANY_007] Safet y ............................................... 7 4 
8. 3. 1. 2. Rec or di n g N o nseri o us A Es a n d S A Es o n t he C R F ................... 7 4 
8. 3. 2. Met h o d of Detecti n g A Es a n d S A Es .......................................................... 7 4 
8. 3. 3. F oll o w -U p of A Es a n d S A Es ................................ ...................................... 7 4 
8. 3. 4. Re g ulat or y  Re p orti n g Re q uire me nts f or S A Es ................................ ........... 7 4 
8. 3. 5. E n vir o n me ntal E x p os ure, E x p os ure D uri n g Pre g na nc y  or 
Breastfee di n g, a n d Occ u pati o nal E x p os ure ..................................................... 7 5 
8. 3. 5. 1. E x p os ure D uri n g Pre g na nc y ................................ ...................... 7 5 
8. 3. 5. 2. E x p os ure D uri n g Breastfee di n g ................................................ 7 7 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
C CI 
C CI 
C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 78. 3. 5. 3. Occ u pati o nal E x p os ure ............................................................. 7 7 
8. 3. 6. Car di o vasc ular a n d Deat h E ve nts ............................................................... 7 7 
8. 3. 7. Disease -Relate d E ve nts a n d/ or Disease - Relate d O utc o mes N ot 
Q ualif yi n g as A Es or S A Es ................................ .............................................. [ADDRESS_81907] ............................................................. 7 8 
8. 3. 8. 1. Lac k of Efficac y ................................ ........................................ 7 8 
8. 3. 9. Me dical De vice Deficie ncies ................................ ...................................... 7 8 
8. 3. 1 0. Me dicati o n Err ors ................................ ..................................................... 7 8 
................................ ................................ .................................... 7 9 
8. 5. G e netics ................................ ................................ ................................................... 8 0 
8. 5. 1. S pecifie d Ge netics ................................ ...................................................... 8 0 
8. 5. 2. Retai ne d Researc h Sa m ples f or Ge netics ................................................... 8 0 
8. 6. Bi o mar kers ................................ ................................ .............................................. 8 0 
8. 6. 1. S peci fie d Ge ne E x pressi o n ( R N A) Researc h ............................................. [ADDRESS_81908] u d y I nter ve nti o n Nee d ( Treata ble B S A) ................................................ [ADDRESS_81909] u d y ................................ ............................................. 8 2 
9. S T A TI S TI C A L C O N SI D E R A TI O N S ................................ ................................ ................ 8 3 
9. 1. Statistical H y p ot heses ................................ ............................................................. 8 3 
9. 1. 1. Esti ma n ds ................................ ................................ .................................... 8 3 
9. 1. 1. 1. Pri mar y  Esti ma n d ................................ ...................................... 8 3 
9. 1. 1. 2. Sec o n dar y  Esti ma n d ................................ .................................. 8 4 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
C CI 
C CI 
C CI 
C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 89. 1. 2. M ulti plicit y  A dj ust me nt ................................ .............................................. 8 5 
9. 2. A nal y sis Sets ................................ ................................ ........................................... 8 5 
9. 3. Statistical A nal y ses ................................ ................................ ................................. 8 5 
9. 3. 1. Ge neral C o nsi derati o ns ................................ ............................................... 8 5 
9. 3. 2. A nal y ses f or Bi nar y  E n d p oi nts ................................ ................................... 8 5 
9. 3. 3. A nal y ses f or C o nti n u o us E n d p oi nts ........................................................... 8 6 
9. 3. 4. Pri mar y  E n d p oi nt(s)/ Esti ma n d(s) A nal ys is ................................................ 8 6 
9. 3. 5. Sec o n dar y  E n d p oi nt(s) / Esti ma n d(s) A nal ys is ............................................ 8 6 
9. 3. 6. Tertiar y / E x pl orat or y  E n d p oi nt(s) ............................................................... 8 6 
9. 3. 7. Safet y A nal ys es ................................ .......................................................... 8 6 
9. 3. 7. 1. Electr ocar di o gra m A nal y ses ...................................................... 8 7 
9. 3. 8. Ot her A nal ys es ................................ ............................................................ 8 7 
....................................................... 8 7 
9. 3. 8. 2. I nteri m A nal ys es ................................ ....................................... 8 7 
9. 4. Sa m ple Size Deter mi nati o n ................................ ................................ ..................... 8 7 
9. 4. 1. Sa m ple Size Deter mi nati o n f or A D ............................................................ 8 7 
9. 4. 2. Sa m ple Size Deter mi nati o n f or Ps O ........................................................... 8 8 
1 0. S U P P O R TI N G D O C U M E N T A TI O N A N D O P E R A TI O N A L 
C O N SI D E R A TI O N S ................................ ................................ .......................................... 8 9 
1 0. 1. A p pe n di x 1: Re g ulat or y , Et hical, a n d St u d y  O versi g ht C o nsi derati o ns ............... 8 9 
1 0. 1. 1. Re g ulat or y a n d Et hical C o nsi derati o ns .................................................... 8 9 
1 0. 1. 1. 1. Re p orti n g of Safet y  I ss ues a n d Seri o us Breac hes of t he 
Pr ot oc ol or I C H G C P ................................ ......................................... 9 0 
1 0. 1. 2. Fi na ncial Discl os ure ................................ ................................ ................. 9 0 
1 0. 1. 3. I nf or me d C o nse nt/asse nt Pr ocess ................................ ............................. [ADDRESS_81910] u d y  a n d Site Start a n d Cl os ure ................................ .............................. 9 5 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 9................................ ................................................... 9 6 
1 0. 1. 1 1. S p o ns or’s Q ualifie d Me dical Pers o n nel ................................................. 9 7 
1 0. 2. A p pe n di x 2: Cli nical La b orat or y  Tests ................................ ................................. 9 8 
1 0. 3. A p pe n di x 3: A d verse E ve nts: Defi niti o ns a n d Pr oce d ures f or Rec or di n g, 
E val uati n g, F oll o w -U p, a n d Re p orti n g ................................ ..................................... 9 9 
1 0. 3. 1. Defi niti o n of A E ................................ ....................................................... 9 9 
1 0. 3. 2. Defi niti o n of a n S A E ................................ .............................................. 1 0 0 
1 0. 3. 3. Rec or di n g/ Re p orti n g a n d F oll o w -U p of A Es a n d/ or S A Es D uri n g 
t he Acti ve C ollecti o n Peri o d ................................ .......................................... 1 0 2 
1 0. 3. 4. Re p orti n g of S A Es ................................ .................................................. 1 0 5 
1 0. 4. A p pe n di x 4: C o ntrace pti v e a n d Barrier G ui da nce .............................................. 1 0 7 
1 0. 4. 1. Male Partici pa nt Re pr o d ucti ve I ncl usi o n Criteria .................................. 1 0 7 
1 0. 4. 2. Fe male Partici pa nt Re pr o d ucti ve I ncl usi o n Criteria ............................... 1 0 7 
1 0. 4. 3. W o ma n of C hil d beari n g P ote ntial .......................................................... 1 0 8 
1 0. 4. 4. C o ntrace pti o n Met h o ds ................................ ........................................... 1 0 9 
1 0. 5. A p pe n di x 5: Ge netics ................................ .......................................................... 1 1 1 
1 0. 6. A p pe n di x 6: L i ver Safet y : S u g geste d Acti o ns a n d F oll o w -U p Assess me nts ..... 1 1 2 
1 0. 7. A p pe n di x 7: E C G Fi n di n gs of P ote ntial Cli nical C o ncer n ................................. 1 1 4 
1 0. 8. A p pe n di x 8: Pr o hi bite d Pri or a n d C o nc o mita nt Me dicati o ns ............................. 1 1 6 
1 0. 8. 1. Pr o hi bite d Pri or a n d C o nc o mita nt Me dicati o ns ..................................... 1 1 6 
1 0. 8. 2. Pr o hi bite d C o nc o mita nt Me dicati o ns w hic h ma y  Res ult i n D DI ........... 1 1 8 
1 0. 9. A p pe n di x 9: Alter nati ve Meas ures D uri n g P u blic E mer ge ncies ........................ [ADDRESS_81911] u d y  I nter ve nti o n ................................ .................................................. 1 2 1 
1 0. 9. 4. H o me Healt h Visits ................................ ................................ ................. 1 2 1 
1 0. 9. 5 . A d verse E ve nts a n d Seri o us A d verse E ve nts ................................ ......... 1 2 2 
1 0. 9. 6. Efficac y  Assess me nts ................................ ................................ ............. 1 2 2 
1 0. 1 0. A p pe n di x 1 0: Dia g n osis Criteria f or A D .......................................................... 1 2 3 
1 0. 1 1. A p pe n di x 1 1: C -S S R S ................................ ....................................................... 1 2 4 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 0 1 0. 1 2. A p pe n di x 1 2: Disease -S pecific Assess me nts .................................................... 1 2 5 
1 0. 1 2. 1. A D -s pecific assess me nts ................................ ...................................... 1 2 5 
1 0. 1 2. 1. 1. I G A ................................ ...................................................... 1 2 5 
1 0. 1 2. 1. 2. E A SI ................................ .................................................... 1 2 5 
1 0. 1 2. 1. 3. B S A ................................ ..................................................... 1 2 8 
1 0. 1 2. 1. 4. Se vere Lesi o n T S S .............................................................. 1 2 8 
1 0. 1 2. 2. Ps oriasis -s pecific assess me nts .............................................................. 1 2 9 
1 0. 1 2. 2. 1. P G A ................................ ..................................................... 1 2 9 
1 0. 1 2. 2. 2. P A SI ................................ .................................................... 1 2 9 
1 0. 1 2. 2. 3. B S A ................................ ..................................................... 1 3 1 
1 0. 1 3. A p pe n di x 1 3: A b bre viati o ns ................................ ............................................. 1 3 2 
1 1. R E F E R E N C E S ................................ ................................ ................................................ 1 3 6 
LI S T O F T A B L E S 
Ta ble 1. P F -0 7 0 3 8 1 2 4  –C o m plete d St u dies 
as of Ja n uar y  2 0 2 2 ................................ .................................................... 3 0 
Ta ble 2. Partici pa nt Distri b uti o n ................................ ............................................. 4 0 
 
.................................. 4 2 
 
....................... 4 3 
Ta ble 5. S ki n T olera bilit y  Gra di n g S ys te m f or N o n -lesi o nal S ki n ......................... 7 2 
Ta ble 6. Pr ot oc ol Re q uire d Safet y L a b orat or y  Assess me nts .................................. 9 8 
Ta ble 7. I n vesti gat or's Gl o bal Assess me nt f or A D ............................................... 1 2 5 
Ta ble 8. Cli nical Si g n Se verit y  Sc ori n g Criteria f or E A SI ................................... 1 2 6 
Ta ble 9. E A SI  Area Sc ore Criteria ................................ ....................................... 1 2 7 
Ta ble 1 0. B o d y  Re gi o n Wei g hti n g ................................ ................................ ......... 1 2 7 
Ta ble 1 1. Se vere Lesi o n T S S ................................ ................................ .................. 1 2 8 
Ta ble 1 2. P h y sicia n Gl o bal Assess me nt ( P G A) Sc ore ................................ ........... 1 2 9 
Ta ble 1 3. C o m p o ne nt Sc ori n g Criteria f or P A SI................................ .................... 1 3 0 
Ta ble 1 4. P A SI  Area Sc ore Criteria................................ ................................ ........ 1 3 0 
Ta ble 1 5. B o d y Re gi o n Wei g hti n g ................................ ................................ ......... 1 3 1 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
C CI 
C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 1 1. P R O T O C O L S U M M A R Y 
1. 1. S y n o psis 
Brief Title: 
A P hase [ADDRESS_81912] u d y  is bei n g 
c o n d ucte d t o assess efficac y , safet y, t olera bilit y a n d P K of P F -0 7 0 3 8 1 2 4 oi nt me nt vers us 
ve hicle c o ntr ol i n t he treat me nt of partici pa nts 1 2 y ears a n d ol der, a n d wit h mil d -t o -m o derate 
A D or mil d -t o -se vere Ps O .
O bjecti ves , E n d p oi nts ,a n d Esti m a n ds 
A T O PI C D E R M A TI TI S 
O bjecti ves E n d p oi nts Esti m a n ds 
Pri m ar y: Pri m ar y: Pri m ar y: 
T o c o m pare t he efficac y of 
2d ose le vels of P F -0 7 0 3 8 1 2 4 
oi nt me nt vers us ve hicle, usi n g 
I G A s uccess as t he e n d p oi nt i n 
partici pa nts wit h mil d or 
m o derate A D. Pr o p orti o n of partici pa nts 
ac hie vi n g I G A sc ore of clear ( 0) 
or al m ost clear ( 1) ( o n a 5 -p oi nt 
scale) a n d a re d ucti o n fr o m 
baseli ne of ≥ 2 p oi nts at 
Wee k 1 2. Esti ma n d E 1: t he differe nce i n 
pr o p orti o ns of t he bi nar y 
e n d p oi nt bet w ee n I P treate d 
( 0. 0 1 % or 0. 0 3 % P F -0 7 0 3 8 1 2 4 
oi nt me nt ) a n d ve hicle i n 
partici pa nts wit h mil d or 
m o derate A D wit h o ut t he 
be nefit of a d diti o nal pr o hi bite d 
me dicati o ns a n d re gar dless of 
treat me nt c o m plia nce. 
Sec o n d ar y: Sec o n d ar y: Sec o n d ar y: 
T o c o m pare t he efficac y of 
2d ose le vels of P F -0 7 0 3 8 1 2 4 
oi nt me nt vers us ve hicle usi n g 
E A SI -7 5 as a n e n d p oi nt i n 
partici pa nts wit h mil d or 
m o derate A D. Pr o p orti o n of partici pa nts 
ac hie vi n g E A SI -7 5 
( 7 5 % i m pr o ve me nt fr o m 
baseli ne )at all st u d y visit ti me 
p oi nts s pecifie d i n t he S o A .Esti ma n d E 1 descri be d a b o ve .
T o c o m pare t he efficac y of 
2d ose le vels of P F -0 7 0 3 8 1 2 4 
oi nt me nt vers us ve hicle, usi n g 
I G A s uccess as t he e n d p oi nt i n 
partici pa nts wit h mil d or 
m o derate A D. Pr o p orti o n of partici pa nts 
ac hie vi n g I G A sc ore of clear ( 0) 
or al m ost clear ( 1) ( o n a 5 -p oi nt 
scale) a n d a re d ucti o n fr o m 
baseli ne of ≥ [ADDRESS_81913] u d y 
visit ti me p oi nts s pecifie d i n t he 
S o A , e xce pt at Wee k 1 2 .Esti ma n d E 1 descri be d a b o ve .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 2 T o c o m pare t he efficac y of 
2d ose le vels of P F -0 7 0 3 8 1 2 4 
oi nt me nt vers us ve hicle, usi n g 
perce nt C F B i n E A SI as t he 
e n d p oi nt i n partici pa nts wit h 
mil d or m o derate A D. Perce nt C F B i n E A SI t otal sc ore 
at all st u d y visit ti me p oi nts 
s pecifie d i n t he S o A .Esti ma n d E 2: t he differe nce i n 
mea n of t he c o nti n u o us 
e n d p oi nt bet w ee n I P treate d 
( 0. 0 1 % or 0. 0 3 % P F -0 7 0 3 8 1 2 4 
oi nt me nt ) a n d ve hicle i n 
partici pa nts wit h mil d or 
m o derate A D wit h o ut t he 
be nefit of a d diti o nal pr o hi bite d 
me dicati o ns a n d re gar dless of 
treat me nt c o m plia nce. 
T o c o m pare t he efficac y of 
2d ose le vels of P F -[ADDRESS_81914] clear as t he 
e n d p oi nt i n partici pa nts wit h 
mil d or m o derate A D. Pr o p orti o n of partici pa nts 
ac hie vi n g I G A sc ore of clear ( 0) 
or al m ost clear ( 1) at all st u d y 
visit ti me p oi nts s pecifie d i n t he 
S o A .Esti ma n d E 1 descri be d a b o ve .
T o c o m pare t he efficac y of 
2d ose le vels of P F -0 7 0 3 8 1 2 4 
oi nt me nt vers us ve hicle, usi n g 
meas ures of P P -N R S P R O, i n 
partici pa nts wit h mil d or 
m o derate A D. Pr o p orti o n of partici pa nts 
ha vi n g ≥ [ADDRESS_81915] u d y 
visit ti me p oi nts s pecifie d i n t he 
S o A .Esti ma n d E 1 descri be d a b o ve .
T o c o m pare t he efficac y of 
2d ose le vels of P F -0 7 0 3 8 1 2 4 
oi nt me nt vers us ve hicle, usi n g 
B S A as t he e n d p oi nt i n 
partici pa nts wit h mil d or 
m o derate A D. Perce nt C F B i n affecte d B S A at 
all st u d y visit ti me p oi nts 
s pecifie d i n t he S o A .Esti ma n d E 2 descri be d a b o ve .
T o c haracterize t he safet y a n d 
t olera bilit y of 2d ose le vels of  
P F -0 7 0 3 8 1 2 4 oi nt me nt vers us 
ve hicle i n partici pa nts wit h mil d 
or m o derate A D. I nci de nce of treat me nt e mer ge nt 
A E s a n d seri o us a d verse e ve nts 
S A Es, cli nicall y si g nifica nt 
c ha n ges i n vital si g ns, E C G, a n d 
la b orat or y tests. 
I nci de nce of i ncrease i n l ocal 
t olera bilit y se verit y gra des at 
ti mes i n dicate d i n t he S o A .N ot A p plica ble .
C o m plete list of Ex pl or at ory/ Tert i ary O bjectives a n d E n d p oi nts are i n Secti o n 3 .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 3 P L A Q U E P S O RI A SI S 
O bjecti ves E n d p oi nts Esti m a n ds 
Pri m ar y: Pri m ar y: Pri m ar y: 
T o c o m pare t he efficac y of 
m ulti ple d ose le vels of 
P F -0 7 0 3 8 1 2 4 oi nt me nt vers us 
ve hicle, usi n g P G A s uccess as 
t he e n d p oi nt i n partici pa nts wit h 
mil d -t o -se vere Ps O. Pr o p orti o n of partici pa nts 
ac hie vi n g P G A sc ore of clear 
( 0) or al m ost clear ( 1) ( o n a 
5- p oi nt scale) a n d a re d ucti o n 
fr o m baseli ne of ≥ 2 p oi nts at 
Wee k 1 2. Esti ma n d E 1: t he differe nce i n 
pr o p orti o ns of t he bi nar y 
e n d p oi nt bet w ee n I P treate d 
( 0. 0 1 %, 0. 0 3 %, or 0. 0 6 % 
P F -0 7 0 3 8 1 2 4 oi nt me nt ) a n d 
ve hicle i n partici pa nts wit h 
mil d -t o -se vere Ps O wit h o ut t he 
be nefit of a d diti o nal pr o hi bite d 
me dicati o ns a n d re gar dless of 
treat me nt c o m plia nce. 
Sec o n d ar y: Sec o n d ar y: Sec o n d ar y: 
T o c o m pare t he efficac y of 
m ulti ple d ose le vels of 
P F -0 7 0 3 8 1 2 4 oi nt me nt vers us 
ve hicle usi n g P A SI -7 5 as a n 
e n d p oi nt, i n partici pa nts wit h 
mil d -t o -se vere Ps O. Pr o p orti o n of partici pa nts 
ac hie vi n g P A SI -7 5 
( 7 5 % i m pr o ve me nt fr o m 
baseli ne) at ti mes i n dicate d i n 
t he S o A .Esti ma n d E 1 descri be d a b o ve .
T o c o m pare t he efficac y of 
m ulti ple d ose le vels of 
P F -0 7 0 3 8 1 2 4 oi nt me nt vers us 
ve hicle, usi n g P G A s uccess as 
t he e n d p oi nt i n partici pa nts wit h 
mil d -t o -se vere Ps O. Pr o p orti o n of partici pa nts 
ac hie vi n g P G A sc ore of clear 
( 0) or al m ost clear ( 1) ( o n a 
5- p oi nt scale) a n d a re d ucti o n 
fr o m baseli ne of ≥ 2 p oi nts at 
ti mes i n dicate d i n t he S o A , 
e xce pt at Wee k 1 2 .Esti ma n d E 1 descri be d a b o ve .
T o c o m pare t he efficac y of 
m ulti ple d ose le vels of 
P F -0 7 0 3 8 1 2 4 oi nt me nt vers us 
ve hicle, usi n g C F B P A SI as t he 
e n d p oi nt i n partici pa nts wit h 
mil d -t o -se ve re Ps O. C ha n ge fr o m baseli ne i n P A SI 
at ti mes i n dicate d i n t he S o A .Esti ma n d E 2: t he differe nce i n 
mea n of t he c o nti n u o us 
e n d p oi nt bet w ee n I P treate d 
( 0. 0 1 %, 0. 0 3 %, or 0. 0 6 % 
P F -0 7 0 3 8 1 2 4 oi nt me nt ) a n d 
ve hicle i n partici pa nts wit h 
mil d -t o -se vere Ps O wit h o ut t he 
be nefit of a d diti o nal pr o hi bite d 
me dicati o ns a n d re gar dless of 
treat me nt c o m plia nce. 
T o c o m pare t he efficac y of 
m ulti ple d ose le vels of 
P F -[ADDRESS_81916] clear as t he e n d p oi nt i n 
partici pa nts wit h mil d -t o -se vere 
Ps O. Pr o p orti o n of partici pa nts 
ac hie vi n g P G A sc ore of clear 
( 0) or al m ost clear ( 1) at all 
st u d y visit ti me p oi nts s pecifie d 
i n t he S o A .Esti ma n d E 1 descri be d a b o ve .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 4 T o c o m pare t he efficac y of 
m ulti ple d ose le vels of 
P F -0 7 0 3 8 1 2 4 oi nt m e nt vers us 
ve hicle, usi n g meas ures of 
P P -N R S P R O, i n a d ult 
partici pa nts ( 1 8 –7 5 years ol d) 
wit h mil d -t o -se vere Ps O. Pr o p orti o n of a d ult partici pa nts 
( 1 8 –7 5 years ol d) ha vi n g 
≥ [ADDRESS_81917] u d y visit ti me 
p oi nts s pecifie d i n t he S o A .Esti ma n d E 1 descri be d a b o ve .
T o c o m pare t he efficac y of 
m ulti ple d ose le vels of 
P F -0 7 0 3 8 1 2 4 oi nt me nt vers us 
ve hicle, usi n g B S A as t he 
e n d p oi nt i n partici pa nts wit h 
mil d -t o -se vere Ps O. Perce nt C F B i n affecte d B S A 
at all st u d y visit ti me p oi nts 
s pecifie d i n t he S o A .Esti ma n d E 2 descri be d a b o ve .
T o c haracterize t he safet y a n d 
t olera bilit y of m ulti ple d ose 
le vels of P F -0 7 0 3 8 1 2 4 oi nt me nt 
vers us ve hicle i n partici pa nts 
wit h mil d- t o -se vere Ps O. I nci de nce of treat me nt e mer ge nt 
A E s a n d S A Es, cli nicall y 
si g nifica nt c ha n ges i n vital 
si g ns, E C G, a n d la b orat or y 
tests. 
I nci de nce of i ncrease i n l ocal 
t olera bilit y se verit y gra des at 
ti mes i n dicate d i n t he S o A .N ot A p plica ble 
C o m plete list of Ex pl or at ory/ Tert i ar y O bjectives a n d E n d p oi nts are i n Secti o n [ADDRESS_81918] u dies : Ta pe stri p pi n g a n d P h ot o gra p h y.  T hese s u b -st u dies will be 
c o n d ucte d at selecte d sites a n d o pti o nal f or partici pa nts. 
N u m ber of P artici p a nts 
At otal of a p pr o xi matel y  [ADDRESS_81919] u d y 
i nter ve nti o n ( P F -0 7 3 0 8 1 2 4 or ve hicle).  
F or A D, a p pr o xi matel y 1 2 0 partici pa nts will be ra n d o ml y  assi g ne d 1: 1: 1 t o recei ve 
eit her 0. 0 1 % P F -0 7 0 3 8 1 2 4 oi nt me nt, 0. 0 3 % P F- 0 7 0 3 8 1 2 4 oi nt me nt or a ve hicle 
oi nt me nt. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 5 F or Ps O , a p pr o xi matel y 1 2 0 partici pa nts will be ra n d o ml y  assi g ne d 1: 1: 1: 1 t o recei ve 
eit her 0. 0 1 % P F -0 7 0 3 8 1 2 4 oi nt me nt, 0. 0 3 % P F - 0 7 0 3 8 1 2 4 oi nt me nt, 0. 0 6 % 
P F -[ADDRESS_81920] u d y I nter ve nti o n A p pr o xi m ate Nu m ber of P artici p a nts 
R a n d o mize d 
A D 0. 0 1 % P F -0 7 0 3 8 1 2 4 4 0 
0. 0 3% P F -0 7 0 3 8 1 2 4 4 0 
Ve hicle 4 0 
Ps O 0. 0 1 % P F -0 7 0 3 8 1 2 4 3 0 
0. 0 3% P F -0 7 0 3 8 1 2 4 3 0 
0. 0 6% P F -0 7 0 3 8 1 2 4 3 0 
Ve hicle 3 0 
D at a M o nit ori n g C o m mittee or Ot her I n de pe n de nt O versi g ht C o m mittee : 
A n i n de pe n de nt , i nter nal re vie w c o m mittee will be use d t o re vie w efficac y , safet y a n d 
t olera bilit y  data as descri be d i n Secti o n [ADDRESS_81921] atistic al Met h o ds 
A D :
T he pri mar y  esti ma n d will be t he differe nce i n pr o p orti o ns of t he bi nar y  e n d p oi nt bet wee n I P 
treate d ( 0. 0 1 % or 0. 0 3 % P F -0 7 0 3 8 1 2 4 oi nt me nt ) a n d ve hicle i n partici pa nts wit h mil d or 
m o derate A D wit h o ut t he be nefit of a d diti o nal pr o hi bite d me dicati o ns a n d re gar dless of 
treat me nt c o m plia nce. 
T he sec o n dar y  esti ma n d will be t he differe nce i n mea n of t he c o nti n u o us e n d p oi nt bet wee n 
I P treate d ( 0. 0 1 % or 0. 0 3 % P F - 0 7 0 3 8 1 2 4 oi nt me nt ) a n d ve hicle i n partici pa nts wit h mil d or 
m o derate A D wit h o ut t he be nefit of a d diti o nal pr o hi bite d me dicati o ns a n d re gar dless of 
treat me nt c o m plia nce. 
Ps O: 
The pri mar y  esti ma n d will be t he differe nce i n pr o p orti o ns of t he bi nar y  e n d p oi nt bet wee n I P 
treate d ( 0. 0 1 %, 0. 0 3 %, or 0. 0 6 % P F -0 7 0 3 8 1 2 4 oi nt me nt ) a n d ve hicle i n partici pa nts wit h 
mil d , m o derate ,or se vere Ps O wit h o ut t he be nefit of a d diti o nal pr o hi bite d me dicati o ns a n d 
re gar dless of trea t me nt c o m plia nce. 
T he sec o n dar y  esti ma n d will be t he differe nce i n mea n of t he c o nti n u o us e n d p oi nt bet wee n 
I P treate d ( 0. 0 1 %, 0. 0 3 %, or 0. 0 6 % P F -0 7 0 3 8 1 2 4 oi nt me nt ) a n d ve hicle i n partici pa nts wit h 
mil d, m o derate, or se vere Ps O wit h o ut t he be nefit of a d diti o nal pr o hi bite d me dicati o ns a n d 
re gar dless of treat me nt c o m plia nce .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 6 1. 2. Sc he m a 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 7 1. 3. S c he d ule of Acti v ities 
T he S o A ta ble pr o vi des a n o ver vie w of t he pr ot oc ol visits a n d pr oce d ures. Refer t o t he S T U D Y  A S S E S S M E N T S A N D 
P R O C E D U R E S secti o n of t he pr ot oc ol f or detaile d i nf or mati o n o n eac h pr oce d ure a n d assess me nt re q uire d f or c o m plia nce wit h t he 
pr ot oc ol. 
T he i n vesti gat or ma y  sc he d ule visits ( u n pla n ne d visits) i n a d diti o n t o t h ose liste d in t he S o A ta ble , i n or der t o c o n d uct e val uati o ns or 
assess me nts re q uire d t o pr otect t he well -bei n g of t he partici pa nt .
1. 3. 1. At o pic Der m atitis 
At o pic Der m atitis 
Visit I de ntifier a
A b bre viati o ns use d i n t his ta ble ma y be f o u n d i n 
A p pe n di x 1 3 Scree ni n g Tre at m e nt P h ase 
All assess me nt s/ pr oce d ures are pre -d ose ,u nless ot her wise st ate d F oll o w - U p 
(E O S) E T 
D a y 1
( B aseli ne) Wee k 1 Wee k 2 Wee k 4 Wee k 6 Wee k 8 Wee k 1 0 Wee k 1 2 
( E O T) 
Visit Wi n d o w D a y -2 8 
t o - 1 N/ A D a y 8 
± 2 D a y 1 5 
± 2 D a y 2 9 
± 2 D a y 4 3 
± 2 D a y 5 7 
± 2 D a y 7 1 
± 2 D a y 8 5 
± 2 2 8 – [ADDRESS_81922] 
dose N A 
Visit N u m ber 1 2 3 4 5 6 7 8 9 1 0 N A 
E nr oll me nt Pr oce d ures 
I nf or me d c o nse nt /asse nt X
Ge neral me dical a n d A D hist or y X X
Me dicati o n hist or y X X
D e m o gra p h y X
Eli gi bilit y assess me nt X Xb
Wei g ht X X
Hei g ht X
Cli nic al Assess me nts 
Ph ysical e xa mi nati o n cX X X X X X
E C G X X X X
Vital si g ns X X X X
C-S S R S dX0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 8 At o pic Der m atitis 
Visit I de ntifier a
A b bre viati o ns use d i n t his ta ble ma y be f o u n d i n 
A p pe n di x 1 3 Scree ni n g Tre at m e nt P h ase 
All assess me nt s/ pr oce d ures are pre -d ose ,u nless ot her wise st ate d F oll o w - U p 
(E O S) E T 
D a y 1
( B aseli ne) Wee k 1 Wee k 2 Wee k 4 Wee k 6 Wee k 8 Wee k 1 0 Wee k 1 2 
( E O T) 
Visit Wi n d o w D a y -2 8 
t o - 1 N/ A D a y 8 
± 2 D a y 1 5 
± 2 D a y 2 9 
± 2 D a y 4 3 
± 2 D a y 5 7 
± 2 D a y 7 1 
± 2 D a y 8 5 
± 2 2 8 – [ADDRESS_81923] 
dose N A 
Visit N u m ber 1 2 3 4 5 6 7 8 9 1 0 N A 
A D -Rel ate d Cli nic al Assess me nts 
I G A X X X X X X X X X X X
E A S I X X X X X X X X X X
B S A X X X X X X X X X X X
L a b or at or y Assess me nts 
H e m at ol o g y, C he mistr y a n d Uri nal ysis X X X X X X
Ser u m F S H ( W O N C B P o nl y) X
Ser u m Pre g na nc y Test ( W O C B P o nl y) X
Uri ne Pre g na nc y test fX X X X X X X X X X
P h ar m ac o ki netics 
Bi o m ar ker Assess me nts 
Ret ai ne d Rese arc h S a m ples 
Pre p B 1. 5 ( plas ma) X X X X
Pre p B 2. 5 (ser u m) X X X X
e-Di ar y 
Dis pe nse e -diar y a n d i nstr uct o n usa ge X0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
C CI 
C CI 
C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 9 At o pic Der m atitis 
Visit I de ntifier a
A b bre viati o ns use d i n t his ta ble ma y be f o u n d i n 
A p pe n di x 1 3 Scree ni n g Tre at m e nt P h ase 
All assess me nt s/ pr oce d ures are pre -d ose ,u nless ot her wise st ate d F oll o w - U p 
(E O S) E T 
D a y 1
( B aseli ne) Wee k 1 Wee k 2 Wee k 4 Wee k 6 Wee k 8 Wee k 1 0 Wee k 1 2 
( E O T) 
Visit Wi n d o w D a y -2 8 
t o - 1 N/ A D a y 8 
± 2 D a y 1 5 
± 2 D a y 2 9 
± 2 D a y 4 3 
± 2 D a y 5 7 
± 2 D a y 7 1 
± 2 D a y 8 5 
± 2 2 8 – [ADDRESS_81924] u d y 
i nter ve nti o n a p plicati o n XiX            X
C ollect e -diar y XjX X
St u d y I nter ve nti o n 
Calc ulate B S A f or st u d y i nter ve nti o n nee d X X X X X X X X
Mar k / u p date areas of a p plicati o n o n b o d y ma p X X X X X X X
Wei g h a n d dis pe nse st u d y i nter ve nti o n t u bes X X X X X X X
St u d y i nter ve nti o n a p plicati o n a n d o bser vati o n X X X X X X X X
C ollect a n d wei g h ret ur ne d st u d y i nter ve nti o n t u bes X X X X X X X X
Re vie w of  e-diar y f or c o m plia nce X X X X X X X X X
S afet y M o nit ori n g 
C o nc o mita nt Me dicati o n X  X  X  X  X  X  X  X  X  X 
C o ntrace pti o n usa ge c o nfir mati o n X  X  X  X  X  X  X  X  X  X  X 
L ocal tolera bilit y assess me nt kX  X  X  X  X  X  X  X X
Seri o us a n d n o n -seri o us A E m o nit ori n g X                X  X 
T a pe Stri p S u b -s t u d yn0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 2 0 At o pic Der m atitis 
Visit I de ntifier a
A b bre viati o ns use d i n t his ta ble ma y be f o u n d i n 
A p pe n di x 1 3 Scree ni n g Tre at m e nt P h ase 
All assess me nt s/ pr oce d ures are pre -d ose ,u nless ot her wise st ate d F oll o w - U p 
(E O S) E T 
D a y 1
( B aseli ne) Wee k 1 Wee k 2 Wee k 4 Wee k 6 Wee k 8 Wee k 1 0 Wee k 1 2 
( E O T) 
Visit Wi n d o w D a y -2 8 
t o - 1 N/ A D a y 8 
± 2 D a y 1 5 
± 2 D a y 2 9 
± 2 D a y 4 3 
± 2 D a y 5 7 
± 2 D a y 7 1 
± 2 D a y 8 5 
± 2 2 8 – [ADDRESS_81925] u d y n
= o n g oi n g/c o nti n u o us e ve nt 
a. D a y  relati ve t o start of st u d y i nter ve nti o n ( Da y 1). E xce pt f or Scree ni n g Visit a n d Da y 1 Visit, Alter nati ve Meas ures ma y be i m ple me nte d i n case of p u blic 
e m er ge ncies. Refer t o A p pe n di x 9 f or t he details a b o ut t he assess me nts t hat ma y be perf or me d d uri n g a Tele hea lt h Visit or a H o me Healt h Visit. 
b. Selecte d eli gi bilit y criteria s h o ul d be met. Refer t o Secti o n 5. 1 f or details.  
c. F oll o w i n g Da y 1 visit, e xa mi nati o n ma y be tar gete d t o s ki n a n d pre vi o us fi n di n gs, ne w/ o pe n A Es, or i n v esti gat or discreti o n. 
d. Site staff is t o a d mi nister t he C -S S R S t o all partici pa nts at Scree ni n g a n d sc ore i m me diatel y. 
f. A ne gati ve res ult fr o m uri ne pre g na nc y test is re q uire d bef ore recei vi n g st u d y i nter ve nti o n. 
j. O nl y f or partici p a nts w h o d o n ot meet eli gi bilit y criteria. If a partici pa nt has n’t wit h dra w n c o nse nt fr o m partici pati o n fr o m t he st u d y, e -diar y ma y be 
c ollecte d at E T or E O S visits. 
k. L ocal t olera bilit y at a n o n -lesi o nal site of st u d y i nter ve nti o n a p plicati o n w ill be assess e d i m me diatel y p ost -a p plicati o n .At E T, l ocal t olera bilit y assess me nt 
will be perf or me d o nl y if I P a p plicati o n w as pla n ne d at t hat visit, b ut was n’t c o n d ucte d d ue t o t olera bilit y assess me nt o utc o me of Gra de 3 (se v ere) or 
Gra de 4 ( ver y se vere), res ulti n g i n disc o nti n uati o n of t he st u d y i nter ve nti o n as o utli ne d i n Secti o n 7. 1. 4 .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
C CI 
C CI C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_81926] a q ue Ps ori asis 
Visit I de ntifier a
A b bre viati o ns use d i n t his ta ble ma y be f o u n d i n 
A p pe n di x 1 3 .Scree ni n g Tre at m e nt P h ase 
All assess me nt s/ pr oce d ures are pre -d ose ,u nless ot her wise st ate d. F oll o w -U p 
( E O S) E T D a y 1 
( B aseli ne) Wee k 1 Wee k 2 Wee k 4 Wee k 6 Wee k 8 Wee k 1 0 Wee k 1 2 
( E O T) 
Visit Wi n d o w D a y -2 8 
t o - 1 N A D a y 8 
± 2 D a y 1 5 
± 2 D a y 2 9 
± 2 D a y 4 3 
± 2 D a y 5 7 
± 2 D a y 7 1
± 2 D a y 8 5
± 2 2 8 – [ADDRESS_81927] 
dose N A 
Visit N u m ber 1 2 3 4 5 6 7 8 9 1 0 N A 
E nr oll me nt Pr oce d ures 
I nf or me d c o nse nt /asse nt X
Ge neral m e dical a n d Ps O hist or y X X
Me dicati o n hist or y X X
D e m o gra p h y X
Eli gi bil it y assess me nt X Xb
Wei g ht X X
Hei g ht X
Cli nic al Assess me nts 
Ph ysical e xa mi nati o n cX X X X X X
E C G X X X X
Vital si g ns X X X X
C-S S R S dX
Ps O- Rel ate d Cli nic al Assess me nts 
P G A X X X X X X X X X X X
P A SI X X X X X X X X X X
B S A X X X X X X X X X X X
L a b or at or y Assess me nts 
H e m at ol o g y, C he mistr y a n d Uri nal ysis X X X X X X
Ser u m F S H ( W O N C B P o nl y) X
Ser u m Pre g na nc y Test ( W O C B P o nl y) X
Uri ne Pre g na nc y Test eX X X X X X X X X X
P h ar m ac o ki netics 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_81928] a q ue Ps ori asis 
Visit I de ntifier a
A b bre viati o ns use d i n t his ta ble ma y be f o u n d i n 
A p pe n di x 1 3 .Scree ni n g Tre at m e nt P h ase 
All assess me nt s/ pr oce d ures are pre -d ose ,u nless ot her wise st ate d. F oll o w -U p 
( E O S) E T D a y 1 
( B aseli ne) Wee k 1 Wee k 2 Wee k 4 Wee k 6 Wee k 8 Wee k 1 0 Wee k 1 2 
( E O T) 
Visit Wi n d o w D a y -2 8 
t o - 1 N A D a y 8 
± 2 D a y 1 5 
± 2 D a y 2 9 
± 2 D a y 4 3 
± 2 D a y 5 7 
± 2 D a y 7 1
± 2 D a y 8 5
± 2 2 8 – [ADDRESS_81929] 
dose N A 
Visit N u m ber 1 2 3 4 5 6 7 8 9 1 0 N A 
Ret ai ne d Rese arc h S a m ples 
Pre p B 1. 5 ( plas ma) X X X X
Pre p B 2. 5 (ser u m) X X X X
e- di ar y 
Dis pe nse e-diar y a n d i nstr uct o n usa ge X
C o m plete assi g ne d P R Os a n d r ec or d st u d y 
i nter ve nti o n a p plicati o n Xh             X
C ollect e-diar y XiX X
St u d y I nter ve nti o n 
Calc ulate B S A f or st u d y i nter ve nti o n nee d X X X X X X X X
Mar k / u p date areas of a p plicati o n o n b o d y ma p X X X X X X X
Wei g h a n d dis pe nse st u d y i nter ve nti o n t u bes X X X X X X X
St u d y inter ve nti o n a p plicati o n a n d o bser vati o n X X X X X X X X
C ollect a n d wei g h ret ur ne d st u d y i nter ve nti o n t u bes X X X X X X X X
Re vie w of  e-diar y f or c o m plia nce X X X X X X X X X
S afet y M o nit ori n g 
C o nc o mita nt Me dicati o n X  X  X  X  X  X  X  X  X  X 
C o ntrace pti o n usa ge c o nfir mati o n X  X  X  X  X  X  X  X  X  X  X 
L ocal tolera bilit y assess me nt jX  X  X  X  X  X  X  X X
Seri o us a n d n o n -seri o us A E m o nit ori n g X                X  X 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_81930] a q ue Ps ori asis 
Visit I de ntifier a
A b bre viati o ns use d i n t his ta ble ma y be f o u n d i n 
A p pe n di x 1 3 .Scree ni n g Tre at m e nt P h ase 
All assess me nt s/ pr oce d ures are pre -d ose ,u nless ot her wise st ate d. F oll o w -U p 
( E O S) E T D a y 1 
( B aseli ne) Wee k 1 Wee k 2 Wee k 4 Wee k 6 Wee k 8 Wee k 1 0 Wee k 1 2 
( E O T) 
Visit Wi n d o w D a y -2 8 
t o - 1 N A D a y 8 
± 2 D a y 1 5 
± 2 D a y 2 9 
± 2 D a y 4 3 
± 2 D a y 5 7 
± 2 D a y 7 1
± 2 D a y 8 5
± 2 2 8 – [ADDRESS_81931] u d y n
= o n g oi n g/c o nti n u o us e ve nt 
a. D a y  relati ve t o start of st u d y i nter ve nti o n ( Da y 1). E xce pt f or Scree ni n g Visit a n d Da y 1 Visit, Alter nati ve Meas ures ma y be i m ple me nte d i n case of p u blic 
e m er ge ncies. Refer t o A p pe n di x 9 f or t he details a b o ut t he assess me nts t hat ma y be perf or me d d uri n g a Tele healt h Visit or a H o me Healt h Visit. 
b. Selecte d eli gi bilit y criteria s h o ul d be met. Refer t o Secti o n 5. 1 f or details. 
c. F oll o w i n g Da y 1 visit, e xa mi nati o ns ma y be tar gete d t o s ki n a n d pre vi o us fi n di n gs, ne w/ o pe n A Es, or i n vesti gat or discreti o n .
d. Site staff is t o a d mi nister t he C -S S R S t o all partici pa nts at Scree ni n g a n d sc ore i m me diatel y. 
e. A ne gati ve res ult fr o m uri ne pre g na nc y tests is re q uire d bef ore recei vi n g st u d y i nter ve nti on. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI C CI 
C CI 
C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 2 4 i. O nl y f or partici pa nts w h o d o n ot meet eli gi bilit y criteria .If a partici pa nt has n’t wit h dra w n c o nse nt fr o m partici pati o n fr o m t he st u d y, e -diar y ma y be 
c ollecte d at E T or E O S visits. 
j. L ocal t olera bilit y at a n o n- lesi o nal site of st u d y i nter ve nti o n a p plicati o n w ill be assesse d i m me diatel y p ost -a p plicati o n .At E T, l ocal t olera bilit y assess me nt 
will be perf or me d o nl y if I P a p plicati o n w as pla n ne d at t hat visit, b ut was n’t c o n d u cte d d ue t o t olera bilit y assess me nt o utc o me of Gra de 3 (se vere) or 
Gra de 4 ( ver y se vere), res ulti n g i n disc o nti n uati o n of t he st u d y i nter ve nti o n as o utli ne d i n Secti o n 7. 1. 4 .
l. T o be c o m plete d usi n g e -diar y, we e kl y  after Da y 1 at h o me/resi de nce or d uri n g site visit, if sc he d ule d. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_81932] y  eit her P F - 0 7 0 3 8 1 2 4 
oi nt me nt or a ve hicle oi nt me nt f o r 1 2 wee ks .
2. 2. B ac k gr o u n d 
R ole of Pr oi nfl a m m at or y C yt o ki nes i n A D a n d Ps O
A T O PI C D E R M A TI TI S: A D, als o k n o w n as at o pic ecze ma, is a c o m m o n, c hr o nic, 
i nfla m mat or y  s ki n dis or der c haracterize d b y  fla k y s ki n lesi o ns, i nte nse pr urit us, a n d a ge neral 
deteri orati o n i n q ualit y  of life. A D ca n affect a n y  a ge gr o u p. Pre vale nce esti mates s u g gest 
a p pr o xi matel y  1 0 % of a d ults a n d 1 0 % - 2 0 % of c hil dre n s uffer fr o m A D, a n d u p t o 1 8 % of 
t h ose affecte d wit h A D s uffer wit h se vere disease. Alt h o u g h A D affects patie nts of all a ges, 
it is o ne of t he m ost c o m m o n, c hr o nic, rela psi n g c hil d h o o d der mat oses affecti n g 1 5 % -3 0 % of 
all c hil dre n i n t he U S. T here are a li mite d n u m ber of t o pi[INVESTIGATOR_2855] s ki n treat me nts a vaila ble f or 
A D. C urre nt treat me nts f or A D i ncl u de e m ollie nts, t o pi[INVESTIGATOR_2855] c ortic oster oi ds 
(e g, beta met has o ne, cl o betas ol, fl u oci n o ni de), t o pi[INVESTIGATOR_75503] n i n hi bit ors 
(e g, pi [INVESTIGATOR_75504] m us, tacr oli m us), a n d c oal tar pre parati o ns. T here ha ve bee n m ore rece nt 
t o pi[INVESTIGATOR_75505] .Crisa b or ole, a P D E -4 i n hi bit or, has bee n use d f or tre at me nt of 
mil d -t o -m o derate A D. T o pi[INVESTIGATOR_2855] J A K i n hi bit ors ha ve als o bee n use d f or tre at me nt of 
mil d -t o -m o derate A D. R u x oliti ni b, a rece ntl y  a p pr o ve d J A K i n hi bit or f or t o pi[INVESTIGATOR_44785] i n 
mil d -t o - m o derate A D ca n be use d o nl y i nter mitte ntl y a n d s h ort -ter m, d ue t o its s y ste mic 
effects . Del g ociti ni b has bee n s h o w n t o be m o destl y  effecti ve i n tre at me nt of 
mil d -t o -m o derate A D. A d diti o nal treat me nts ge nerall y  reser ve d f or se vere A D i ncl u de 
p h ot ot hera p y (e g, U V A li g ht wit h or wit h o ut ps orale n) a n d s ys te mic a ge nts 
(e g, c ortic oster oi ds, c y cl o s p ori ne, rec o m bi na nt I F N -, m y c o p he n olate m ofetil, met h otre xate). 
N o ne of t he c urre ntl y  a vaila ble t hera pi[INVESTIGATOR_22728] a c ure; t heref ore, t he mai n ai ms of e xisti n g 
treat me nts are t o re d uce t he occ urre nce of ac ute flares, i ncrease t he ti me bet wee n rela pses, 
re d u ce pr urit us a n d re d uce t he res ulti n g slee p dist ur ba nces. F or m ost A D patie nts n ot 
res p o n di n g t o t o pi[INVESTIGATOR_2855] t hera pi[INVESTIGATOR_014] a n d p h ot ot hera p y, off -la bel use of s ys te mic a ge nts, w hic h 
i ncl u des b ot h oral c ortic oster oi ds a n d oral i m m u n os u p pressa nts re mai n t he last via bl e 
treat me nt o pti o n. M ore rece ntl y, t here ha ve bee n oral J A K i n hi bit ors t hat ha ve bee n a p pr o ve d 
f or treat me nt of m o derate- t o -se vere at o pic der matitis, s uc h as A br ociti ni b a n d U pa daciti ni b. 
D u pil u ma b i njecti o n, a n I L -[ADDRESS_81933], was a p pr o ve d f or use i n patie nts wit h 
m o derate -t o -se vere A D. S y ste mic t hera p y  o pti o ns are ass ociate d wit h p ote ntiall y  se vere 
a d verse effects a n d re q uire caref ul m o nit ori n g. T heref ore, t he pr o mi ne nt u n met me dical nee d 
i n A D is f or a n effecti ve, safe t o pi[INVESTIGATOR_2855] a ge nt f or once -a- d a y d osi n g wit h o ut restricti o ns o n 
l o n g -ter m or c o nti n u o us use, a n d wit h o ut l ocal or s y ste mic si de effects. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 2 6 T he T h2 res p o nse c o ntri b ute s t o A D- ass ociate d s ki n i nfla m mati o n a n d itc h. 1T he pat h o ge nic 
r ole t hat t he T h 2 deri ve d c y t o ki nes, I L -4 a n d I L -1 3, pla y  i n A D has bee n de m o nstrate d 
t hr o u g h t he cli nical efficac y  of d u pil u ma b, a n a nti b o d y  t o t he I L -4 rece pt or t hat bl oc ks t he 
acti vit y  of b ot h I L - 4 a n d I L -1 3. 2
P S O RI A SI S: T he m ost c o m m o n varia nt of ps oriasis, Ps O ( ps oriasis v ul garis), is a c hr o nic 
i nfla m mat or y  s ki n disease c haracterize d b y re d, s cal y , raise d pla q ues. C hr o nic Ps O is a 
c o m m o n s ki n dis or der wit h a w orl d wi de pre vale nce of 2 %. Alt h o u g h ps oriasis pri maril y  
affects t he s ki n a n d is n ot a life -t hreate ni n g disease, it ca n pr of o u n dl y i m pact t he patie nt’s 
Q o L  res ulti n g i n a n i m pair me nt a ki n t o ot her maj or diseases, s uc h as t y pe 2 dia betes, 
m y ocar dial i nfarcti o n, a n d art hritis. C urre nt treat me nts f or ps oriasis i ncl u de t o pi[INVESTIGATOR_8593], 
p h ot ot hera p y, s ys te mic n o n -bi ol o gical t hera pi[INVESTIGATOR_014] ( met h otre xate, c y cl os p ori n, acitreti n, 
a pre milast [ Otezla ®]) a n d bi ol o gics. Pr oi nfla m mat or y  c y t o ki nes s uc h as T N F -, I F N -a n d 
I L -2 3/ T -hel per -1 7 res p o nse c y t o ki nes pla y  a n i m p orta nt r ole i n t he pat h o ge nesis of 
ps oriasis. 3Se veral bi ol o gic m o n ocl o nal a nti b o dies t hat tar get t hese pr oi nfla m mat or y  
c y t o ki nes ha ve bee n s h o w n t o be effecti ve f or t he treat me nt of ps oriasis i n cli nical trials. 4
Bi ol o gic a ge nts use d i n t he treat me nt of ps oriasis i ncl u de m ulti ple a nti -T N F a ge nts (s uc h as 
i nfli xi ma b, a dali m u ma b, eta nerce pt), a nti- I L -1 2/I L -[ADDRESS_81934] ( Otezla ®) ma y re d uce pr o d ucti o n of pr o -i nfla m mat or y  
T N F -a n d I F N -b y  i ncreasi n g c A M P le vels. 
Descri pti o n of I n vesti g ati o n al Pr o d uct: Mec h a nis m of Acti o n 
Ph os p h o dia esterases are a fa mil y  of e nz y m es t hat brea k d o w n t he u bi q uit o us sec o n d 
messe n gers, c A M P a n d c G M P, t hat re g ulate vari o us cell ular pr ocesses. P D E [ADDRESS_81935] ( Otezla ®) is a n oral s mall - m olec ule i n hi bit or of P D E 4 t hat is a p pr o ve d 
f or t he tre at me nt of patie nts wit h m o derate- t o -se vere Ps O a n d acti ve ps oriatic art hritis. 
Crisa b or ole ( E ucrisa ®, Sta q uis ®) is a t o pi[INVESTIGATOR_1306] y  deli vere d P D E [ADDRESS_81936] 
( A R Q -1 5 1), ha ve s h o w n acti vit y  i n t he treat me nt of ps ori asis. [ADDRESS_81937]- i n -class, o xa b or ole -base d p ote nt P D E 4 i n hi bit or   
 
P F -0 7 0 3 8 1 2 4 is a p ote nt a n d selecti ve P D E 4 i n hi bit or i nte n de d t o be use d f or t o pi[INVESTIGATOR_2855] 
a d mi nistrati o n f or t he treat me nt of A D a n d Ps O .  
 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 2 7 Precli nic al S afet y D at a 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_81938] u dies : 
1. A P hase 1, m ulti ple asce n di n g d ose st u d y  i n a d ult healt h y  partici pa nts ( C 3 9 4 1 0 0 1 , 
c o m plete d ).  
 
2. A P hase 2a ra n d o mize d, d o u ble- bli n d st u d y  i n partici pa nts wit h mil d -t o -m o derate A D or 
Ps O , treate d wit h 0. 0 1 % P F - 0 7 0 3 8 1 2 4 oi nt me nt or ve hicle oi nt me nt Q D f or 6 wee ks 
( C 3 9 4 1 0 0 2 , c o m plete d ). T he t otal d urati o n of st u d y  partici pati o n was a p pr o xi matel y  [ADDRESS_81939] u d y, t here were n o deat hs or S A Es. All treat me nt -relate d (all -ca usalit y  a n d 
treat me nt -relate d) se vere A Es ( 4 partici pa nts) occ urre d i n t he ve hicle gr o u p. T here were 
n o treat me nt -relate d A Es i n t he 0. 0 1 % P F- 0 7 0 3 8 1 2 4 oi nt me nt gr o u p. T he n u m ber of 
T E A Es (all -ca usalit y ) a n d partici pa nts re p orti n g T E A Es were hi g her i n t he ve hicle gr o u p 
( 1 5 [ 2 9. 4 %] partici pa nts wit h 2 6 e ve nts) c o m pare d t o t he P F -0 7 0 3 8 1 2 4 gr o u p 
( 1 2 [ 2 2. 6 %] partici pa nts wit h 1 6 e ve nts). 
T he m ost c o m m o n all -ca usalit y  T E A Es b y S O C i n t he 0. 0 1 % P F -0 7 0 3 8 1 2 4 oi nt me nt 
gr o u p swas I nfecti o ns a n d I nfestati o ns ( 1 1. 3 %), a n d i n ve hicle gr o u p was S ki n a n d 
S u bc uta ne o us Tiss ue Dis or ders ( 1 3. 7 %). T here were n o partici pa nts wit h a p plicati o n site 
pai n or ot her s ki n reacti o n at a p plicati o n site i n t he 0. 0 1 % P F - 0 7 0 3 8 1 2 4 o i nt me nt gr o u p s. 
T here were 3 ( 5. 9 %) partici pa nts i n t he ve hicle gr o u p wit h 3 T E A Es relate d t o 
C O VI D -1 9, a n d 1 ( 2. 0 %) partici pa nt ha d a te m p orar y  disc o nti n uati o n d ue t o C O VI D -1 9. 
N o partici pa nts i n t he 0. 0 1 % P F - 0 7 0 3 8 1 2 4 oi nt me nt gr o u ps e x perie nce d A E relate d t o 
C O VI D - 1 9. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_81940] u d y  met t he statistical si g nifica nce f or t he pri mar y  e n d p oi nt f or b ot h i n dicati o ns. 
A D 
P F - 0 7 0 3 8 1 2 4 ( 0. 0 1 % oi nt me nt Q D ) met t he pri mar y  efficac y  e n d p oi nt i n t he C [ADDRESS_81941] u d y  f or A D: P F -0 7 0 3 8 1 2 4 ( 0. 0 1 % oi nt me nt Q D) was statisticall y  si g nifica ntl y  differe nt 
fr o m ve hicle i n perce nta ge c ha n ge fr o m baseli ne i n E A SI  sc ore at Wee k 6. 
T here was a statisticall y si g nifica nt differe nce i n t he k e y  sec o n dar y  e n d p oi nt: res p o nse 
rate f or I G A (clear =[ADDRESS_81942] clear = 1 a n d a re d ucti o n fr o m baseli ne of ≥ 2 p oi nts) at 
Wee k 6 bet wee n P F - 0 7 0 3 8 1 2 4 ( 0. 0 1 % oi nt me nt Q D) gr o u p a n d ve hicle gr o u p, w hic h 
s u p p orte d t he fi n di n gs of t he pri mar y  e n d p oi nt a nal y sis. 
T he res ults fr o m ot her i m p orta n tsec o n dar y  e n d p oi nts i ncl u di n g E A SI -7 5 a n d P P -N R S 
res p o nse at Wee k 6 were c o nsiste nt wit h t he pri mar y  a n d ke y  sec o n dar y  e n d p oi nt 
fi n di n gs. 
Ps O 
P F -0 7 0 3 8 1 2 4 ( 0. 0 1 % oi nt me nt Q D) met t he pri mar y  efficac y  e n d p oi nt i n t he C [ADDRESS_81943] u d y  f or P s O : P F -0 7 0 3 8 1 2 4 ( 0. 0 1 % oi nt me nt Q D) was statisticall y  si g nifica ntl y  
differe nt fr o m ve hicle i n c ha n ge fr o m baseli ne i n P A SI  sc ore at Wee k 6. 
T here was n o statisticall y si g nifica nt differe nce i n t he k e y  sec o n dar y  e n d p oi nt: res p o nse 
rate f or P G A (clear = [ADDRESS_81944] clear = 1 a n d a re d ucti o n fr o m baseli ne of ≥ 2 p oi nts) at 
Wee k 6 bet wee n P F -0 7 0 3 8 1 2 4 ( 0. 0 1 % oi nt me nt Q D) gr o u p a n d ve hicle gr o u p, alt h o u g h 
o bser ve d res p o nse rate was hi g her i n P F- 0 7 0 3 8 1 2 4 ( 0. 0 1 % oi nt me nt Q D) gr o u p t ha n 
ve hicle gr o u p. 
T he res ults fr o m P A SI -[ADDRESS_81945] u d y  t o e val uate 
t he safet y, t olera bilit y , s ki n irritati o n p ote ntial a n d p har mac o ki netics of m ulti ple -d ose , 
t o pi[INVESTIGATOR_2855] a d mi nistrati o n of P F - 0 7 0 3 8 1 2 4 t o Ja pa nese healt h y partici pa nts ( C 3 9 4 1 0 0 3, 
e nr oll me nt c o m plete, C S R pe n di n g). Preli mi nar y  data s u g gest t hat 0. 0 1 % P F - 0 7 0 3 8 1 2 4 
oi nt me nt is ge nerall y safe a n d well t olerate d i n Ja pa nese healt h y  partici pa nts .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 3 0 T a ble 1. P F -0 7 0 3 8 1 2 4  –C o m plete d St u dies as of 
J a n u ar y [ADDRESS_81946] u d y I D Descri pti o n P F -0 7 0 3 8 1 2 4 
D ose/ Re gi me n N u m ber of 
P artici p a nts 
C 3 9 4 1 0 0 1 
(c o m plete d) Part A: 
Part A e val uate dt he s ki n irritati o n 
p ote ntial of 0. 0 6 % P F -0 7 0 3 8 1 2 4 
( C o h ort 1; 0. 0 6 %) a n d ve hicle ( place b o) 
a p plie d t o n or mal s ki n wit h a s mall 
s urface area of 0. 1 % B S A ( 2 0 c m 2). 
Part B: 
Part B e val uate d t he safet y, t olera bilit y, 
s ki n irritati o n p ote ntial a n d P K f oll o wi n g 
a p plicati o n of P F -0 7 0 3 8 1 2 4 at i ncreasi n g 
c o nce ntrati o ns ( C o h orts 1- 4; 0. 0 1 %, 
0. 0 3 %, a n d 0. 0 6 %) a n d ve hicle ( place b o) 
t o 1 0 % B S A ( 2 0 0 0 c m 2). 
C 3 9 4 1 0 0 2 
(c o m plete d) A P hase 2a, ra n d o mize d, d o u ble bli n d, 
ve hicle c o ntr olle d, parallel gr o u p st u d y 
t o assess efficac y, safet y, t olera bilit y a n d 
p har mac o ki netics of P F -0 7 0 3 8 1 2 4 
oi nt me nt i n partici pa nts wit h A D a n d 
Ps O. 0. 0 1 % Q D a p plie d t o 
20 0 0 -4 0 0 0 c m 2( 5 -2 0 % 
f or A D; 5 -1 5 %Ps O) 
f or 6 w ee ks. 
 1 0 4 
A D: 3 6acti ve; 
34ve hicle 
Ps O: 1 7 acti ve; 
1 7 ve hicle 
C 3 9 4 1 0 0 3 
(e nr oll me nt 
c o m plete , C S R 
pe n di n g )Ra n d o mize d, d o u ble -bli n d, ve hicle -
c o ntr olle d, parallel c o h ort st u d y t o 
e val uate t he safet y, t olera bilit y, s ki n 
irritati o n p ote ntial a n d P K 0. 0 1 % Q D a p plie d t o 
2 0 0 0 ( 1 0 % B S A) or 
4 0 0 0 c m 2( 2 0 % B S A) 
f or 1 0 da ys .
 1 2 
4acti ve; 2
ve hicle a p plie d 
at 2 0 0 0 c m 2,
4 acti ve; [ADDRESS_81947] u dies, C 3 9 4 1 0 0 1 a n d C 3 9 4 1 0 0 2, are pr o vi de d i n t he c urre nt 
versi o n of t he I B. 
2. 3. Be nefit/ Ris k Assess me nt 
M ore detaile d i nf or mati o n a b o ut t he k n o w n a n d e x pecte d be nefits a n d ris ks a n d reas o na bl y 
e x pecte d A Es of P F -[ADDRESS_81948] u d y . 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
C CI 
C CI 
C CI 
C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 3 1 P ote nti al Ris k of Cli nic al Si g nific a nce S u m m ar y of D at a/ R ati o n ale f or Ris k Miti g ati o n Str ate g y 
St u d y I nter ve nti o nP F -[ADDRESS_81949] (a class effect of A Es o bser ve d w it h P D E 4 
i n hi bit ors) – n o n- cli nical fi n di n gs Cli nical si g ns i n dicati ve of ner v o us s yste m 
effects (e g, ata xia, decrease d acti vit y, h u nc he d 
p ost ure, t witc hi n g, a n d/ or tre m ors) a n d 
gastr oi ntesti nal effects (e mesis, sali vati o n, a n d/ or 
s oft/li q ui d feces) w ere o bser ve d i n rats, d o g s, 
a n d/ or mi ni pi [INVESTIGATOR_14107], at n o n -t olerate d d oses. I P a p plicati o n w ill be u p t o 4 0 % B S A re d uci n g t he 
ris k of s yste mic e x p os ure. 
S y ste mic e x p os ure w ill be assesse d i n t he st u d y. 
Partici pa nts will be assesse d f or safet y at re g ular 
i nter vals t hr o u g h o ut t he st u d y. 
W orse ni n g of disease ( A D or Ps O ) 1. Partici pa nts i n ve hicle ( or i n l o w er d ose 
ar m ) m a y  e x perie nce a w orse ni n g of 
disease .
2. Partici pa nts ma y e x perie nce a 
w orse ni n g of disease d uri n g was h o ut 
a n d/ or f oll o w -u p peri o ds .A D a n d Ps O are n ot life -t hreate ni n g diseases .
Partici pa nts ma y disc o nti n ue treat me nt or 
wit h dra w fr o m t he st u d y at a n y ti me f or a n y 
reas o n. 
Partici pa nts meeti n g wit h dra wal/ disc o nti n uati o n 
criteria ma y be a ble t o use alter nati ve treat me nts 
after wit h dra w al fr o m t he st u d y. 
Partici pa nts will be assesse d f or safet y at re g ular 
i nter vals t hr o u g h o ut t he st u d y. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 3 2 Ot her 
Ris k of S A R S -C o V -2 i nfecti o n Partici pa nts atte n di n g site visit ma y be e x p ose d .  Use of tele healt h, h o me healt h, etc a n d a p pr o priate 
l ocal a n d gl o bal restricti o ns g ui deli nes will be 
utilize d a n d f oll o we d t o m i ni mize p ote ntial 
e x p os ure of trial partici pa nts t o S A R S -C o V -2 (see 
A p pe n di x 9). 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 3 3 2. 3. 2. Be nefit Assess me nt 
Base d o n its c y t o ki ne i n hi biti o n pr ofile, t o pi[INVESTIGATOR_2855] a d mi nistrati o n of P F - 0 7 0 3 8 1 2 4 is a ntici pate d 
t o pr o vi de p ote ntial t hera pe utic be nefit i n t he treat me nt of A D  
 a n d i n t he treat me nt of Ps O . Ot her P D E 4 
i n hi bit ors, s uc h as crisa b or ole ( E ucrisa ®, Sta q uis ®), a pre mila st ( Otezla ®), a n d r ofl u milast 
( A R Q -1 5 1) 6ha ve de m o nstrate d efficac y  i n t he treat me nt of A D or Ps O . I n a d diti o n, i n 
cli nical St u d y  C [ADDRESS_81950], i n a d diti o n t o re g ular i nte nsi ve cli nical trial assess me nt t o s u p p ort 
partici pa nts’ ma na ge me nt of A D or Ps O .
T he i ncl u de d ve hicle has i m p orta nt e m ollie nt pr o perties. S o me ve hicle e xci pie nts ha ve a 
m ore pr o n o u nce d be neficial effect o n t he s ki n a n d ca n i m pr o ve cli nical a p peara nce a n d s ki n 
barrier f u ncti o n. I n partic ular, w hite petr olat u m, t he pri mar y  e xci pie nt a n d base of 
P F - 0 7 0 3 8 1 2 4 oi nt me nt was selecte d f or its e m ollie nt p r o perties a n d fa v ora ble t olera bilit y  
pr ofile. T he use of t o pi[INVESTIGATOR_2855] e m ollie nts is a n esse ntial ele me nt of A D a n d Ps O treat me nt a n d is 
rec o m me n de d b y p u blis he d g ui deli nes. 
2. 3. 3. O ver all Be nefit /Ris k C o ncl usi o n 
Ta ki n g i nt o acc o u nt t he meas ures t o mi ni mize ris k t o st u d y partici pa nts , t he p ote ntial ris ks 
i de ntifie d i n ass ociati o n wit h P F - 0 7 0 3 8 1 2 4 are j ustifie d b y  t he a ntici pate d be nefits t hat ma y  
be aff or de d t o partici pa nts wit h A D or Ps O .
T he Be nefit/ Ris k bala nce of P F -0 7 0 3 8 1 2 4 is c o nsi dere d fa v ora ble a n d s u p p orte d b y :
T he satisfact or y  safet y a n d l ocal t olera bilit y  pr ofile o n P F -[ADDRESS_81951] u dies a n d cli nical S t u dies C 3 9 4 1 0 0 1 , C 3 9 4 1 0 0 2 , a n d C 3 9 4 1 0 0 3. 
T he e x pecte d efficac y  of P F -[ADDRESS_81952] u d y  
C 3 9 4 1 0 0 2, a n d efficac y  of ot her a p pr o ve d t o pi[INVESTIGATOR_2855] P D E 4 i n hi bit ors f or t he treat me nt 
of mil d -t o -m o derate A D ( E ucrisa ®/ Sta q uis ®) a n d oral P D E 4 i n hi bit ors f or t he 
trea t me nt of m il d -t o -se vere ps oriasis ( Otezla ®). 
Partici pa nts will be m o nit ore d cl osel y d uri n g t he st u d y f or safet y a n d l ocal t olera bilit y  
a d verse e ve nts b y t he st u d y  i n vesti gat ors a n d s p o ns or t o e ns ure partici pa nt safet y. 
I n c o ncl usi o n, [COMPANY_007] c o nsi ders t hat t he cli nical e x perie nce t o date wit h P F- 0 7 0 3 8 1 2 4 s u p p ort 
t he c o nti n ue d de vel o p me nt of P F- 0 7 0 3 8 1 2 4 f or t he treat me nt of A D a n d Ps O s u p p orti n g t he 
i nitiati o n of P hase 2 b S t u d y  C 3 9 4 1 0 0 5. 
A d diti o nal bac k gr o u n d i nf or mati o n o n P F -0 7 0 3 8 1 2 4 ca n be f o u n d i n t he c ur re nt versi o n of 
t he I B ( versi o n 3. 0, 2 0 2 2) , es peciall y  t he S u m mar y  of Data a n d G ui da nce f or t he I n vesti gat or 
( Secti o n 7 of t he I B). 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 3 4 3. O B J E C TI V E S, E N D P OI N T S, A N D E S TI M A N D S 
A T O PI C D E R M A TI TI S 
O bjecti ves E n d p oi nts Esti m a n ds 
Pri m ar y: Pri m ar y: Pri m ar y: 
T o c o m pare t he efficac y of 
2d ose le vels of P F -0 7 0 3 8 1 2 4 
oi nt me nt vers us ve hicle, usi n g 
I G A s uccess as t he e n d p oi nt i n 
partici pa nts wit h mil d or 
m o derate A D. Pr o p orti o n of partici pa nts 
ac hie vi n g I G A sc ore of clear ( 0) 
or al m ost clear ( 1) ( o n a 5 -p oi nt 
scale ) a n d a re d ucti o n fr o m 
baseli ne of ≥ 2 p oi nts at 
Wee k 1 2 .Esti ma n d E 1: the differe nce i n 
pr o p orti o ns of t he bi nar y 
e n d p oi nt bet w ee n I P treate d 
(0. 0 1 % or 0. 0 3 % P F -0 7 0 3 8 1 2 4 
oi nt me nt ) a n d ve hicle i n 
partici pa nts wit h mil d or 
m o derate A D wit h o ut t he 
be nefit of a d diti o nal pr o hi bite d 
me dicati o ns a n d re gar dless of 
treat me nt c o m plia nce .
Sec o n d ar y: Sec o n d ar y: Sec o n d ar y: 
T o c o m pare t he efficac y of 
2d ose le vels of P F -0 7 0 3 8 1 2 4 
oi nt me nt vers us ve hicle usi n g 
E A SI -7 5 as a n e n d p oi nt i n 
partici pa nts wit h mil d or 
m o derate A D. Pr o p orti o n of partici pa nts 
ac hie vi n g E A SI -7 5 
( 7 5 % i m pr o ve me nt fr o m 
baseli ne )at all st u d y visit ti me 
p oi nts s pecifie d i n t he S o A .Esti ma n d E 1 descri be d a b o ve .
T o c o m pare t he efficac y of 
2d ose le vels of P F -0 7 0 3 8 1 2 4 
oi nt me nt vers us ve hicle, usi n g 
I G A s uccess as t he e n d p oi nt i n 
partici pa nts wit h mil d or 
m o derate A D. Pr o p orti o n of partici pa nts 
ac hie vi n g I G A sc ore of clear ( 0) 
or al m ost clear ( 1) ( o n a 5 -p oi nt 
scale ) a n d a re d ucti o n fr o m 
baseli ne of ≥ [ADDRESS_81953] u d y 
visit ti me p oi nts s pecifie d i n t he 
S o A , e xce pt at Wee k 1 2 .Esti ma n d E 1 descri be d a b o ve .
T o c o m pare t he efficac y of 
2d ose le vels of P F -0 7 0 3 8 1 2 4 
oi nt me nt vers us ve hicle, usi n g 
perce nt C F B i n E A SI as t he 
e n d p oi nt i n partici pa nts wit h 
mil d or m o derate A D. Perce nt C F B i n E A SI t otal sc ore 
at all st u d y visit ti me p oi nts 
s pecifie d i n t he S o A .Esti ma n d E 2: t he differ e nce i n 
mea n of t he c o nti n u o us 
e n d p oi nt bet w ee n I P treate d 
( 0. 0 1 % or 0. 0 3 % P F -0 7 0 3 8 1 2 4 
oi nt me nt ) a n d ve hicle i n 
partici pa nts wit h mil d or 
m o derate A D wit h o ut t he 
be nefit of a d diti o nal pr o hi bite d 
me dicati o ns a n d re gar dless of 
treat me nt c o m plia nce. 
T o c o m pare t he efficac y of 
2d ose le vels of P F -[ADDRESS_81954] clear as t he 
e n d p oi nt i n partici pa nts wit h 
mil d or m o derate A D. Pr o p orti o n of partici pa nts 
ac hie vi n g I G A sc ore of clear ( 0) 
or al m ost clear ( 1) at al l st u d y 
visit ti me p oi nts s pecifie d i n t he 
S o A .Esti ma n d E 1 descri be d a b o ve .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 3 5 T o c o m pare t he efficac y of 
2d ose le vels of P F -0 7 0 3 8 1 2 4 
oi nt me nt vers us ve hicle, usi n g 
meas ures of P P -N R S P R O, i n 
partici pa nts wit h mil d or 
m o derate A D. Pr o p orti o n of partici pa nts 
ha vi n g ≥ [ADDRESS_81955] u d y 
visit ti me p oi nts s pecifie d i n t he 
S o A .Esti ma n d E 1 descri be d a b o ve .
T o c o m pare t he efficac y of 
2d ose le vels of P F -0 7 0 3 8 1 2 4 
oi nt me nt vers us ve hicle, usi n g 
B S A as t he e n d p oi nt i n 
partici pa nts wit h mil d or 
m o derate A D. Perce nt C F B i n affecte d B S A at 
all st u d y visit ti me p oi nts 
s pecifie d i n t he S o A .Esti ma n d E 2 descri be d a b o ve .
T o c haracte rize t he safet y a n d 
t olera bilit y of 2d ose le vels of  
P F -0 7 0 3 8 1 2 4 oi nt me nt vers us 
ve hicle i n partici pa nts wit h mil d 
or m o derate A D. I nci de nce of treat me nt e mer ge nt 
A E s a n d S A Es, cli nicall y 
si g nifica nt c ha n ges i n vital 
si g ns, E C G, a n d la b orat or y 
tests. 
I nci de nce of i ncrease i n l ocal 
t olera bilit y se verit y gra des at 
ti mes i n dicate d i n t he S o A .N ot A p plica ble .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_81956] u d y 
T o e val uate p har mac ol o gical 
effects of a p pl y i n g m ulti ple 
d oses of P F - [ADDRESS_81957] u d y 
T o c o m pare t he efficac y of t w o 
d ose le vels of P F -0 7 0 3 8 1 2 4 
oi nt me nt vers us ve hicle   
 
 
T o d oc u me nt effects of a p pl y i n g 
m ulti ple d oses of P F -0 7 0 3 8 1 2 4 
oi nt me nt vers us ve hicle 
oi nt me nt usi n g p h ot o gra p hic 
i m a ges .
P L A Q U E P S O RI A SI S 
O bjecti ves E n d p oi nts Esti m a n ds 
Pri m ar y: Pri m ar y: Pri m ar y: 
T o c o m pare t he efficac y of 
m ulti ple d ose le vels of 
P F -0 7 0 3 8 1 2 4 oi nt me nt vers us 
ve hicle, usi n g PG A s uccess as 
t he e n d p oi nt i n partici pa nts wit h 
mil d -t o -se vere Ps O. Pr o p orti o n of partici pa nts 
ac hie vi n g PG A sc ore of clear 
( 0) or al m ost clear ( 1) ( o n a 
5- p oi nt scale) a n d a re d ucti o n 
fr o m baseli ne of ≥ 2 p oi nts at 
Wee k 1 2. Esti ma n d E 1: t he differe nce i n 
pr o p orti o ns of t he bi nar y 
e n d p oi nt bet w ee n I P treate d 
(0. 0 1 %, 0. 0 3 % , or 0. 0 6 % 
P F -0 7 0 3 8 1 2 4 oi nt me nt ) a n d 
ve hicle i n partici pa nts wit h 
mil d -t o -se vere Ps O wit h o ut t he 
be nefit of a d diti o nal pr o hi bite d 
me dicati o ns a n d re gar dless of 
treat me nt c o m plia nce. 
Sec o n d ar y: Sec o n d ar y: Sec o n d ar y: 
T o c o m pare t he efficac y of 
m ulti ple d ose le vels of 
P F -0 7 0 3 8 1 2 4 oi nt me nt vers us 
ve hicle usi n g P A SI -7 5 as a n 
e n d p oi nt, i n partici pa nts wit h 
mil d -t o -se vere Ps O .Pr o p orti o n of partici pa nts 
ac hie vi n g PA SI -7 5 
( 7 5 % i m pr o ve me nt fr o m 
baseli ne) at ti mes i n dicate d i n 
t he S o A .Esti ma n d E 1 descri be d a b o ve .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 3 7 T o c o m pare t he efficac y of 
m ulti ple d ose le vels of 
P F -0 7 0 3 8 1 2 4 oi nt me nt vers us 
ve hicle, usi n g P G A s uccess as 
e n d p oi nt i n partici pa nts wit h 
mil d -t o -se vere Ps O .Pr o p orti o n of partici pa nts 
ac hie vi n g P G A sc ore of clear 
( 0) or al m ost clear ( 1) ( o n a 
5- p oi nt scale) a n d a re d ucti o n 
fr o m baseli ne of ≥ 2 p oi nts at 
ti mes i n dicate d i n t he S o A , 
e xce pt at Wee k 1 2 .Esti ma n d E 1 descri be d a b o ve .
T o c o m pare t he efficac y of 
m ulti ple d ose le vels of 
P F -0 7 0 3 8 1 2 4 oi nt me nt vers us 
ve hicle, usi n g C F B PA SI as t he 
e n d p oi nt i n partici pa nts wit h 
mil d -t o -se vere Ps O .Cha n ge fr o m baseli ne i n PA SI 
at ti mes i n dicate d i n t he S o A .Esti ma n d E 2: t he differe nce i n 
mea n of t he c o nti n u o us 
e n d p oi nt bet w ee n I P treate d 
(0. 0 1 %, 0. 0 3 %, or 0. 0 6 % 
P F -0 7 0 3 8 1 2 4 oi nt me nt ) a n d 
ve hicle i n partici pa nts wit h 
mil d -t o -se vere Ps O wit h o ut t he 
be nefit of a d diti o nal pr o hi bite d 
me dicati o ns a n d re gar dless of 
treat me nt c o m plia nce. 
T o c o m pare t he efficac y of 
m ulti ple d ose le vels of 
P F -[ADDRESS_81958] clear as t he e n d p oi nt i n 
partici pa nts wit h mil d -t o -se vere 
Ps O .Pr o p orti o n of partici pa nts 
ac hie vi n g PG A sc ore of clear 
( 0) or al m ost clear ( 1) at all 
st u d y visit ti me p oi nts s pecifie d 
i n t he S o A .Esti ma n d E 1 descri be d a b o ve .
T o c o m pare t he efficac y of 
m ulti ple d ose le vels of 
P F -0 7 0 3 8 1 2 4 oi nt me nt vers us 
ve hicle, usi n g meas ures of 
P P -N R S P R O, i n a d ult 
( 1 8 -7 5 years ol d) partici pa nts 
wit h mil d -t o -se vere Ps O .Pr o p orti o n of a d ult ( 1 8 -7 5 years 
ol d) partici pa nts ha vi n g 
≥ [ADDRESS_81959] u d y visit ti me 
p oi nts s pecifie d i n t he S o A .Esti ma n d E 1 descri be d a b o ve .
T o c o m pare t he efficac y of 
m ulti ple d ose le vels of 
P F -0 7 0 3 8 1 2 4 oi nt me nt vers us 
ve hicle, usi n g B S A as t he 
e n d p oi nt i n partici pa nts wit h 
mil d -t o -se vere Ps O. Perce nt C F B i n affecte d B S A at 
all st u d y visit ti me p oi nts 
s pecifie d i n t he S o A .Esti ma n d E 2 descri be d a b o ve .
T o c haracterize t he safet y a n d 
t olera bilit y of m ulti ple d ose 
le vels of P F -0 7 0 3 8 1 2 4 oi nt me nt 
vers us ve hicle i n partici pa nts 
wit h mil d- t o -se vere Ps O. I nci de nce of treat me nt e mer ge nt 
A E s a n d S A Es, cli nicall y 
si g nifica nt c ha n ges i n vital 
si g ns, E C G, a n d la b orat or y 
tests. 
I nci de nce of i ncrease i n l ocal 
t olera bilit y se verit y gra des at 
ti mes i n dicate d i n t he S o A .N ot A p plica ble .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_81960] u d y 
T o e val uate p har mac ol o gical 
effects of a p pl y i n g m ulti ple 
d oses of P F -[ADDRESS_81961] u d y 
T o d oc u me nt effects of 
a p pl yi n g m ulti ple d oses of 
P F -0 7 0 3 8 1 2 4 oi nt me nt vers us 
ve hicle oi nt me nt usi n g 
p h ot o gra p hic i ma ges. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_81962] u d y i nter ve nti o n (P F - 0 7 0 3 8 1 2 4 or ve hicle ).
Partici pa nts will be scree ne d f or eli gi bilit y  t o partici pate i n t he trial wit hi n 4wee ks of 
ra n d o mizati o n , o n Da y  [ADDRESS_81963] u d y  i nter ve nti o n ( P F - 0 7 0 3 8 1 2 4 oi nt me nt o rve hicle oi nt me nt) will be o nce 
dail y  f or [ADDRESS_81964] u d y  partici pati o n is a p pr o xi matel y  
2 1 wee ks. 
F or A D, a p pr o xi matel y 1 2 0 partici pa nts will be ra n d o ml y  assi g ne d 1: 1: 1 t o recei ve 
eit her 0. 0 1 % P F -0 7 0 3 8 1 2 4 oi nt me nt, 0. 0 3 % P F -0 7 0 3 8 1 2 4 oi nt me nt or a ve hicle 
oi nt me nt .
Ra n d o mizati o n will be stratifie d b y baseli ne disease se verit y ( mil d [I G A = 2] vs 
m o derate [I G A = 3]) a n d b y  ta pe stri p pi n g s u b -st u d y  partici pati o n .  
 
F or Ps O, a p pr o xi matel y 1 2 0 partici pa nts will be ra n d o ml y  assi g ne d 1: 1: 1: 1 t o recei ve 
eit her 0. 0 1 % P F -0 7 0 3 8 1 2 4 oi nt me nt, 0. 0 3 % P F - 0 7 0 3 8 1 2 4 oi nt me nt, 0. 0 6 % 
P F -0 7 0 3 8 1 2 4 or a ve hicle oi nt me nt. 
Ra n d o mizati o n will be stratifie d b y baseli ne disease se verit y ( mil d [ P G A = 2], 
m o derate [ P G A = 3], se vere [ P G A =4]) a n d b y ta pe stri p pi n g s u b -st u d y  
partici pati o n .  0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_81965] u d y 
A D 0. 0 1 % P F -0 7 0 3 8 1 2 4 4 0 
0. 0 3% P F -0 7 0 3 8 1 2 4 4 0 
Ve hicle 4 0 
Ps O 0. 0 1 % P F -0 7 0 3 8 1 2 4 3 0 
0. 0 3% P F -0 7 0 3 8 1 2 4 3 0 
0. 0 6% P F -[ADDRESS_81966] u dies: 
4. 2. Scie ntific R ati o n ale f or St u d y Desi g n 
A si n gle ,pri mar y  e n d p oi nt base d o n re g ulat or y  prece de nce is pla n ne d f or b ot h A D a n d Ps O. 
F D A re q uires pri mar y  e n d p oi nt f or A D a n d Ps O t o be I G A a n d P G A, res pecti vel y a n d 
sec o n dar y  e n d p oi nts t o be E A SI a n d P A SI. Si nce I G A a n d E A SI i n A D a n d P G A a n d P A SI 
i n Ps O are n ot i n de pe n de nt varia bles a n d s h o ul d trac k i n parallel, t here is a hi g h pr o ba bilit y  
t hat t hese will be c o nsiste nt. T hese are well -vali date d e n d p oi nts a n d ha ve bee n use d as 
re g ulat or y  a n d cli nical e n d p oi nts i n A D/ Ps O st u dies f or ma n y ye ars , t heref ore, f or A D, I G A 
is c h ose n t o be t he pri mar y  e n d p oi nt a n d E A SI as sec o n dar y. Si milarl y, f or Ps O, P G A is 
c h ose n as t he pri mar y  e n d p oi nt a n d P A SI  as sec o n dar y .
 
 
 
 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_81967] u d y  i nter ve nti o n i n cli nical practice .
4. 2. 2. C h oice of C o ntr ace pti o n/ B arrier Re q uire me nts 
H u ma n re pr o d ucti ve safet y  data are li mite d f or P F - 0 7 0 3 8 1 2 4 , b ut t here is n o s us pi[INVESTIGATOR_37180] o n of 
h u ma n terat o ge nicit y base d o n t he i nte n de d p har mac ol o g y of t he c o m p o u n d. T heref ore, t he 
use of a hi g hl y effecti ve met h o d of c o ntrace pti o n is re q uire d (see A p pe n di x 4 ). 
4. 2. 3. C ollecti o n of Ret ai ne d Rese arc h S a m ples 
Retai ne d Researc h Sa m ples will be c ollecte d a n d st ore d f or f urt her a nal ys es w hic h ma y , f or 
e xa m ple, pr o vi de greater u n dersta n di n g of t he st u d y  i nter ve nti o n. 
4. 3. J ustific ati o n f or D ose 
T he n o ncli nical safet y pr ofile of P F -[ADDRESS_81968] u dies of u p t o 3 m o nt hs i n d urati o n 
( See Secti o n 2. 2 ). 
T he d ose spr o p ose d f or t his st u d y  were deter mi ne d c o nsi deri n g all rele va nt i nf or mati o n 
o btai ne d fr o m n o ncli nical safet y st u dies, i nc or p orati n g t he N O A E L fr o m [ADDRESS_81969] u d y C 3 9 4 1 0 0 1 (Ta ble 3)a n d St u d y  
C3 9 4 1 0 0 3 ( preli mi nar y  data) , a n d i n partici pa nts wit h A D or Ps O i n [ADDRESS_81970] -d ose, greater t ha n 8 6 % a n d 9 8 % of plas ma 
P K sa m ples of P F -0 7 0 3 8 1 2 4 were B L Q of 1 0 p g/ m L  i n A D a n d Ps O partici pa nts, 
res pecti vel y.  
 
 I n a d diti o n, t he u p date d f or m ulati o n  
was als o i n vesti gate d i n healt h y  Ja pa nese partici pa nts ( C 3 9 4 1 0 0 3) a n d t he fi n di n gs were 
c o nsiste nt wit h t he e x p os ure o bser ve d i n A D a n d Ps O patie nts ( C 3 9 4 1 0 0 2). 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
C CI 
C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_81971] u d y  are 0. 0 1 %, 0. 0 3 % a n d 0. 0 6 % P F -[ADDRESS_81972] u d y (C 3 9 4 1 0 0 2 ), t he cli nical efficac y  criteri o n f or 
%c ha n ge fr o m base li ne i n E A SI  a n d %I G A res p o n ders i n A D were met usi n g t he 0. 0 1 % d ose 
stre n gt h f oll o wi n g Q D a p plicati o n, a n d c o m para ble t o efficac y  wit h ot her t o pi[INVESTIGATOR_2855] a ge nts 
a p pr o ve d f or mil d- t o - m o derate A D. T he d ose stre n gt hs of P F- [ADDRESS_81973] u d y  are 0. 0 1 % a n d a hi g her d ose of 0. 0 3 % i n partici pa nts wit h A D t o i n vesti gate t he a bilit y  
t o ac hie ve greater efficac y  c o m pare d t o ot her t o pi[INVESTIGATOR_2855] a ge nts, w hile still mi ni mizi n g s y ste mic 
e x p os ure .F or Ps O, e ve n t h o u g h t he cli nical efficac y  criteri o n of c ha n ge fr o m baseli ne i n 
P A SI  sc ore was met wit h t he 0. 0 1 % Q D re gi me n, t he efficac y  criteri o n f or % P G A 
res p o n ders was n ot ac hie ve d. As a res ult , t he i nte nt of t his P h ase [ADDRESS_81974] p ossi ble d ose 
ra n ge (e g , 0. 0 1 %, 0. 0 3 %, a n d 0. 0 6 %) is re q uire d. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
C CI 
C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 4 3 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_81975] u d y  if he/s he has c o m plete d all peri o ds of 
t he st u d y , i ncl u di n g t he last visit. 
5. S T U D Y P O P U L A TI O N 
T his st u d y  ca n f ulfill its o bjecti ves o nl y  if a p pr o priate partici pa nt s are e nr olle d. T he 
f oll o wi n g eli gi bil it y  criteria are desi g ne d t o select partici pa nt s f or w h o m partici pati o n i n t he 
st u d y  is c o nsi dere d a p pr o priate. All rele va nt me dical a n d n o n me dical c o n diti o ns s h o ul d be 
ta ke n i nt o c o nsi derati o n w he n deci di n g w het her a partic ular partici pa nt is s uita ble f or t his 
pr ot oc ol .
Pr os pecti ve a p pr o val of pr ot oc ol de viati o ns t o recr uit me nt a n d e nr oll me nt criteria ,als o 
k n o w n as pr ot oc ol wai vers or e xe m pti o ns, is n ot per mitte d .
5. 1. I ncl usi o n Criteri a 
T he i ncl usi o n criteria f or A D a n d Ps O are o verla p pi n g b ut differe nt. Det ails of t he 
o verla p pi n g i ncl usi o n criteria are pr o vi de d i n Secti o n 5. 1. 1 ; Disease -s pecific i ncl usi o n 
criteria are pr o vi de d i n Secti o n 5. 1. 2. [ADDRESS_81976] y: 
A ge a n d Se x :
1. P artici pa nts a ges 1 2ye ars (i ncl usi ve) a n d a b o ve , at Scree ni n g .
Refer t o A p pe n di x 4 f or re pr o d ucti ve criteria f or male ( Secti o n 1 0. 4. 1 ) a n d fe male 
(Secti o n 1 0. 4. 2 ) partici pa nts. 
T y pe of P artici p a nt a n d Dise ase C h ar acteristics: 
2. Partici pa nts w h o are willi n g a n d a ble t o c o m pl y wit h all sc he d ule d visits, treat me nt 
pla n, la b orat or y  tests , lifest y le c o nsi derati o ns, a n d ot her st u d y  pr oce d ures. 
I nf or me d C o nse nt / asse nt :
3. Ca pa ble of gi vi n g si g ne d i nf or me d c o nse nt /asse nt as descri be d i n A p pe n di x 1 ,w hic h 
i ncl u des c o m plia nce wit h t he re q uire me nts a n d restricti o ns liste d i n t he I C Da n d i n 
t his pr ot oc ol. 
T he i n vesti gat or, or a pers o n desi g nate d b y  t he i n vesti gat or, will o btai n 
writte n/electr o nicall y  si g ne d i nf or me d c o nse nt fr o m eac h st u d y  partici pa nt’s le gal 
g uar dia n (as defi ne d i n A p pe n di x 1 )a n d t he partici pa nt’s asse nt, w he n a p plica ble, 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_81977] u d y- s pecific acti vit y  is perf or me d u nless a wai ver of i nf or me d c o nse nt 
has bee n gra nte d b y a n I R B/ E C. All le gal g uar dia ns s h o ul d be f ull y  i nf or me d, a n d 
partici pa nts s h o ul d be i nf or me d t o t he f ull est e xte nt p ossi ble, a b o ut t he st u d y  i n 
la n g ua ge a n d ter ms t he y  are a ble t o u n dersta n d. T he i n vesti gat or will retai n t he 
ori gi nal c o p y of eac h partici pa nt's si g ne d c o nse nt/asse nt d oc u me nt. 
5. 1. 2. Dise ase - S pecific I ncl usi o n Criteri a: 
5. 1. 2. 1. A D S pecific I ncl usi o n Criteri a 
4. Ha ve bee n dia g n ose d wit h A D f or at least 3 m o nt hs pri or t o Scree ni n g .
N ote : T he cli nical dia g n osis of A D will be c o nfir me d acc or di n g t o t he criteria of 
Ha nifi n a n d Raj ka 7(A p pe n di x 1 0 ). 
5. Ha ve a n I G A sc ore of 2 ( mil d), or 3 ( m o derate) at Scree ni n g a n d Da y  1 , pri or t o 
ra n d o mizati o n .Refer t o Secti o n 8. 1. 1. 1. 1 a n d A p pe n di x 1 2 f or t he assess me nt of 
5-p oi nt I G A. 
6. Ha ve A D c o veri n g 5 % a n d u p t o 40 % of B S A (e xcl u di n g t he hair -beari n g scal p) at 
Scree ni n g a n d Da y  [ADDRESS_81978] i o n 1 0. 1 2. 1. 3 
(A p pe n di x 1 2 )f or detaile d met h o ds of calc ulati n g treata ble %B S A .
7. Ha ve a P P -N R S a vera ge sc ore of ≥ 2 assesse d at Da y  1 , pri or t o r a n d o mizati o n. 
5. 1. 2. 2. P s O S pecific I ncl usi o n Criteri a 
8. Ha ve a dia g n osis of Ps O ( ps oriasis v ul garis) f or at least 6 m o nt hs pri or t o Scree ni n g .
9. Ha ve a P G A sc ore of 2 ( mil d), 3 ( m o derate) , or 4(se vere ) at Scree ni n g a n d Da y 1, 
pri or t o ra n d o mizati o n. Refer t o Secti o n 8. 1. 2. 1. 1 a n d A p pe n di x 1 2 f or t he assess me nt 
of 5 -p oi nt P G A .
1 0. Ha v e Ps O c o veri n g 2% t o 2 0 % (i ncl usi ve) of B S A ( e xcl u di n g t he hair -beari n g scal p , 
pal ms, s oles, fi n ger nails a n d t oe nails ) at Scree ni n g a n d Da y  1, pri or t o 
ra n d o mizati o n. Refer t o Secti o n 1 0. 1 2. 2. 3 (A p pe n di x 1 2 ) f or detaile d met h o ds of 
calc ulati n g treata ble B S A .
5. 2. E xcl usi o n Criteri a 
T he e xcl usi o n criteri a f or A D a n d Ps O p o p ul ati o n are t he s a me. 
Partici pa nts are e xcl u de d fr o m t he st u d y  if a n y  of t he f oll o wi n g criteria a p pl y :
Me dic al C o n diti o ns: 
1. Prese nce of s ki n c o m or bi dities t hat w o ul d i nterfere wit h st u d y  assess me nt or res p o nse 
t o treat me nt. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_81979] or y  ( wit hi n a p pr o xi matel y  3 m o nt hs pri or t o Da y  1) of se vere, 
pr o gressi ve, or u nc o ntr olle d re nal, he patic, he mat ol o gical, gastr oi ntesti nal, meta b olic, 
e n d ocri ne, p ul m o nar y , car di o vasc ular, or ne ur ol o gical disease. 
4. A hist or y  ( wit hi n a p pr o xi matel y  3 m o nt hs pri or t o Da y  1) of s ys te mic, c hr o nic or 
ac ute s ki n i nfecti o n ( wit hi n a p pr o xi matel y  2 wee ks pri or t o Da y  1 ) re q uiri n g 
h os pi[INVESTIGATOR_1314] o n, pare nteral a nti micr o bial t hera p y, or as ot her wise j u d ge d cli nicall y  
si g nifica nt b y t he i n vesti gat or. 
5. U n der g o ne si g nifica nt tra u ma or maj or s ur ger y wit hi n [ADDRESS_81980] or y  of a n gi oe de ma or a n a p h yl a xis t o t o pi[INVESTIGATOR_75506] o d ucts or k n o w n se nsiti vit y  
t o a n y  of t he c o m p o ne nts of t he i n vesti gati o nal pr o d ucts. 
8. Ot her me dical or ps y c hiatric c o n diti o n i ncl u di n g rece nt ( wit hi n t he past year) or 
acti ve s uici dal i deati o n /be ha vi or or la b orat or y  a b n or malit y  t hat m a y  i ncrease t he ris k 
of st u d y  partici pati o n or , i n t he i n vesti g at or’s j u d g me nt ,ma ke t he partici pa nt 
i na p pr o priate f or t he st u d y .
Pri or/ C o nc o mit a nt T her a p y: 
9. C urre nt use of a n y  pr o hi bite d c o nc o mita nt me dicati o n(s) or t h ose u n willi n g/ u na ble t o 
use a per mitt e d c o nc o mita nt me dicati o n(s). Refer t o Secti o n 6. 8 a n d Secti o n 1 0. 8 f or 
g ui da nce o n per mitte d a n d pr o hi bite d c o nc o mita nt me dicati o ns .
Pri or/ C o nc urre nt Cli nic al St u d y E x perie nce: 
[ADDRESS_81981] u g wit hi n 3 0 d a y s ( or as deter mi ne d 
b y  t he l ocal re q uire me nt) or [ADDRESS_81982] u d y ( w hic he ver is l o n ger). 
N ote : A n y  i n vesti gati o nal or e x peri me ntal t hera p y ta ke n or pr oce d ure perf or me d f or 
A D, Ps O , Ps A or R A i n t he pre vi o us ye ar s h o ul d be disc usse d wit h t he [COMPANY_007] m e dical 
mo nit or ( or desi g nee). Partici pa nts ca n n ot partici pate i n st u die s of ot her 
i n vesti gati o nal or e x peri me ntal t hera pi[INVESTIGATOR_75507] d ures at a n y ti me d uri n g t heir 
partici pati o n i n t his st u d y .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 4 7 Di a g n ostic Assess me nts: 
1 1. Partici pa nts wit h A N Y of t he f oll o wi n g a b n or malities i n cli nical la b orat or y  tests at 
Scree ni n g, as assesse d b y t he s p o ns or defi ne d la b orat or y  a n d c o nfir me d b y a si n gle 
re peat (t he last val ue will be use d t o deter mi ne eli gi bilit y ), if dee me d necessar y :
Re nal im pair me nt as defi ne d b y  a n e G F R of < 4 0 m L / mi n/ 1. 7 3 m 2calc ulate d usi n g 
t he ser u m creati ni ne -base d C K D -E PI  f or m ula f or a d ults a n d ser u m creati ni ne 
> 1. 5 x U L N i n a d olesce nts ( 1 2 -1 8 y ears ol d). 
He patic d ys f u ncti o n defi ne d as total bilir u bi n ≥2 x U L N ( ≥ 3 x U L N f or Gil bert’s 
disease) , A S T ≥ 2. 5 x U L N , A L T ≥2. [ADDRESS_81983] u d y res ults (e g, Q Tc Fi nter val 
> 4 5 0 msec, c o m plete L B B B, si g ns of a n ac ute or i n deter mi nate a ge m y ocar dial 
i nfarcti o n, S T - T i nter val c ha n ges s u g gesti ve of m y ocar dia l isc he mia, sec o n d or t hir d 
de gree A V bl oc k, or seri o us bra d yarr h yt h mias or tac h y arr h y t h mias). If t he baseli ne 
u nc orrecte d Q T i nter val is > 4 5 0 msec, t his i nter val s h o ul d be rate c orrecte d usi n g t he 
Fri dericia met h o d a n d t he res ulti n g Q Tc F s h o ul d be use d f o r decisi o n ma ki n g a n d 
re p orti n g. If Q Tc Fe xcee ds 4 5 0 msec, or Q R S e xcee ds 1 2 0 msec, t he E C G s h o ul d be 
re peate d 2 m ore ti mes a n d t he a vera ge of t he 3 Q Tc For Q R S val ues s h o ul d be use d 
t o deter mi ne t he partici pa nt’s eli gi bilit y . C o m p uter i nter prete d E C Gs s h o ul d be 
o verrea d b y a p h ys icia n e x perie nce d i n rea di n g E C Gs bef ore e xcl u di n g a partici pa nt. 
Ot her E xcl usi o ns: 
[ADDRESS_81984] yle C o nsi der ati o ns 
5. 3. 1. C o ntr ace pti o n 
T he i n vesti gat or or his or her desi g nee, i n c o ns ultati o n wit h t he partici pa nt, will c o nfir m t hat 
t he partici pa nt has selecte d a n a p pr o priate met h o d of c o ntrace pti o n f or t he i n di vi d ual 
partici pa nt a n d his or her part ner(s) fr o m t he per mitte d list of c o ntrace pti o n met h o ds ( see 
A p pe n di x 4 Secti o n 1 0. 4. 4 ) a n d will c o nfir m t hat t he partici pa nt has bee n i nstr ucte d i n its 
c o nsiste nt a n d c orrect use. At ti me p oi nts i n dicate d i n t he S o A , t he i n vesti gat or or desi g nee 
will i nf or m t he partici pa nt of t he nee d t o use acce pta ble effecti ve c o ntrace pti o n c o nsiste ntl y  
a n d c orrectl y a n d d oc u me nt t he c o n v ersati o n a n d t he partici pa nt’s affir mati o n i n t he 
partici pa nt’s c hart ( partici pa nts nee d t o affir m t heir c o nsiste nt a n d c orrect use of at least 1 of 
t he selecte d met h o ds of c o ntrace pti o n) c o nsi deri n g t hat t heir ris k f or pre g na nc y  ma y  ha ve 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_81985] t he 
partici pa nt t o call i m me diatel y  if t he selecte d c o ntrace pti o n met h o d is disc o nti n ue d or if 
pre g na nc y  is k n o w n or s us pecte d i n t he partici pa nt or part ner. 
5. 3. 2. Diet ar y S u p ple me nts 
F or t he p ur p oses of t his pr ot oc ol, dietar y s u p ple me nts are defi ne d as vita mi ns, mi nerals, 
p urifie d f o o d s u bsta nces, a n d her bals wit h p har mace utical pr o perties. Vita mi ns, mi nerals a n d 
p urifie d f o o d s u bsta nces are all o we d i n a m o u nts n ot k n o w n t o be ass ociat e d wit h a d verse 
effects (s uc h as h y p er vita mi n osis). Her bal s u p ple me nts are o nl y all o we d o n a case -b y -case 
basis; please c o ntact t he [COMPANY_007] staff. Her bals e g, St. J o h n’s W ort t hat are k n o w n t o ha ve a n 
effect o n dr u g meta b olis m m ust be disc o nti n ue d at least 4 wee ks or 5 half -li ves ( w hic he ver is 
l o n ger) bef ore Da y  1. 
5. 3. 3. Me dic ati o ns/ Tre at me nts Disc o nti n u ati o n, N o n -Me dic ate d E m ollie nts 
Partici pa nts are re q uire d t o disc o nti n ue a n d a v oi d usi n g certai n me dicati o ns a n d treat me nts as 
descri be d i n A p pe n di x 8 .
All t o pi[INVESTIGATOR_21041] o ns a n d treat me nts t hat c o ul d affect A D or Ps O s ki n areas m ust be 
disc o nti n ue d pri or t o Da y  1, as s pecifie d i n A p pe n di x [ADDRESS_81986] u d y  i nter ve nti o n . 
U nless s pecifie d i n A p pe n di x 8 , a n y  ot her c o nc o mita nt me dicati o n f or A D or Ps O 
will be c o nsi dere d o n a case- b y -case basis b y  t he i n vesti gat or i n c o ns ultati o n wit h t he 
s p o ns or me dical m o ni t or. 
Partici pa nts will st o p a p pl y i n g bla n d ( n o n -me dicate d , urea -a n d lactic aci d free -) 
e m ollie nt s a n d s u nscree n o n A D /Ps O affecte d s ki n 2 4 h o urs pri or t o Da y  1. 
After Da y  1 Visit, use of n o n- me dicate d bla n d e m ollie nt(s) is per mitte d d uri n g t he 
st u d y  t o ma na ge dr y  s ki n i n areas s urr o u n di n g b ut n ot o n or o verla p pi n g t he 
treata ble A D /Ps O affecte d s ki n areas , n or mal s ki n or areas w hic h were ne ver 
treate d wit h st u d y i nter ve nti o n (ie pal ms, s oles or nails f or Ps O ). A n y 
n o n -me dicate d e m ollie nt use d b y  t he partici pa nt d uri n g t he st u d y  s h o ul d be 
d oc u me nte d i n st u d y  rec or ds a n d t he C R F. 
D ue t o t he p ote ntial t o affect A D a n d Ps O wit h ultra vi olet li g ht e x p os ure, partici pa nts 
m ust a v oi d pr ol o n ge d e x p os ure t o t he s u n a n d a v oi d t he use of ta n ni n g b o ot hs, s u n 
la m ps or ot her ultra vi olet li g ht s o urces d uri n g t he st u d y . Please see A p pe n di x 8 f or 
details o n pr o hi bite d li g ht t hera p y. 
L o w or least p ote nt ( Class 6 or 7) t o pi[INVESTIGATOR_2855] c ortic o ster oi ds ( H y dr oc ortis o ne ≤ 1 % a n d 
h y dr oc ortis o ne acetate ≤ 1 %) are t he o nl y t o pi[INVESTIGATOR_2855] c ortic oster oi ds per mitte d f or t he 
treat me nt of areas ne ver treate d wit h I P (e g, pal ms, s oles, a n d fi n ger a n d t oe nails 
[ Ps O o nl y ]). Scal p tar pre parati o ns, salic y lic aci d pre p arati o ns a n d s ha m p o os free of 
c ortic oster oi ds are per mitte d f or t he treat me nt of scal p. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_81987] yle Re q uire me nts 
Partici pa nts s h o ul d n ot a p pl y  occl usi ve dressi n g(s) t o t he areas treate d wit h st u d y  
i nter ve nti o n .
Partici pa nts s h o ul d n ot s wi m, bat he, be bat he d or ha ve treat me nt areas was he d f or at 
least [ADDRESS_81988] u d y  i nter ve nti o n .
T he partici pa nt s h o ul d a v oi d wi pi n g t he st u d y  i nter ve nti o n off t he s ki n a n d t he st u d y  
i nter ve nti o n s h o ul d n ot be re -a p plie d t o areas t hat were i na d verte ntl y wi pe d u ntil t he 
ne xt sc he d ule d d ose. 
Partici pa nts will a gree t o a v oi d stre n u o us e xercise d uri n g t he st u d y, es peciall y  wit hi n 
[ADDRESS_81989] u d y  visits a n d mai ntai n a de q uate h y drati o n, if 
p ossi ble. 
O n st u d y  visit da y s, t he partici pa nts will n ot s m o ke or use nic oti ne -c o ntai ni n g 
pr o d ucts, or i n gest caffei ne (e g, tea, c offee, s o me s oft dri n ks/c olas/e ner g y  dri n ks a n d 
p o wer bars) d uri n g t he 2 h o urs pri or t o bl o o d press ure a n d p ulse ( heart) rate 
meas ure me nts. 
O n st u d y  visit da y s, s h o weri n g or bat hi n g is per mitte d pri or t o atte n di n g t he st u d y  
visit, b ut m oist urizi n g will n ot be d o ne. 
O n st u d y  visit da y s, prescri be d per mitte d c o nc o mita nt me dicati o n will be ta ke n, as 
nee de d. 
T he partici pa nts will c o ntact t he st u d y  site i n vesti gat or if t here are a n y c ha n ges or 
a d diti o ns t o c o nc o mita nt me dicati o ns. 
T he partici pa nts will a v oi d ha vi n g maj or electi ve s ur ger y  u ntil after t he fi nal st u d y  
assess me nts. 
T he partici pa nts s h o ul d c o nti n ue all n o n- p har mac ol o gical t hera pi[INVESTIGATOR_014], s uc h as p h y sical 
t hera p y, as i n dicate d. H o we ver, t he partici pa nts s h o ul d a v oi d c ha n gi n g t he t y pe or 
i nte nsit y  of t hera p y  or i nitiati n g ne w t hera p y  u ntil after Wee k 1 2 visit. 
W he n a p pl y i n g t he st u d y i nter ve nti o n , t he partici pa nt will n ot be re q uire d t o wear 
gl o ves. H o we ver, partici pa nts s h o ul d be i nstr ucte d t o was h t heir ha n ds wit h mil d s oa p 
a n d water bef ore a n d after eac h a p plicati o n. 
If st u d y  partici pa nts nee d s o me o ne else t o assist wit h a p pl y i n g st u d y  i nter ve nti o n o n 
har d -t o -reac h areas (e g , bac k), t his pers o n m ust wear gl o ves t o a v oi d acci de ntal 
e x p os ure t o t he st u d y  i nter ve nti o n .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_81990] u d y  (scree n fail ure) ma y  be 
re -scree ne d o nce if t he y  fail t he scree ni n g e val uati o n f or reas o ns relate d t o i nci de ntal 
tra nsit or y  c o n diti o ns, u nless t he reas o n f or t he scree n fail ure is t he disease se verit y i ncl usi o n 
criteria. Partici pa nts ma y n ot be rescree ne d u nless a p pr o ve d b y t he s p o ns or. As a n e xce pti o n, 
a partici pa nt w h o ot her wise q ualifie d f or t his st u d y  b ut di d n ot e nr oll d ue t o p ositi ve 
C O VI D -[ADDRESS_81991] be re peate d. Rescree ne d 
partici pa nts s h o ul d be assi g ne d a ne w partici pa nt n u m ber. 
6. S T U D Y I N T E R V E N TI O N( S ) A N D C O N C O MI T A N T T H E R A P Y 
St u d y  i nter ve nti o n is defi ne d as a n y  i n vesti gati o nal i nter ve nti o n (s), mar kete d pr o d uct(s), 
place b o, me dical de vice(s) , or st u d y  pr oce d ure(s) i nte n de d t o be a d mi nistere d t o a st u d y  
partici pa nt acc or di n g t o t he st u d y  pr ot oc ol. 
F or t he p ur p oses of t his pr ot oc ol, st u d y  i nter ve nti o n refers t o :
P F - 0 7 0 3 8 1 2 4 0. 0 1 % oi nt me nt; 
P F - 0 7 0 3 8 1 2 4 0. 0 3 % oi nt me nt; 
P F - 0 7 0 3 8 1 2 4 0. 0 6 % oi nt me nt ;
Ve hicle oi nt me nt ( place b o). 
6. 1. St u d y I nter ve nti o n(s) A d mi nistere d 
St u d y I nter ve nti o ns (s) 
I nter ve nti o n 
N a m eP F -0 7 0 3 8 1 2 4 
0. 0 1 % oi nt me nt P F -0 7 0 3 8 1 2 4 
0. 0 3% oi nt me nt P F -0 7 0 3 8 1 2 4 
0. 0 6% oi nt me nt P F -0 7 0 3 8 1 2 4 
ve hicle oi nt me nt 
A R M N a m e
( gr o u p of p atie nts 
recei vi n g a 
s pecific tre at m e nt 
( or n o tre at m e nt) Partici pa nts wit h 
mil d or m o derate 
A D, a n d mil d , 
m o derate ,or se vere 
Ps O Partici pa nts wit h 
mil d or m o derate 
AD, a n d mil d , 
m o derate , or se vere 
Ps O Partici pa nts wit h 
mil d , m o derate ,or 
se vere Ps O Partici pa nts wit h 
mil d or m o derate 
A D, a n d mil d , 
m o derate , or se vere 
Ps O 
T y pe Dr u g Dr u g Dr u g Dr u g 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_81992] u d y I nter ve nti o ns (s) 
D ose F or m ul ati o n Oi nt me nt Oi nt me nt Oi nt me nt Oi nt me nt 
U nit D ose 
Stre n gt h(s) 0. 1 m g/ g oi nt me nt 
i n 6 0 -gra m t u be 0. 3m g/ g oi nt me nt 
i n 6 0 -gra m t u be 0. 6m g/ g oi nt me nt 
i n 6 0 -gra m t u be 0 m g/ g oi nt me nt i n 
6 0 -gra m t u be 
D os a ge Le vel(s) 0. 0 1 % ( w t/ wt), Q D 0. 0 3% ( w t/ wt), Q D 0. 0 6% ( w t/ wt), Q D 0 % ( w t/ wt), Q D 
R o ute of 
A d mi nistr ati o n T o pi[INVESTIGATOR_2855] T o pi[INVESTIGATOR_2855] T o pi[INVESTIGATOR_2855] T o pi[INVESTIGATOR_75508] E x peri me ntal E x peri me ntal E x peri me ntal Place b o 
I M P or NI M P I M P I M P I M P I M P 
S o urci n g Pr o vi de d ce ntrall y 
b y t he s p o ns or. Pr o vi de d ce ntrall y 
b y t he s p o ns or. Pr o vi de d ce ntrall y 
b y t he s p o ns or. Pr o vi de d ce ntrall y 
b y t he s p o ns or. 
P ac k a gi n g a n d 
L a beli n g St u d y i nter ve nti o n 
will be pr o vi de d i n 
cart o ns. Eac h 
cart o n w ill c o ntai n 
o ne t u be. B ot h t he 
cart o n a n d t u be 
will be la bele d i n a 
bli n de d f or mat as 
re q uire d per 
c o u ntr y 
re q uire me nt. St u d y inter ve nti o n 
will be pr o vi de d i n 
cart o ns. Eac h 
cart o n w ill c o ntai n 
o ne t u be. B ot h t he 
ca rt o n a n d t u be 
will be la bele d i n a 
bli n de d f or mat as 
re q uire d per 
c o u ntr y 
re q uire me nt. St u d y inter ve nti o n 
will be pr o vi de d i n 
cart o ns. Eac h 
cart o n w ill c o ntai n 
o ne t u be. B ot h t he 
cart o n a n d t u be 
will be la bele d i n a 
bli n de d f or mat as 
re q uire d per 
c o u ntr y 
re q uire me nt. St u d y inter ve nti o n 
will be pr o vi de d i n 
cart o ns. Eac h 
cart o n w ill c o ntai n 
o ne t u be. B ot h t he 
cart o n a n d t u be 
will be la bele d i n a 
bli n de d f or mat as 
re q uire d per 
c o u ntr y 
re q uire me nt. 
P F - 0 7 0 3 8 1 2 4 oi nt me nt, 0. 1 m g/ g , 0. 3 m g/ g a n d 0. 6 m g/ g will be pr o vi de d as t he acti ve 
i n gre die nt wit h  
Ve hicle ( place b o, n o acti ve dr u g i n t he f or m ulati o n) oi nt me nt will be pr o vi de d as t he 
 
6. 1. 1. A d mi nistr ati o n 
A D treata ble areas will be all areas affecte d b y  A D, e xce pt hair -beari n g scal p .
Ps O treata ble areas will be all areas affecte d b y Ps O , e xce pt hair -beari n g scal p , pal ms, s oles, 
fi n ger nails, a n d t oe nails. 
A la y er of st u d y  i nter ve nti o n oi nt me nt will be a p plie d at a tar get a p plicati o n rate of 
a p pr o xi matel y  3 m g/c m 2b y  usi n g a fi n gerti p u nit met h o d. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_81993] u d y  i nt er ve nti o n a p plicati o n is perf or me d, t he 
desi g nate d areas f or treat me nt will be i de ntifie d a n d d oc u me nte d i n t he partici pa nt’s s o urce 
d oc u me nt st u d y  rec or ds ( b o d y  ma p). T he partici pa nt a n d/ or care gi ver will be pr o vi de d wit h a 
pa per versi o n of t he b o d y ma p. 
Partici pa nts a n d/ or care gi vers will be e nc o ura ge d t o o bser ve a n d partici pate i n t he i nitial 
st u d y  i nter ve nti o n a p plicati o n o n Da y  1. 
P ost Da y  [ADDRESS_81994] u d y  i nter ve nti o n s h o ul d 
be a p plie d o nce d ail y (ar o u n d sa me ti me of t he da y), t o all treata ble A D or Ps O i n v ol ve d 
areas i de ntifie d at t he Da y 1 visit as well as t o ne w areas i de ntifie d as “treata ble” d uri n g t he 
c o urse of 1 2 wee ks . All partici pa nts will be s u p plie d wit h i nstr ucti o ns o n a p plicati o n. 
N ote: A n y  ne w A D or Ps O areas i de ntifie d b y t he partici pa nt or care gi ver(s) s h o ul d 
als o be treate d wit h t he st u d y  i nter ve nti o n after assess me nt by t he investi g at or or 
his/ her desi g nee . A n u nsc he d ule d visit f or assess me nt of t he ne w lesi o n ma y  be 
re q uire d a t t he discreti o n of t he In vesti gat or. If t he ne w lesi o n is i de ntifie d as 
treata ble, t he n b o d y  ma p will be u p date d, a n d st u d y  i nter ve nti o n nee d will be 
re -assesse d .
T he st u d y  i nter ve nti o n will be a p plie d at h o me/resi de nce e xce pt o n t he da ys of i n -cli nic 
vi sits . O n t he d a ys of sc he d ule d i n -cli nic visit , p artici p a nts will be i nstr ucte d t o refr ai n 
fr o m a p pl yi n g t he st u d y i nter ve nti o n at h o me /resi de nce . T he last d ose of st u d y  
i nter ve nti o n will be a p plie d d uri n g t he Wee k 1 2 i n -cli nic visit ( E O T visit) as s pecifie d i n t he 
S o A .
N ote: If d ue t o p u blic e mer ge nc y , l ocal re g ulati o ns d o n’t all o w partici pa nt t o visit t he 
cli nic o n sc he d u le d visit da y s, t he partici pa nt will refrai n fr o m a p pl yi n g t he st u d y  
i nter ve nti o n u ntil selecte d assess me nts ca n be c o m plete d usi n g tele visit or h o me 
healt h visit. 
T he partici pa nt a n d/ or care gi ver will be i nstr ucte d t o c o m plete t he d osi n g diar y  secti o n of t he 
e- diar y , starti n g wit h t he first d ose a p plie d i n t he cli nic o n Da y  1 t hr o u g h Wee k 1 2 (eac h ti me 
st u d y  i nter ve nti o n is a p plie d). If a partici pa nt misses a p pl y i n g a d ose, t he partici pa nt s h o ul d 
a p pl y  t his d ose pr o vi de d t his d ose s h o ul d ha ve bee n a p plie d wit hi n t he last [ADDRESS_81995] a nti al 
i m pr o ve me nt or cle ari n g of A D or Ps O occ urs .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_81996] u d y  i nter ve nti o n a p plicati o n re gi me n be m o difie d 
(e g, fre q ue nc y  of a p plicati o n i ncrease d or re d uce d, n ot st o p pe d, or t he a p plicati o n rate [tar get 
3m g/c m 2] i ncrease d or re d uce d) d uri n g t he st u d y . Te m p orar y  disc o nti n uati o n of st u d y  
i nter ve nti o n ma y  be a p pr o priate u n der s o me circ u msta nces (e g, s ur ger y , n o n -seri o us 
i nfecti o ns) a n d s h o ul d be disc usse d wit h t he me dical m o nit or ( or desi g nee) prefera bl y pri or 
t o te m p orar y  disc o nti n uati o n of the st u d y  i nter ve nti o n .
St u d y  i nter ve nti o n a d mi nistrati o n details will be rec or de d o n t he C R F. 
6. 2. Pre p ar ati o n , H a n dli n g , St or a ge , a n d Acc o u nt a bilit y 
1. T he i n vesti gat or or desi g nee m ust c o nfir m a p pr o priate te m perat ure c o n diti o ns ha ve 
bee n mai ntai ne d d uri n g tra nsi t f or all st u d y  i nter ve nti o n srecei ve d a n d a n y 
discre pa ncies are re p orte d a n d res ol ve d bef ore use of t he st u d y  i nter ve nti o n. 
2. O nl y  partici pa nts e nr olle d i n t he st u d y  ma y  recei ve st u d y  i nter ve nti o n a n d o nl y  
a ut h orize d site staff ma y  s u p pl y  or a d mi nister st u d y  i nter ve nti o n. All st u d y  
i nter ve nti o n sm ust be st ore d i n a sec ure, e n vir o n me ntall y c o ntr olle d, a n d m o nit ore d 
( ma n ual or a ut o mate d rec or di n g ) area i n acc or da nce wit h t he la bele d st ora ge 
c o n diti o ns wit h access li mite d t o t he i n vesti gat or a n d a ut h orize d sit e staff. At a 
mi ni m u m, dail y  mi ni m u m a n d ma xi m u m te m perat ures f or all site st ora ge l ocati o ns 
m ust be d oc u me nte d a n d a vaila ble u p o n re q uest. Data f or n o n w or ki n g da y s m ust 
i n dicate t he mi ni m u m a n d ma xi m u m te m perat ures si nce pre vi o usl y d oc u me nte d f or 
all site st ora ge l ocati o ns u p o n ret ur n t o b usi ness. 
3. A n y  e xc ursi o ns fr o m t he st u d y  i nter ve nti o n la bel st ora ge c o n diti o ns s h o ul d be 
re p orte d t o [COMPANY_007] u p o n disc o ver y  al o n g wit h a n y acti o ns ta ke n. T he site s h o ul d 
acti vel y p urs ue o pti o ns f or ret ur ni n g t he st u d y i nter v e nti o n t o t he st ora ge c o n diti o ns 
descri be d i n t he la beli n g, as s o o n as p ossi ble. O nce a n e xc ursi o n is i de ntifie d, t he 
st u d y  i nter ve nti o n m ust be q uara nti ne d a n d n ot use d u ntil [COMPANY_007] pr o vi des per missi o n 
t o use t he st u d y  i nter ve nti o n. S pecific details re gar di n g t he defi niti o n of a n e xc ursi o n 
a n d i nf or mati o n t he site s h o ul d re p ort f or eac h e xc ursi o n will be pr o vi de d t o t he site 
i n t he I P ma n ual. 
4. A n y  st ora ge c o n diti o ns state d i n t he S R S D will be s u perse de d b y  t he st ora ge 
c o n diti o ns state d o n t he la bel. 
5. St u d y  i nter ve nti o ns s h o ul d be st ore d i n t heir ori gi nal c o ntai ners. 
6. Site staff will i nstr uct partici pa nts o n t he pr o per st ora ge re q uire me nts f or ta ke -h o me 
st u d y  i nter ve nti o n. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 5 4 7. T he i n vesti gat or, i nstit uti o n, or t he hea d of t he me dical i nstit uti o n ( w here a p plica ble) 
is res p o nsi ble f or st u d y i nter ve nti o n acc o u nta bilit y, rec o nciliati o n, a n d rec or d 
mai nte na nce (ie, recei pt, rec o nciliati o n, a n d fi nal dis p ositi o n rec or ds) , s uc h as t he 
I P A L or s p o ns or -a p pr o ve d e q ui vale nt . All st u d y  i nter ve nti o n s will be acc o u nte d f or 
usi n g a st u d y  i nter ve nti o n acc o u nta bilit y f or m/rec or d. All st u d y  i nter ve nti o n t hat is 
ta ke n h o me b y t he partici pa nt, b ot h use d a n d u n use d, m ust be ret ur ne d t o t he 
i n vesti gat or b y t he partici pa nt. Ret ur ne d st u d y i nter ve nti o n m ust n ot be re dis pe nse d 
t o t he partic i pa nts. 
8. F urt her g ui da nce a n d i nf or mati o n f or t he fi nal dis p ositi o n of u n use d st u d y  
i nter ve nti o ns are pr o vi de d i n t he I P ma n ual. All destr ucti o n m ust be a de q uatel y  
d oc u me nte d. If destr ucti o n is a ut h orize d t o ta ke place at t he i n vesti gat or site, t he 
i n vesti gat or m ust e ns ure t hat t he materials are destr o y e d i n c o m plia nce wit h 
a p plica ble e n vir o n me ntal re g ulati o ns, i nstit uti o nal p olic y , a n d a n y  s pecial i nstr ucti o ns 
pr o vi de d b y [COMPANY_007]. 
U p o n i de ntificati o n of a pr o d uct c o m plai nt, n otif y t he s p o ns or w it hi n [ADDRESS_81997] u d y  i nter ve nti o n rea d y  f or a p plicati o n or dis pe nsi n g t o t he partici pa nt/care gi ver b y 
q ualifie d st aff. 
Dis pe nsi n g is defi ne d as t he pr o visi o n of st u d y  i nter ve nti o n , c o nc o mita nt treat me nts, a n d 
acc o m pa n yi n g i nf or mati o n b y  q ualifie d staff me m ber(s) t o a healt hcare pr o vi der, partici pa nt, 
or care gi ver i n acc or da nce wit h t his pr ot oc ol. L ocal healt h a ut h orit y re g ulati o ns or 
i n vesti gat or site g ui deli nes ma y  use alter nati ve ter ms f or t hese acti vities. 
T he st u d y  i nter ve nti o n will be dis pe nse d i n a bli n de d fas hi o n usi n g a n I R T s y ste m at 
D a y 1/ Baseli ne, Wee k 1, Wee k 2, Wee k 4, Wee k 6, Wee k [ADDRESS_81998] u d y  visit sc he d ule a n d t he treata ble 
%B S A. 
F or d oses t o be a p plie d at h o me, t he partici pa nt or care gi ver s h o ul d be i nstr ucte d t o mai ntai n 
t he pr o d uct i n its ori gi nal pac ka ge pr o vi de d t hr o u g h o ut t he c o urse of d osi n g a n d ret ur n t he 
pr o d uct a n d its ori gi nal pac ka ge (i ncl u di n g e m pt y,  partial use d a n d u n use d t u bes) t o t he site 
at t he ne xt st u d y  visit. 
St u d y  i nter ve nti o n will be assi g ne d t o partici pa nts at t he Da y  [ADDRESS_81999] u d y  i nter ve nti o n 
dis pe nsi n g visits t o e nter i nf or mati o n i ncl u di n g, b ut n ot li mite d t o ,% affecte d B S A ,hei g ht , 
a n d wei g ht t o recei ve c orrect t u be n u m bers t o be dis pe nse d t o t he partici pa nt. Alter nati vel y , 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82000] u d y  
sites ma y  be pr o vi de d b y t he s p o ns or. 
T he calc ulati o n of treata ble %B S A is descri be d i n Secti o n [ADDRESS_82001] u g acc o u nta bilit y  f or m/rec or d. All t u bes of t he st u d y  i nter ve nti o n m ust be 
ret ur ne d t o t he i n vesti gat or b y  t he partici pa nt at e ver y  visit a n d at t he e n d of t he trial. 
T he partici pa nt wil l be as ke d t o bri n g all dis pe nse d st u d y  i nter ve nti o n (i ncl u di n g e m pt y, 
partiall y  use d a n d u n use d t u bes) at e ver y  visit; partici pa nts will be as ke d t o bri n g e- diar y  t o 
t he cli nic at e ver y  cli nic visit. All pre vi o usl y  dis pe nse d st u d y  i nter ve nti o n t u bes will be 
retai ne d b y t he site. F or eac h partici pa nt, st u d y  i nter ve nti o n t u bes wit h ca ps will be wei g he d 
i n di vi d uall y  b y  t he st u d y  site bef ore dis pe nsi n g a n d after ret ur n a n d t he wei g hts will be 
rec or de d. T he s p o ns or will use t he rec or de d wei g hts t o esti mate usa g e 
(e g, m g/c m 2/a p plicati o n) f or eac h partici pa nt. N ote t hat t he wei g ht rec or de d o n t he st u d y  
i nter ve nti o n la bel is a n o mi nal wei g ht a n d n ot a n e xact wei g ht of t he st u d y i nter ve nti o n a n d 
t u be. Detaile d dr u g acc o u nta bilit y  rec or ds, i ncl u di n g t u be wei g hts meas ure d i n t he cli nic, 
will be mai ntai ne d b y  st u d y  staff f or eac h partici pa nt. 
T he ori gi nal st u d y  i nter ve nti o n acc o u nta bilit y  l o g, or e q ui vale nt d oc u me nt, m ust be 
acc uratel y c o m plete d, si g ne d b y t he in vesti gat or, a n d retai ne d at t he st u d y s ite ( wit h a c o p y 
s u p plie d t o t he sp o ns or) w he n t he st u d y is c o m plete. 
6. 2. 3. Destr u cti o n of St u d y I nter ve nti o n S u p plies 
F or all st u d y  i nter ve nti o n ret ur ne d t o t he i n vesti gat or b y  t he partici pa nt, t he i n vesti gat or will 
mai n tai n t he ret ur ne d s u p pl y u ntil destr ucti o n is a ut h orize d. 
T he s p o ns or or desi g nee will pr o vi de g ui da nce o n t he destr ucti o n of u n use d st u d y  
i nter ve nti o n (e g, at t he site). If destr ucti o n is a ut h orize d t o ta ke place at t he i n vesti gat or site, 
t he i n vesti gat or m ust e ns ure t hat t he materials are destr o ye d i n c o m plia nce wit h a p plica ble 
e n vir o n me ntal re g ulati o ns, i nstit uti o nal p olic y , a n d a n y  s pecial i nstr ucti o ns pr o vi de d b y  
[COMPANY_007], a n d all destr ucti o n m ust be a de q uatel y d oc u me nte d. 
F urt her g ui da nce a n d i nf or mati o n f or t he fi nal dis p ositi o n of u n use d st u d y  i nter ve nti o ns are 
pr o vi de d i n t he I P ma n ual. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 5 6 6. 3. Me as ures t o Mi ni mize Bi as: R a n d o miz ati o n a n d Bli n di n g 
6. 3. 1. All oc ati o n t o St u d y I nter ve nti o n 
All ocati o n of partici pa nts t o treat me nt gr o u ps will pr ocee d t hr o u g h t he use of a n I R T s ys te m 
(I W R). T he site pers o n nel (st u d y  c o or di nat or or s pecifie d desi g nee) will be re q uire d t o e nter 
or select i nf or mati o n i ncl u di n g b ut n ot li mite d t o t he user’s I D a n d pass w or d, t he pr ot oc ol 
n u m ber, a n d t he partici pa nt n u m ber. T he site pers o n nel will t he n be pr o vi de d wit h a 
treat me nt assi g n me nt, ra n d o mizati o n n u m ber, a n d D U or c o ntai ner n u m ber w he n st u d y  
i nter ve nti o n is bei n g s u p plie d via t he I R T s ys te m. T he I R T s y ste m w ill pr o vi de a 
c o nfir mati o n re p ort c o ntai ni n g t he partici pa nt n u m ber, ra n d o mizati o n n u m ber, a n d D U or 
c o ntai ner n u m ber assi g ne d. T he c o nfir mati o n re p ort m ust be st ore d i n t he site’s files. 
St u d y  i nter ve nti o n will be dis pe nse d at t he st u d y visits s u m marize d i n t he S o A . 
Ret ur ne d st u d y  i nter ve nti o n m ust n ot be re- dis pe nse d t o t he partici pa nts. 
T he st u d y -s pecific I R T refere nce ma n ual a n d I P ma n ual will pr o vi de t he c o ntact i nf or mati o n 
a n d f urt her details o n t he use of t he I R T s ys te m. 
6. 3. 2. Bre a ki n g t he Bli n d 
T he I R T will be pr o gra m me d wit h bli n d -brea ki n g i nstr ucti o ns. I n case of a n e mer ge nc y , t he 
i n vesti gat or has t he s ole res p o nsi bilit y  f or deter mi ni n g if u n bli n di n g of a partici pa nt’s 
treat me nt assi g n me nt is warra nte d. Partici pa nt safet y m ust al wa y s be t he first c o nsi derati o n 
i n ma ki n g s uc h a deter mi nati o n. If t he i n vesti gat or deci des t hat u n bli n di n g is warra nte d, t he 
i n vesti gat or s h o ul d ma ke e ver y  eff ort t o c o ntact t he s p o ns or pri or t o u n bli n di n g a 
partici pa nt’s treat me nt assi g n me nt u nless t hi s c o ul d dela y  f urt her ma na ge me nt of t he 
partici pa nt. If a partici pa nt’s treat me nt assi g n me nt is u n bli n de d, t he s p o ns or m ust be n otifie d 
wit hi n [ADDRESS_82002] u d y  i nter ve nti o n will be assesse d o n visits i de ntifie d i n t he 
S o A . C o m plia nce will be assess e d b y re vie w of t he partici pa nt/care gi ver c o m plete d d osi n g 
diar y  secti o n of t he e -diar y  a n d t h or o u g h re vie w of d osi n g i nstr ucti o ns at e ver y visit . T he 
differe nce i n wei g ht(s) of t he ret ur ne d st u d y  i nter ve nti o n t u bes will be use d t o esti mate t he 
d oses a p pli e d at t he e n d of t he st u d y . S o urce d oc u me nts will be place d i n t he partici pa nt’s 
st u d y  file. De viati o n(s) fr o m t he prescri be d d osa ge re gi me n s h o ul d be rec or de d i n t he C R F. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82003] u d y  
i nter ve nti o n less t ha n 8 0 % i n a wee k or m ore t ha n 1 2 0 % of st u d y  i nter ve nti o n a p plicati o ns. I f 
n o n-c o m plia nce is i de ntifie d, or e ve n if a fe w d ose a p plicati o ns are misse d or o ver- a p plie d 
(as i nf or me d b y t he partici pa nt t o t he site staff) , t he n, partici pa nts will be re -trai ne d o n t he 
i m p orta nce a n d t he pr ocess of pr o per st u d y  i nter ve nti o n a p plicati o n. If n o n -c o m plia nce 
persists, t he i n vesti gat or, i n c o ns ultati o n wit h t he s p o ns or , ma y  wit h dra w a n y  partici pa nt 
fr o m t he st u d y  f or reas o ns of n o n -c o m plia nce wit h t he d osi n g re gi me n. I n vesti gat ors s h o ul d 
i n dicate o n t he a p pr o priate C R F pa ge n o nc o m plia nce wit h st u d y  i nter ve nti o n a n d pr o vi de a n 
e x pla nati o n. 
I n ve nt or y  c o ntr ol of all st u d y  i nter ve nti o n m ust be ri g or o usl y mai ntai ne d t hr o u g h o ut t he 
d urati o n of t he st u d y  u ntil all me dicati o n has bee n acc o u nte d f or a n d/ or ret ur ne d t o t he 
s p o ns or. A n y  discre pa ncies n ote d bet wee n dr u g dis pe nsi n g rec or ds a n d t he dr u g i n ve nt or y  
m ust be re p orte d t o [COMPANY_007]. 
6. 5. D ose M o dific ati o n 
N ot a p plica ble. 
6. 6. C o nti n ue d Access t o St u d y I nter ve nti o n After t he E n d of t he St u d y 
N o i nter ve nti o n will be pr o vi de d t o st u d y  partici pa nts at t he e n d of t heir st u d y partici pati o n .
6. 7. Tre at me nt of O ver d ose 
F or t his st u d y , a n y  d ose of st u d y  i nter ve nti o n greater t ha n 1 d ose wit hi n a 1 2 - h o ur ti me 
peri o d will be c o nsi de re d a n o ver d ose.  
I n vesti gat ors s h o ul d be a ware t hat a d mi nistrati o n t o si g nifica ntl y greater area ma y  als o be 
treate d as a n o ver d ose at in vesti gat or discreti o n. 
T he s p o ns or d oes n ot rec o m me n d s pecific treat me nt f or a n o ver d ose. 
I n t he e ve nt of a n o ver d ose , t he i n vesti gat or s h o ul d: 
1. C o ntact t he me dical m o nit or wit hi n 2 4 h o urs. 
2. Cl osel y  m o nit or t he partici pa nt f or a n y A Es/ S A Es a n d la b orat or y  a b n or malities f or at 
least [ADDRESS_82004] u d y  i nter ve nti o n. 
3. D oc u me nt t he q ua ntit y of t he e xces s d ose as well as t he d urati o n of t he o ver d ose i n 
t he C R F. 
4. O ver d ose is re p orta ble t o [COMPANY_007] Safet y  o nl y w he n ass ociate d wit h a n S A E. 
 
 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82005] o p dates of 
a d mi nistrati o n. Partici pa nts will be q uerie d a b o ut c o nc o mita nt me dicati o n (i ncl u di n g t o pi[INVESTIGATOR_75509] o ns a n d treat me nts, o ver t he c o u nter a n d prescri pti o n me dicati o ns a n d treat me nts, 
a n d vacci nati o ns) at eac h visit. A n y  ne w c o nc o mit a nt me dicati o ns or d ose c ha n ges t o c urre nt 
c o nc o mita nt me dicati o ns s h o ul d be e val uate d f or p ote ntial ne w or w orse ni n g A Es. 
Refer t o A p pe n di x [ADDRESS_82006] u d y  are all o we d t o be use d i n 
partici pa nts w h o are W O C B P (see A p pe n di x 4 ). 
Me dicati o ns f or ot her sta ble c hr o nic me dical c o n diti o ns are per mitte d d uri n g t he st u d y u nless 
t he me dicati o n/t hera p y is s pecificall y pr o hi bite d b y t he pr ot oc ol or is e x pecte d t o affect t he 
st u d y  assess me nts. N o nster oi dal a nti- i nfla m mat or y  dr u gs are all o we d t hr o u g h o ut t he st u d y . 
R o uti ne pre ve ntati ve i m m u niz ati o ns are per mitte d d uri n g t he st u d y;  h o we ver, it is preferre d 
t hat i m m u nizati o ns be a d mi nistere d at least [ADDRESS_82007] u d y . Vacci nes use d i n t he e ve nt of a disease o ut brea k or 
pa n de mic are all o we d .
6. 8. 1. Resc ue Me dici ne 
T here is n o resc ue t hera p y t o re verse t he A Es o bser ve d wit h P F - 0 7 0 3 8 1 2 4; sta n dar d me dical 
s u p p orti ve care m ust be pr o vi de d t o ma na ge t he A Es. 
7. DI S C O N TI N U A TI O N O F S T U D Y I N T E R V E N TI O N A N D P A R TI CI P A N T 
DI S C O N TI N U A TI O N/ WI T H D R A W A L 
7. 1. Disc o n ti n u ati o n of St u d y I nter ve nti o n 
It ma y  be necessar y  f or a partici pa nt t o per ma ne ntl y  disc o nti n ue st u d y  i nter ve nti o n .Reas o ns 
f or per ma ne nt disc o nti n uati o n of st u d y  i nter ve nti o n i ncl u de t he f oll o wi n g :Li ver i nj ur y , E C G 
c ha n ges, pre g na nc y , l ocal t olera bilit y , a n d A Es .
N ote t hat disc o nti n uati o n of st u d y  i nter ve nti o n d oes n ot re prese nt wit h dra wal fr o m t he st u d y. 
If st u d y i nter ve nti o n is per ma ne ntl ydisc o nti n ue d, t he partici pa nt will re mai n i n t he st u d y  t o 
be e val uate d f or safet y. See t he S o A f or data t o be c ollecte d at t he ti me of disc o nti n uati o n of 
st u d y  i nter ve nti o n a n d f oll o w -u p f or a n y f urt her e val uati o ns t hat nee d t o be c o m plete d. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82008] be d oc u me nte d o n t he 
a p pr o pr iate C R F/i n t he me dical rec or ds w het her t he partici pa nt is disc o nti n ui n g f urt her 
recei pt of st u d y i nter ve nti o n or als o fr o m st u d y  pr oce d ures, p osttreat me nt st u d y  f oll o w - u p, 
a n d/ or f ut ure c ollecti o n of a d diti o nal i nf or mati o n. 
7. 1. 1. Li ver I nj ur y 
Please refer t o Secti o n [ADDRESS_82009] u g -I n d uce d Li ver I nj ur y ( DI LI; H y ’s 
la w). 
7. 1. 2. E C G C h a n ges 
A partici pa nt w h o meets eit her b ullete d c riteri abase d o n t he a vera ge of tri plicate E C G 
rea di n gs will be wit h dra w n fr o m t he st u d yi nter ve nti o n . 
Q Tc F > 5 0 0 ms ec .
C ha n ge fr o m baseli ne: Q Tc F> 6 0 ms ec a n d Q Tc F > 4 5 0 msec .
If a cli nicall y  si g nifica nt fi n di n g is i de ntifie d (i ncl u di n g, b ut n ot li mite d t o ,c ha n ges fr o m 
baseli ne i n Q T c F after e nr oll me nt ), t he i n vesti gat or or q ualifie d desi g nee will deter mi ne if 
t he partici pa nt ca n c o nti n ue i n t he st u d y  a n d if a n y c ha n ge i n partici pa nt ma na ge me nt is 
nee de d. T his re vie w of t he E C G pri nte d at t he ti me of c olle cti o n m ust be d oc u me nte d. A n y 
ne w cli nicall y rele va nt fi n di n g s h o ul d be re p orte d as a n A E. 
7. 1. 3. Pre g n a nc y 
Pre g na nc y  c o nfir me d b y  ser u m -h C G testi n g. sp o ns or cli nicia n or sp o ns or me dical m o nit or 
s h o ul d be n otifie d i m me diatel y . 
T w o ne gati ve pre g na nc y  tests are re q uire d bef ore ra n d o mizati o n ( [ADDRESS_82010] at Da y 1 visit). I f uri ne 
pre g na nc y  test is p ositi ve after st u d y  i nter ve nti o n a p plicati o n, ser u m pre g na nc y  test will be 
c o n d ucte d, st u d y i nter v e nti o n a p plicati o n pa use d a n d s p o ns or cli nicia n or s p o ns or me dical 
mo nit or n otifie d i m me diatel y .
7. 1. 4. L oc al T oler a bilit y 
If a partici pa nt e x perie nces se verit y Gra de 3 (se vere) or 4 ( ver y  se vere) o n t he l ocal 
t olera bilit y  assess me nt ( Secti o n 8. 2. 7 ), st u d y  treat me nt will be disc o nti n ue d per ma ne ntl y, a n d 
partici pa nt will pr ocee d t o E T visit a n d f oll o w- u p as descri be d i n S o A . 
If a partici pa nt e x perie nces a p plicati o n site reacti o n of Gra de 2 ( m o derate) o n t he l ocal 
t olera bilit y  assess me nt, i n vesti gat or ma y  te m p oraril y  disc o nti n ue a p plicati o n of st u d y  
i nter ve nti o n f or u p t o [ADDRESS_82011] u d y  i nter ve nti o n i nterr u pti o n f or m ore t ha n 5 c o nsec uti ve da y s is 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 6 0 nee de d, t he n t he partici pa nt s h o ul d be per ma ne ntl y wit h dra w n fr o m treat me nt a n d s h o ul d 
f oll o w u p wit h t he site u ntil c o m plete or near c o m plete res ol uti o n of t he A E. T his d osi n g ga p 
ma y  occ ur o nl y o nce f or t he sa me partici pa nt. 
7. 1. 5. A Es 
H y perse nsiti vit y  Reacti o ns: I f si g ns a n d s y m pt o ms of h y perse nsiti vit y  are attri b uta ble t o t he 
i n vesti gati o nal pr o d uct, i ncl u di n g c o ntact urticaria, it m ust be disc o nti n ue d i m me diatel y , a n d 
a p pr o priate t hera p y i nitiat e d. 
7. 1. 6. Te m p or ar y Disc o nti n u ati o n 
Te m p orar y  disc o nti n uati o ns of st u d y  i nter ve nti o n :
Will occ ur i n cases of p ositi ve uri ne pre g na nc y  test w hic h if c o nfir me d b y ser u m 
pre g na nc y  test will lea d t o per ma ne nt disc o nti n uati o n ( Secti o n 7. 1 ). 
Ma y  a p pl y i n s o me cases of a p plicati o n site reacti o n d uri n g l ocal t olera bilit y  
assess me nts ( Secti o n 8. 2. 7 ). 
A d diti o nal i nsta nces of te m p orar y  disc o nti n uati o n ma y  be a p pr o priate (e g, s ur ger y , 
i nfecti o n, etc). 
All te m p orar y  disc o nti n uati o ns s h o ul d be disc usse d wit h s p o ns or cli nicia n or s p o ns or 
me dical m o nit or t o deter mi ne if partici pa nt ma y  c o nti n ue i n t he st u d y . If p ossi ble, site will 
c o ns ult t he s p o ns or pri or t o te m p orar y  disc o nti n uati o n. 
7. 2. P artici p a nt Disc o nti n u ati o n/ Wit h dr a w al F r o m t he St u d y 
A partici pa nt ma y  wit h dra w fr o m t he st u d y  at a n y ti me at his/ her o w n re q uest . Reas o ns f or 
disc o nti n uati o n fr o m t he st u d y  m a y  i ncl u de t he f oll o wi n g: 
Ref use d f urt her st u d y  pr oce d ures ;
L ost t o f oll o w - u p; 
Deat h ;
St u d y  ter mi nate d b y  s p o ns or .
At t he ti me of disc o nti n ui n g fr o m t he st u d y, if p ossi bl e, a n earl y disc o nti n uati o n visit s h o ul d 
be c o n d ucte d .See t he S o A f or assess me nts t o be c ollecte d at t he ti me of st u d y  
disc o nti n uati o n a n d f oll o w- u p a n d f or a n y f urt her e val uati o ns t hat nee d t o be c o m plete d. 
T he earl y  disc o nti n uati o n visit a p plies o nl y  t o partici pa nts w h o are e nr olle d/ ra n d o mize d a n d 
t he n are pre mat urel y wit h dra w n fr o m t he st u d y .Partici pa nts s h o ul d be q uesti o ne d re gar di n g 
t heir reas o n f or wit h dra wal. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82012] u d y , he/s he ma y  re q uest destr ucti o n of a n y  re mai ni n g 
sa m ples ta ke n a n d n ot teste d ,a n d the i n vesti gat or m ust d oc u me nt a n y  s uc h re q uests i n t he 
site st u d y  rec or ds a n d n otif y  t he s p o ns or acc or di n gl y .
If t he partici pa nt wit h dra ws fr o m t he st u d y  a n d als o wit h dra ws c o nse nt (see Secti o n 7. 2. 1 ) 
f or discl os ure of f ut ure i nf or mati o n, n o f urt her e val uati o ns s h o ul d be perf or me d a n d n o 
a d diti o nal data s h o ul d b e c ollecte d. T he s p o ns or ma y retai n a n d c o nti n ue t o use a n y  data 
c ollecte d bef ore s uc h wit h dra wal of c o nse nt. 
7. 2. 1. Wit h dr a w al of Co nse nt 
Partici pa nt s w h o re q uest t o disc o nti n ue recei pt of st u d y  i nter ve nti o n will re mai n i n t he st u d y  
a n d m ust c o nti n ue t o be f oll o we d f or pr ot oc ol -s pecifie d f oll o w - u p pr oce d ures. T he o nl y 
e xce pti o n t o t his is w he n a partici pa nt s pecificall y wit h dra ws c o nse nt f or a n y f urt her c o ntact 
wit h hi m or her or pers o ns pre vi o usl y  a ut h orize d b y  t he partici pa nt t o pr o vi de t his 
i nf or mati o n. Partici pa nt s s h o ul d n otif y  t he i n vesti gat or i n writi n g of t he decisi o n t o wit h dra w 
c o nse nt fr o m f ut ure f oll o w - u p, w he ne ver p ossi ble. T he wit h dra wal of c o nse nt s h o ul d be 
e x plai ne d i n detail i n t he me dical rec or ds b y t he i n vesti gat or, as t o w het her t he wit h dr a wal is 
o nl y  fr o m f urt her recei pt of st u d y  i nter ve nti o n or als o fr o m st u d y  pr oce d ures a n d/ or 
p osttreat me nt st u d y  f oll o w -u p, a n d e ntere d o n t he a p pr o priate C R F pa ge. I n t he e ve nt t hat 
vital stat us ( w het her t he partici pa nt is ali ve or dea d) is bei n g meas ure d , p u blicl y  a vaila ble 
i nf or mati o n s h o ul d be use d t o deter mi ne vital stat us o nl y  as a p pr o priatel y directe d i n 
acc or da nce wit h l ocal la w. 
7. 3. L ost t o F ol l o w - U p 
A partici pa nt will be c o nsi dere d l ost t o f oll o w- u p if he or s he re peate dl y fails t o ret ur n f or 
sc he d ul e d visits a n d is u na ble t o be c o ntacte d b y t he st u d y  site. 
T he f oll o wi n g acti o ns m ust be ta ke n if a partici pa nt fails t o ret ur n t o t he cli nic f or a re q uire d 
st u d y  visit: 
T he site m ust atte m pt t o c o ntact t he partici pa nt a n d resc he d ule t he misse d visit as 
s o o n as p ossi ble . C o u nsel t he partici pa nt o n t he i m p orta nce of mai ntai ni n g t he 
assi g ne d visit sc he d ule, a n d ascertai n w het her t he partici pa nt wis hes t o a n d/ or s h o ul d 
c o nti n ue i n t he st u d y ;
Bef ore a partici pa nt is dee me d l ost t o f oll o w- u p, t he i n vesti gat or or desi g nee m ust 
ma ke e ver y  eff ort t o re gai n c o ntact wit h t he partici pa nt ( w here p ossi ble, 3 tele p h o ne 
calls a n d, if necessar y , a certifie d letter t o t he partici pa nt’s last k n o w n maili n g 
a d dress or l ocal e q ui vale nt met h o ds). T hese c o ntact atte m pts s h o ul d be d oc u me nte d 
i n t he partici pa nt’s me dical rec or d ;
S h o ul d t he partici pa nt c o nti n ue t o be u nreac ha ble, he/s he will be c o nsi dere d t o ha ve 
wit h dra w n fr o m t he st u d y. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 6 2 8. S T U D Y A S S E S S M E N T S A N D P R O C E D U R E S 
T he i n vesti gat or ( or a n a p pr o priate dele gate at t he i n vesti gat or site) m ust o btai n a si g ne d a n d 
date d I C D /asse nt bef ore perf or mi n g a n y st u d y- s pecific pr oce d ures.   
St u d y  pr oce d ures a n d t heir ti mi n g are s u m marize d i n t he S o A . Pr ot oc ol wai vers or 
e xe m pti o ns are n ot all o we d. 
Safet y  iss ues s h o ul d be disc usse d wit h t he s p o ns or i m me diatel y  u p o n occ urre nce or 
a ware ness t o deter mi ne w het her t he partici pa nt s h o ul d c o nti n ue or disc o nti n ue st u d y  
i nter ve nti o n. 
A d here nce t o t he st u d y  desi g n re q uire me nts, i ncl u di n g t h ose s pecifie d i n t he S o A , is esse ntial 
a n d re q uire d f or st u d y c o n d uct. 
All scree ni n g e val uati o ns m ust be c o m plete d a n d re vie we d t o c o nfir m t hat p ote ntial 
partici pa nts meet all eli gi bilit y  criteria. T he i n vesti gat or will mai ntai n a scree ni n g l o g t o 
rec or d details of all partici pa nts scree ne d a n d t o c o nfir m eli gi bilit y  or rec or d reas o ns f or 
scree ni n g fail ure, as a p plica ble. 
E ver y  eff ort s h o ul d be ma de t o e ns ure t hat pr ot oc ol -re q uire d tests a n d pr oce d ures are 
c o m plete d as descri be d .H o we ver, it is a ntici pate d t hat fr o m ti me t o ti me t here ma y  be 
circ u msta nces o utsi de t he c o ntr ol of t he i n vesti gat or t hat ma y  ma ke it u nfeasi ble t o perf or m 
t he test. I n t hese cases, t he i n vesti gat or m ust ta ke all ste ps necessar y  t o e ns ure t he safet y a n d 
well -bei n g of t he partici pa nt . W he n a pr ot oc ol -re q uire d test ca n n ot be perf or me d, t he 
i n vesti gat or will d oc u me nt t he reas o n f or t he misse d test a n d a n y c orrecti ve a n d pre ve nti ve 
acti o ns t hat he or s he has ta ke n t o e ns ure t hat re q uire d pr ocesses are a d here d t o as s o o n as 
p ossi ble. T he st u d y  tea m m ust be i nf or me d of t hese i nci de nts i n a ti mel y  ma n ner. 
F or sa m ples bei n g c ollecte d a n d s hi p pe d, detaile d c ollecti o n, pr ocessi n g, st ora ge, a n d 
s hi p me nt i nstr ucti o ns a n d c o ntact i nf or mati o n will be pr o vi de d t o t he i n v esti gat or site pri or 
t o i nitiati o n of t he st u d y .
T he t otal bl o o d sa m pli n g v ol u me f or i n di vi d ual partici pa nt s i n t his st u d y  is a p pr o xi matel y  
[ADDRESS_82013] u d y i nter ve nti o n .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 6 3 8. 1. 1. 1. P h ysici a n Assess me nt s
8. 1. 1. 1. 1. I G A 
T he I G A of A D is sc ore d o n a 5- p oi nt scale ra n gi n g fr o m 0 (clear) t o 4 (se vere), reflecti n g a 
gl o bal c o nsi derati o n of t he er y t he ma, i n d urati o n a n d scali n g. T he cli nical e val uat or of A D 
will perf or m a n assess me nt of t he o verall se verit y of A D a n d assi g n a n I G A sc ore a n d 
cate g or y  as descr i be d i n Secti o n 1 0. 1 2. 1. 1 (A p pe n di x 1 2 ). T he assess me nt will be a static 
e val uati o n wit h o ut re gar d t o t he sc ore at a pre vi o us visit. 
8. 1. 1. 1. 2. E A SI 
T he E A SI q ua ntifies t he se verit y of a partici pa nt’s A D base d o n b ot h se verit y  of lesi o n b y 
cli nical si g ns a n d t he perce nt of B S A affecte d. E A SI  is a c o m p osite sc ori n g of t he de gree of 
er yt he ma, i n d urati o n/ pa p ulati o n, e xc oriati o n, a n d lic he nificati o n (eac h sc ore d se paratel y) f or 
eac h of f o ur b o d y  re gi o ns, wit h a dj ust me nt f or t he perce nt of B S A i n v ol ve d f or eac h b o d y  
re gi o n a n d f or t he pr o p orti o n of t he b o d y  re gi o n t o t he w h ole b o d y .8T he cl i nical e val uat or of 
A D will perf or m a n assess me nt of se verit y a n d area i n v ol ve d as descri be d i n 
Secti o n 1 0. 1 2. 1. 2 (A p pe n di x 1 2 ).
8. 1. 1. 1. 3. B S A 
Assess me nt of B S A f or efficac y  is perf or me d se paratel y f or f o ur areas of t he b o d y: 
Hea d , i ncl u di n g nec k a n d face b ut excl u di n g hair -beari n g scal p; 
Tr u n k , i ncl u di n g a xillae a n d gr oi n; 
U p per li m bs ; 
Lo wer li m bs , i ncl u di n g b utt oc ks. 
T he perce nta ge s urface area affecte d b y A D is esti mate d b y  mea ns of t he “ ha n d pri nt 
met h o d”, w here t he f ull ha n d of t he partici pa nt (ie, t he partici pa nt’s f ull y  e xte n de d pal m, 
fi n gers a n d t h u m b t o get her) re prese nts a p pr o xi matel y  1 % of t he t otal B S A. 
T he cli nical e val uat or of A D will perf or m a n assess me nt of t he % B S A as descri be d i n 
Secti o n 1 0. 1 2. 1. 3 (A p pe n di x 1 2 ). 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82014] u d y  i nter ve nti o n d ose is a p plie d ,prefera bl y at t he sa me ti me of eac h da y, 
as n ote d i n t he S o A . All partici pa nts will c o m plete t he q uesti o n n aire at t he f oll o w -u p visit i n 
cli nic .
N ote t hat t he a vera ge of 7 da y s ( mi ni m u m of 4 da y s) of P P -N R S sc ores i m me diatel y  
prece di n g ra n d o mizati o n will be use d t o calc ulate t he baseli ne a vera ge sc ore a n d assess 
eli gi bilit y , as i n Secti o n 5. 1 .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 6 5 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 6 6  
 
T he P P -N R S a n d  q uesti o n naire swill be c o m plete d at t he partici pa nts’ 
h o me /resi de nce , usi n g t he e-diar y  pr o vi de d b y s p o ns or . T he P P -N R S will be 
c o m plete d o nl y  b y  partici pa nts [ADDRESS_82015] u d y  i nter ve nti o n d ose is a p plie d, prefera bl y at t he sa me ti me of eac h da y, 
as n ote d i n t he S o A .All a d ult ( 1 8 -7 5 y ears ol d at Scree ni n g) partici pa nts will c o m plete t he 
q uesti o n naire at t he f oll o w -u p visit i n -cli nic .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
C CI C CI 
C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 6 7 8. 1. 3. R ater Q u alific ati o ns 
F or s pecific rati n g assess me nts, o nl y  q ualifie d raters will be all o we d t o e val uate a n d/ or rate 
partici pa nts i n t his st u d y . T he mi ni m u m q ualificati o ns a rater m ust meet f or eac h st u d y  rati n g 
assess me nt will be o utli ne d i n t he Rater Assess me nt G ui de or Rater Q ualificati o n Pla n . T he 
le vel of e x perie nce wit h t he tar get p o p ulati o n ( or e q ui vale nt), s pecific scale e x perie nce ( or 
e q ui vale nt), a n d certificati o n re q uire d (if a p plica ble) will be liste d a n d use d t o deter mi ne 
w het her a rater is a p pr o ve d f or a gi ve n assess me nt. 
T o ass ure c o nsiste nc y a n d re d uce v ari a bilit y, t he s a me e v al u at or s h o ul d assess all 
der m at ol o gic al cli nic al e v al u ati o ns f or a n y i n di vi d u al p artici p a nt t hr o u g h o ut t he st u d y 
w he ne ver p ossi ble .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 6 8 A bac k u p e x perie nce d a n d q ualifie d pr ot oc ol -trai ne d e val uat or will o nl y  be all o we d 
a n d d oc u me nte d i n case of e mer ge nc y  or s pecial sit uati o ns w he n t he desi g nate d 
e val uat or is u na ble t o perf or m t he e val uati o n. 
T he rater (s) m ust bec o me certifie d t o perf or m selecte d st u d y  assess me nts bef ore he or 
s he ca n partici pate i n t he c o n d uct of t he st u d y. 
F or s pecificall y defi ne d assess me nts, rater trai ni n g a n d sta n dar dizati o n e xercises ma y be 
c o n d ucte d, a n d writte n d oc u me ntati o n will be pr o vi de d b y t he site f or eac h rater’s 
certificati o n. I n ret ur n , eac h site will be pr o vi de d writte n d oc u me ntati o n o utli ni n g eac h 
rater’s certificati o n f or s pecific st u d y assess me nts. Recertificati o n ma y be re q uire d at 
peri o dic i nter vals d uri n g t he st u d y . T he raters w h o a d mi nister s pecific st u d y  assess me nts will 
be d oc u me nte d i n a ce ntralize d l ocati o n a n d all site staff w h o a d mi nister rati n gs will be 
verifie d i n t he site st u d y d oc u me ntati o n d uri n g t he c o n d uct of t he st u d y. 
8. 2. S afet y Assess me nts 
Pla n ne d ti me p oi nts f or all safet y  assess me nts are pr o vi de d i n t he S o A .U nsc he d ule d cli nical 
la b orat or y  meas ure me nts ma y  be o btai ne d at a n y  ti me d uri n g t he st u d y t o assess a n y 
percei ve d safet y  iss ues. 
8. 2. 1. Me dic al a n d Me dic ati o n Hist or y 
I n vesti gat ors s h o ul d ma ke all reas o na ble eff orts t o o btai n a n acc urate a n d c o m plete me dical 
hist or y  a n d hist or y  of pri or me dicati o n use w he n e val uati n g w het her a partici pa nt is eli gi ble 
f or t he st u d y. 
T he f oll o wi n g will be c ollecte d at Scree ni n g: c o m plete me dical hist or y , A D or Ps O disease 
hist or y ,me dicati o n sa n d n o n- me dicati o n t hera pi[INVESTIGATOR_75510] y , a n d alc o h ol a n d t o bacc o use 
stat us/ hist or y . 
C o m plete A D or Ps O disease hist or y  i ncl u des c ollecti o n of details of A D or Ps O : A D 
or Ps O dia g n osis, t he use of t o pi[INVESTIGATOR_75505], s yste mic tr eat me nts a n d ot her 
treat me nts (e g ,use of bi ol o gic dr u gs) f or A D or Ps O ta ke n d uri n g t he [ADDRESS_82016] u gs (i ncl u di n g s u nscree n, o ver t he c o u nter me dicati o n, vita mi n s, a n d dietar y  
s u p ple me nts) ta ke n wit hi n 2 8 da y s pri or t o t he Scree ni n g visit s h o ul d be rec or de d. 
If t he stat us of a partici pa nt’s me dical hist or y is i n d o u bt or i nf or mati o n pertai ni n g t o a 
critical varia ble is c o nflicti n g, e ver y  reas o na ble ste p t o sec ure pr o per d oc u me ntati o n of 
c orrect me dical stat us s h o ul d be atte m pte d. D oc u me ntati o n of t he me dical a n d me dicati o n 
hist ories o ver t he pr ot oc ol- defi ne d ti me peri o ds s h o ul d be a vaila ble f or s p o ns or re vie w 
d uri n g t he s o urce data verificati o n pr ocess. Q uesti o ns a b o ut pri or me dicati o ns or eli gi bilit y  
s h o ul d be directe d t o t he s p o ns or cli nicia n or s p o ns or me dical m o nit or .
Me dical hist or y  will be c ollecte d at t he Scree ni n g visit a n d re vie we d at t h eBaseli ne Da y 1 
visit f or a n y  c ha n ges. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 6 9 8. 2. 2. P h ysic al E x a mi n ati o ns (I ncl u di n g Hei g ht a n d Wei g ht) 
P h y sical e xa mi nati o ns, i ncl u di n g c o m plete p h y sical e xa mi nati o n, tar gete d p h y sical 
e xa mi nati o n, hei g ht a n d wei g ht will be perf or me d at ti mes s pecifie d i n t he S o A .
P h y sical e xa mi nati o ns m ust be perf or me d b y  t he i n vesti gat or, s u b -i n vesti gat or, or a q ualifie d 
healt hcare pr ofessi o nal per l ocal g ui deli nes. I n vesti gat ors s h o ul d pa y  s pecial atte nti o n t o 
cli nical si g ns relate d t o pre vi o us seri o us ill nesses. 
It is rec o m me n de d t hat wei g ht be meas ure d i n k g t o t he nearest 0. [ADDRESS_82017] als o re m o ve t he c o nte nts of t heir p oc kets a n d 
re mai n still d uri n g meas ure me nt of wei g ht. 
A co m plete p h ys ical e xa mi nati o n will i ncl u de, at a mi ni m u m, assess me nts of t he 
ge neral a p peara nce, s ki n ( prese nce of ras h), H E E N T, l u n gs (a usc ultati o n), heart 
(a usc ultati o n f or prese nce of m ur m urs, gall o ps, r u bs), a b d o me n ( pal pati o n a n d 
a usc ultati o n), m usc ul os keletal ( prese nce of peri p heral e de ma), ne ur ol o gic ( me ntal 
stat us, stati o n, gait, refle xes, m ot or a n d se ns or y  f u ncti o n, c o or di nati o n) a n d l y m p h 
n o des. 
Disease f oc use d ph y sical exa mi nati o n: i ncl u des all A D or Ps O i n v ol ve d s ki n (i n 
treata ble a n d n o n -treata ble areas) a n d e val uati o n of a n y  c urre nt or re p orte d s y m pt o ms 
f or cli nicall y si g nifica nt c ha n ges. 
A n y  cli nical l y  si g nifica nt c ha n ges fr o m t he m ost rece nt p h ys ical e xa mi nati o n s h o ul d be 
rec or de d as A Es. Lac k of efficac y  is ge nerall y n ot c o nsi dere d a n A E. 
I n vesti gat ors s h o ul d pa y  s pecial atte nti o n t o cli nical si g ns relate d t o pre vi o us seri o us 
ill nesses. 
Please see Secti o n 8. 2. [ADDRESS_82018] u d y  will be c o nsi dere d s o urce data a n d 
will n ot be re q uire d t o be re p orte d , u nless ot her wise n ote d. A n y u nt o war d p h ysical 
e xa mi nati o n fi n di n gs t hat are i de ntifie d d uri n g t he acti ve c ollecti o n peri o d a n d meet t he 
defi niti o n of a n A E or S A E (A p pe n di x 3 ) m ust be re p orte d acc or di n g t o t he pr ocesses i n 
Secti o ns 8. 3. 1 t o 8. 3. 3 .
8. 2. 3. Electr oc ar di o gr a ms 
Sta n dar d 1 2 -lea d E C Gs utilizi n g li m b lea ds ( wit h a 1 0 sec o n d r h yt h m stri p) s h o ul d be 
c ollecte d at ti mes s pecifie d i n t he S o A secti o n of t his pr ot oc ol usi n g a n E C G mac hi ne t hat 
a ut o maticall y  calc ulates t he heart rate a n d meas ures P R, Q T, a n d Q Tc i nter vals a n d Q R S 
c o m ple x .Alter nati ve lea d place me nt met h o d ol o g y usi n g t ors o lea ds (e g, Mas o n -Li kar) 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82019] 5mi n ute s i n a s u pi [INVESTIGATOR_050] p ositi o n. 
D uri n g scree ni n g, if partici pa nts ha ve i nitial scree ni n g val ue Q Tc F > 4 5 0 ms ec , E C G 
s h o ul d be re peate d t w o m ore ti mes a n d t he a vera ge of t he 3Q Tc F s h o ul d be use d t o 
deter mi ne t he partici pa nt eli gi bilit y . 
T o e ns ure safet y of t he pa rtici pa nt, a q ualifie d i n di vi d ual (e g, s u b -i n vesti gat or) at t he 
i n vesti gat or site will ma ke c o m paris o ns t o baseli ne meas ure me nts ta ke n at Da y  1. I n 
t he e ve nt of mar ke d pr ol o n gati o n of t he Q Tc F i nter val t o > 5 0 0 msec or > 6 0 msec 
c ha n ge fr o m baseli ne ( Da y  1), t he E C G s h o ul d be re peate d [ADDRESS_82020] u d y  
i nter ve nti o n ( Secti o n 7. [ADDRESS_82021] u d y I nter ve nti o n). 
If a) a p ost - d ose Q Tc F i nter val re mai ns ≥ 6 0 msec fr o m t he baseli ne a n d is 
> 4 5 0 msec; or b) a n a bs ol ute Q T val ue is ≥ 5 0 0 msec f or a n y sc he d ule d E C G f or 
greater t ha n 4 h o urs ( or s o o ner , at t he discreti o n of t he i n vesti gat or); or c) Q Tc F
i nter vals get pr o gressi vel y l o n ger, t he partici pa nt s h o ul d u n der g o c o nti n u o us E C G 
m o nit ori n g . A car di ol o gist s h o ul d be c o ns ulte d if Q Tc F i nter vals d o n ot ret ur n t o 
less t ha n t he criteria liste d a b o ve after 8 h o urs of m o nit ori n g ( or s o o ner ,at t he 
discreti o n of t he i n vesti gat or). 
I n s o me cases, it ma y  be a p pr o priate t o re peat a b n or mal E C Gs t o r ule o ut i m pr o per lea d 
place me nt as c o ntri b uti n g t o t he E C G a b n or malit y. It is i m p or ta nt t hat lea ds be place d i n t he 
sa me p ositi o ns eac h ti me i n or der t o ac hie ve precise E C G rec or di n gs. If a mac hi ne -rea d Q Tc 
val ue is pr ol o n ge d, as defi ne d a b o ve, re peat meas ure me nts ma y  n ot be necessar y  if a 
q ualifie d me dical pr o vi der ’s i nter pretati o n det er mi nes t hat t he Q Tc F val ues are i n t he 
acce pta ble ra n ge. 
W he n t he ti mi n g of t hese meas ure me nts c oi nci des wit h a bl o o d c ollecti o n, t he E C G s h o ul d be 
o btai ne d pri or t o t he n o mi nal ti me of t he bl o o d c ollecti o n. 
E C G val ues of p ote ntial cli nical c o ncer n are liste d i n A p pe n di x 7.
8. 2. 4. Vit al Si g ns 
Te m perat ure, p ulse rate, a n d bl o o d press ure will be assesse d. 
B o d y te m perat ure will be c ollecte d usi n g oral, ty m pa nic, axillar y  or te m p oral 
met h o ds a n d t he sa me met h o d s h o ul d be use d c o nsiste ntl y  t hr o u g h o ut t he st u d y .
Bl o o d press ure a n d p ulse rate meas ure me nts will be assesse d wit h t he partici pa nt i n a 
s u pi [INVESTIGATOR_75511] d p ositi o n usi n g a c o m pletel y  a ut o mate d de vice. Ma n ual tec h ni q ues 
will be use d o nl y  if a n a ut o mate d de vice is n ot a vaila ble. A p pr o priatel y size d c uff 
s h o ul d be use d a n d i t is preferre d t hat t he sa me ar m ( prefera bl y t he d o mi na nt ar m) 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82022] 
f or t he partici pa nt i n a q uiet setti n g wit h o ut distracti o ns (e g, tele visi o n, cell p h o nes). 
Assess me nt of vital si g ns s h o ul d prece de bl o o d dra w f or cli nical la b orat or y  visits. 
8. 2. 5. Cli nic al S afet y L a b or at or y Assess me nts 
See A p pe n di x [ADDRESS_82023] u d y  i n t he A E secti o n of t he C R F. 
Cli nicall y  si g nifica nt a b n or mal la b orat or y  fi n di n gs are t h ose w hic h are n ot ass ociate d wit h 
t he u n derl yi n g disease, u nless j u d ge d b y  t he i n vesti gat or t o be m ore se vere t ha n e x pecte d f or 
t he partici pa nt's c o n d iti o n. 
All la b orat or y  tests wit h val ues c o nsi dere d cli nicall y  si g nifica ntl y a b n or mal d uri n g 
partici pati o n i n t he st u d y  or wit hi n [ADDRESS_82024] u d y i nter ve nti o n s h o ul d be 
re peate d u ntil t he val ues ret ur n t o n or mal or baseli ne or are n o l o n ger c o nsi dere d cli nicall y  
si g nifica nt b y t he i n vesti gat or or me dical m o nit or. 
If s uc h val ues d o n ot ret ur n t o n or mal/ baseli ne wit hi n a peri o d of ti me j u d ge d reas o na ble b y  
t he i n vesti gat or, t he eti ol o g y  s h o ul d be i de ntifie d a n d t he s p o ns or n otifie d. 
See A p pe n di x [ADDRESS_82025] u g -i n d uce d li ver i nj ur y. 
8. 2. 6. S uici d al I de ati o n a n d Be h a vi or Ris k M o nit ori n g - C- S S R S 
T he C -S S R S is a vali date d t o ol f or i n vesti gati ve sta ff t o use t o e val uate s uici dal i deati o n a n d 
be ha vi or. 1 2 At t he Scree ni n g visit , per E xcl usi o n Criteri o n # 2, if t here is s uici dal i deati o n 
ass ociate d wit h act ual i nte nt a n d/ or pla n i n t he past y ear, or pre vi o us hist or y  of s uici dal 
be ha vi ors i n t he past [ADDRESS_82026] u d y ( See 
A p pe n di x 1 1 f or details) . Trai ne d site staff is t o a d mi ni ster t he C - S S R S t o all partici pa nts at 
Scree ni n g a n d assess t he partici pa nt’s eli gi bilit y  base d o n t he a ns wers. 
F or partici pa nts meeti n g e xcl usi o nar y  res ults of t he C -S S R S, it is rec o m me n de d t hat t he 
partici pa nt’s P C P s h o ul d be i nf or me d, a n d t he partici pa n t referre d t o a me ntal healt h 
pr ofessi o nal, eit her b y t he P C P or t he i n vesti gat or acc or di n g t o t heir us ual practice. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82027] u d y i nter ve nti o n . T his assess me nt 1 3 
will f oc us o n t he n o n -lesi o n al s ki n usi n g t he scale i n Ta ble 5. All partici pa nt re p orte d a n d 
o bser ve d a p p licati o n site A Es s h o ul d be rec or de d al o n g wit h t he b o d y  re gi o n l ocati o n, 
se verit y, d urati o n a n d o utc o me as i n dicate d o n t he C R F. See Secti o n 7. 1 f or per ma ne nt a n d 
te m p orar y  disc o nti n uati o n criteria base d o n l ocal t olera bilit y assess me nt. 
T a ble 5.S ki n T oler a bilit y Gr a di n g S yste m f or N o n- lesi o n al Ski n 
Gr a de Se verit y Descri pti o n 
0 N o ne N o e vi de nce of l ocal i nt olera nce 
1 Mil d Mi ni mal er yt he ma a n d/ or e de ma, sli g ht glaze d a p peara nce 
2 M o derate Defi nite er yt he ma a n d/ or e de ma wit h peeli n g a n d/ or 
crac ki n g b ut nee ds n o a da ptati o n of p os ol o g y 
3 Se vere (t o be re p orte d as a n A E) Er yt he ma, e de ma glazi n g wit h fiss ures, fe w vesicles or 
pa p ules: c o nsi der re m o vi n g t o pi[INVESTIGATOR_2855] a ge nt (if still i n place) 
4 Ver y  se vere (t o be re p orte d as a n A E) Str o n g reacti o n s prea di n g be y o n d t he treate d area, b ull o us 
reacti o n, er osi o ns: re m o val of t o pi[INVESTIGATOR_2855] a ge nt (if still i n 
place) 
8. 2. 8. Pre g n a nc y Testi n g 
Pre g na nc y  tests ma y  be uri ne or ser u m tests b ut m ust ha ve a se nsiti vit y of at least 
2 5 mI U/ m L. Pre g na nc y  tests will be perf or me d i n W O C B P at t he ti mes liste d i n t he S o A . 
F oll o wi n g a ne gati ve pre g na nc y  test res ult at scree ni n g, a p pr o priate c o ntrace pti o n m ust be 
c o m me nce d a n d a sec o n d ne gati ve pre g na nc y test res ult will be re q uire d at t he baseli ne visit 
pri or t he partici pa nt ’s recei vi n g t he st u d y  i nter ve nti o n . Pre g na nc y  tests will als o be d o ne 
w he ne ver 1 me nstr ual c y cle is misse d d uri n g t he acti ve treat me nt peri o d ( or w he n p ote ntial 
pre g na nc y  is ot her wise s us pecte d) a n d at t he e n d of t he st u d y . Pre g na nc y  tests ma y  als o be 
re peate d if re q ueste d b y I R Bs/ E Cs or if re q uire d b y l ocal re g ulati o ns. 
If a uri ne test ca n n ot be c o nfir me d as ne gati ve (e g, a n a m bi g u o us res ult), a ser u m pre g na nc y  
test is re q uire d. I n s uc h cases, t he partici pa nt m ust be e xcl u de d if t he ser u m pre g na nc y  res ult 
is p ositi ve .
T w o ne gati ve pre g na nc y  tests are re q uire d bef ore ra n d o mizati o n ( [ADDRESS_82028] at Da y  1 v isit). 
If uri ne pre g na nc y  test is p ositi ve after st u d y  i nter ve nti o n a p plicati o n, ser u m pre g na nc y  test 
will be c o n d ucte d, st u d y i nter ve nti o n a p plicati o n pa use d a n d s p o ns or cli nicia n a n d s p o ns or 
me dical m o nit or n otifie d i m me diatel y .
8. 3. A d verse E ve nts ,Seri o us A d verse E ve nts , a n d Ot her S afet y Re p orti n g 
T he defi niti o ns of a n A E a n d a n S A E ca n be f o u n d i n A p pe n di x 3 .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 7 3 A Es ma y  arise fr o m s y m pt o ms or ot h er c o m plai nts re p orte d t o t he i n vesti gat or b y  t he 
partici pa nt ( or, w he n a p pr o priate, b y a care gi ver, s urr o gate, or t he partici pa nt's le gall y 
a ut h orize d re prese ntati ve), or t he y  ma y  arise fr o m cli nical fi n di n gs of t he I n vesti gat or or 
ot her healt hcare pr o vi ders (cli nical si g ns , test res ults, etc.). 
T he i n vesti gat or a n d a n y q ualifie d desi g nees are res p o nsi ble f or detecti n g, d oc u me nti n g, a n d 
rec or di n g e ve nts t hat meet t he defi niti o n of a n A E or S A E a n d re mai n res p o nsi ble t o p urs ue 
a n d o btai n a de q uate i nf or mati o n b ot h t o deter mi ne t he o utc o me a n d t o assess w het her t he 
e ve nt meets t he criteria f or classificati o n as a n S A E or ca use d t he partici pa nt t o dis c o nti n ue 
t he st u d y  i nter ve nti o n (see Secti o n 7. 1 ). 
D uri n g t he acti ve c ollecti o n peri o d as descri be d i n Secti o n 8. 3. 1 , e ac h partici pa nt /pare nt/le gal 
g uar dia n will be q uesti o ne d a b o ut t he occ urre nce of A Es i n a n o nlea di n g ma n ner. 
I n a d diti o n , t he i n vesti gat or ma y  be re q ueste d b y P fizer Safet y t o o btai n s pecific f oll o w - u p 
i nf or mati o n i n a n e x pe dite d fas hi o n. 
8. 3. 1. Ti me Peri o d a n d Fre q ue nc y f or C ollecti n g A E a n d S A E I nf or m ati o n 
T he ti me peri o d f or acti vel y  eliciti n g a n d c ollecti n g A Es a n d S A Es (“acti ve c ollecti o n 
peri o d”) f or eac h partici pa nt be gi ns fr o m t he ti me t he partici pa nt pr o vi des i nf or me d 
c o nse nt /asse nt , w hic h is o btai ne d bef ore t he partici pa nt ’s partici pati o n i n t he st u d y (ie, bef ore 
u n der g oi n g a n y st u d y- relate d pr oce d ure a n d/ or recei vi n g st u d y  i nter ve nti o n ), t hr o u g h a n d 
i ncl u di n g a mi ni m u m of [ADDRESS_82029] u d y , a n d he/s he 
c o nsi ders t he e ve nt t o be reas o na bl y relate d t o t he st u d y  i nter ve nti o n , t he i n vesti gat or m ust 
pr o m ptl y  re p ort t he S A E t o [COMPANY_007] usi n g t he C T S A E Re p ort F or m. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 7 4 8. 3. 1. 1. Re p orti n g S A Es t o [COMPANY_007] S afet y 
All S A Es occ urri n g i n a partici pa nt d uri n g t he acti ve c ollecti o n peri o d as descri be d i n 
Secti o n 8. 3. 1 are re p orte d t o [COMPANY_007] Safet y o n t he C T S A E Re p ort F or m i m me diatel y  u p o n 
a ware ness a n d u n der n o circ u msta nce s h o ul d t his e xcee d 2 4 h o urs, as i n dicate d i n 
A p pe n di x 3. T he i n vesti gat or will s u b mit a n y  u p date d S A E data t o t he s p o ns or wit hi n 
2 4 h o urs of it bei n g a vaila ble. 
8. 3. 1. 2. Rec or di n g N o nseri o us A Es a n d S A Es o n t he C R F 
All n o nseri o us A Es a n d S A Es occ urri n g i n a partici pa nt d uri n g t he acti ve c ollecti o n peri o d , 
w hic h be gi ns after o btai ni n g i nf or me d c o nse nt /asse nt as descri be d i n Secti o n 8. 3. 1 , will be 
rec or de d o n t he A E secti o n of t he C R F. 
T he i n vesti gat or is t o rec or d o n t he C R F all directl y  o bser ve d a n d all s p o nta ne o usl y  re p orte d 
A Es a n d S A Es re p orte d b y t he partici pa nt. 
8. 3. 2. Met h o d of Detecti n g A Es a n d S A Es 
T he met h o d of rec or di n g, e val uati n g, a n d assessi n g ca usalit y  of A Es a n d S A E sa n d t he 
pr oce d ures f or c o m pleti n g a n d tra ns mitti n g S A E re p orts are pr o vi de d i n A p pe n di x 3 .
Care will be ta ke n n ot t o i ntr o d uce bias w he n detecti n g A Es a n d/ or S A Es. O pe n -e n de d a n d 
n o nlea di n g ver bal q uesti o ni n g of t he partici pa nt is t he preferre d met h o d t o i n q uire a b o ut 
A E occ urre nces. 
8. 3. 3. F oll o w - U p of A Es a n d S A Es 
After t he i nitial A E or S A E re p ort, t he i n vesti gat or is re q uire d t o pr oacti vel y  f oll o w eac h 
partici pa nt at s u bse q ue nt visits/c o ntacts. F or ea c h e ve nt, t he i n vesti gat or m ust p urs ue a n d 
o btai n a de q uate i nf or mati o n u ntil res ol uti o n, sta bilizati o n, t he e ve nt is ot her wise e x plai ne d, 
or t he partici pa nt is l ost t o f oll o w- u p (as defi ne d i n Secti o n 7. 3 ). 
I n ge neral, f oll o w - u p i nf or mati o n will i ncl u de a descri pti o n of t he e ve nt i n s ufficie nt detail t o 
all o w f or a c o m plete me dical assess me nt of t he case a n d i n de pe n de nt deter mi nati o n of 
p ossi ble ca usalit y . A n y i nf or mati o n rele va nt t o t he e ve nt, s uc h as c o nc o mita nt me dicati o ns 
a n d ill nesses, m ust be pr o vi de d. I n t he case of a partici pa nt deat h, a s u m mar y  of a vaila ble 
a ut o ps y  fi n di n gs m ust be s u b mitte d as s o o n as p ossi ble t o [COMPANY_007] Safet y . 
F urt her i nf or mati o n o n f oll o w -u p pr oce d ures is gi ve n i n A p pe n di x [ADDRESS_82030] u d y  i nter ve nti o n u n der cli nical i n vesti gati o n are met. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82031] y  wit h c o u ntr y -s pecific re g ulat or y  re q uire me nts relati n g t o safet y 
re p orti n g t o t he re g ulat or y  a ut h orit y, I R B s/ E C s, a n d i n vesti gat ors. 
I n vesti gat or safet y  re p orts m ust be pre pare d f or S U S A R sacc or di n g t o l ocal re g ulat or y  
re q uire me nts a n d s p o ns or p olic y a n d f or war de d t o i n vesti gat ors as necessar y. 
A n i n vesti gat or w h o recei ves S U S A R sor ot her s pecific saf et y i nf or mati o n (e g, s u m mar y or 
listi n g of S A Es) fr o m t he s p o ns or will re vie w a n d t he n file it al o n g wit h t he S R S D (s) f or t he 
st u d y a n d will n otif y  t he I R B/ E C, if a p pr o priate acc or di n g t o l ocal re q uire me nts. 
8. 3. 5. E n vir o n me nt al E x p os ure, E x p os ure D uri n g Pre g n a nc y or Bre astfee di n g, a n d 
Occ u p ati o n al E x p os ure 
E n vir o n me ntal e x p os ure, occ urs w he n a pers o n n ot e nr olle d i n t he st u d y  as a partici pa nt 
recei ves u n pla n ne d direct c o ntact wit h or e x p os ure t o t he st u d y  i nter ve nti o n. S uc h e x p os ure 
ma y  or ma y  n ot lea d t o t he occ urre nce of a n A E or S A E. Pers o ns at ris k f or e n vir o n me ntal 
e x p os ure i ncl u de healt hcare pr o vi ders, fa mil y me m bers, a n d ot hers w h o ma y be e x p ose d . A n 
e n vir o n me ntal e x p os ure ma y i ncl u de e x p os ure d uri n g pre g na nc y , e x p os ure d uri n g 
breastfee di n g ,a n d occ u pati o nal e x p os ure .
A n y  s uc h ex p os ure t o t he st u d y  i nter ve nti o nu n der st u d y  are re p orta ble t o [COMPANY_007] Safet y 
wit hi n 2 4 h o urs of i n vesti gat or a ware ness. 
8. 3. 5. 1. E x p os ure D uri n g Pre g n a nc y 
A n E D P occ urs if: 
A fe male partici pa nt is f o u n d t o be pre g na nt w hile recei vi n g or after disc o nti n ui n g 
st u d y  i nter ve nti o n .
A male partici pa nt w h o is recei vi n g or has disc o nti n ue d st u d y  i nter ve nti o n e x p oses a 
fe male part ner pri or t o or ar o u n d t he ti me of c o nce pti o n .
A fe male is f o u n d t o be pre g na nt w hile bei n g e x p ose d or ha vi n g bee n e x p ose d t o 
st u d y  i nter ve nti o n d ue t o e n vir o n me ntal e x p os ure. Bel o w are e xa m ples of 
e n vir o n me ntal E D P : 
A fe male fa mil y  me m ber or healt hcare pr o vi der re p orts t hat s he is pre g na nt after 
ha vi n g bee n e x p ose d t o t he st u d y  i nter ve nti o n b y  i n gesti o n or s ki n c o nt act .
A male fa mil y me m ber or healt hcare pr o vi der w h o has bee n e x p ose d t o t he st u d y  
i nter ve nti o n b y  i n gesti o n or s ki n c o ntact t he n e x p oses his fe male part ner pri or t o 
or ar o u n d t he ti me of c o nce pti o n. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82032] re p ort E D P t o [COMPANY_007] Safet y wit hi n 2 4 h o urs of t he i n vesti gat or’s 
a ware ness, irres pecti ve of w het her a n S A E has occ urre d. T he i nitial i nf or mati o n s u b mitte d 
s h o ul d i ncl u de t he a ntici pate d date of deli ver y  (see bel o w f or i nf or mati o n relate d t o 
ter mi nati o n of pre g na nc y). 
If E D P occ urs i n a p artici pa nt or a partici pa nt’s part ner, t he i n vesti gat or m ust re p ort 
t his i nf or mati o n t o [COMPANY_007] Safet y o n t he C T S A E Re p ort F or m a n d a n E D P 
Su p ple me ntal For m, re gar dless of w het her a n S A E has occ urre d. Details of t he 
pre g na nc y  will be c ollecte d after t he st art of st u d y i nter ve nti o n a n d u ntil [ADDRESS_82033] d ose. 
If E D P occ urs i n t he setti n g of e n vir o n me ntal e x p os ure, t he i n vesti gat or m ust re p ort 
i nf or mati o n t o [COMPANY_007] Safet y  usi n g t he C T S A E Re p ort F or m a n d E D P Su p ple me ntal 
For m. Si nce t he e x p os ure i nf or mati o n d oes n ot pertai n t o t he partici pa nt e nr olle d i n 
t he st u d y , t he i nf or mati o n is n ot rec or de d o n a C R F; h o we ver, a c o p y  of t he 
c o m plete d C T S A E Re p ort F or m is mai ntai ne d i n t he i n vesti gat or site file. 
F oll o w - u p is c o n d ucte d t o o btai n ge ner al i nf or mati o n o n t he pre g na nc y  a n d its o utc o me f or 
all E D P re p orts wit h a n u n k n o w n o utc o me. T he i n vesti gat or will f oll o w t he pre g na nc y  u ntil 
c o m pleti o n ( or u ntil pre g na nc y  ter mi nati o n) a n d n otif y  [COMPANY_007] Safet y of t he o utc o me as a 
f oll o w -u p t o t he i nitial E D P Su p ple me ntal F or m. I n t he case of a li ve birt h, t he str uct ural 
i nte grit y of t he ne o nate ca n be assesse d at t he ti me of birt h. I n t he e ve nt of a ter mi nati o n, t he 
reas o n(s) f or ter mi nati o n s h o ul d be s pecifie d a n d, if cli nicall y  p ossi ble, t he str uct ural 
inte grit y of t he ter mi nate d fet us s h o ul d be assesse d b y gr oss vis ual i ns pecti o n ( u nless pre -
pr oce d ure test fi n di n gs are c o ncl usi ve f or a c o n ge nital a n o mal y  a n d t he fi n di n gs are 
re p orte d). 
A b n or mal pre g na nc y  o utc o mes are c o nsi dere d S A Es. If t he o utc o me of t he pre g na nc y  meets 
t he criteria f or a n S A E (ie, ect o pic pre g na nc y , s p o nta ne o us a b orti o n, i ntra uteri ne fetal 
de mise, ne o natal deat h, or c o n ge nital a n o mal y i n a li ve -b or n ba b y, a ter mi nate d fet us, a n 
i ntra uteri ne fetal de mise, or a ne o natal deat h), t he i n vesti gat or s h o ul d f oll o w t he pr oce d ures 
f or re p orti n g S A Es. A d diti o nal i nf or mati o n a b o ut pre g na nc y o utc o mes t hat are re p orte d t o 
[COMPANY_007] Safet y  as S A Es f oll o ws: 
S p o nta ne o us a b orti o n i ncl u d i n g miscarria ge a n d misse d a b orti o n; 
Ne o natal deat hs t hat occ ur wit hi n [ADDRESS_82034] u d y  i nter ve nti o n. 
A d diti o nal i nf or mati o n re gar di n g t he E D P ma y  be re q ueste d b y  t he s p o ns or. F urt her 
f oll o w - u p of birt h o utc o mes will be ha n dle d o n a case- b y -case basis (e g, f oll o w - u p o n 
preter m i nfa nt st o i de ntif y  de vel o p me ntal dela y s). I n  t he case of pater nal e x p os ure, t he 
i n vesti gat or will pr o vi de t he partici pa nt wit h t he Pre g na nt Part ner Release of I nf or mati o n 
F or m t o deli ver t o his part ner. T he i n vesti gat or m ust d oc u me nt i n t he s o urce d oc u me nts t ha t 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 7 7 t he partici pa nt was gi ve n t he Pre g na nt Part ner Release of I nf or mati o n F or m t o pr o vi de t o his 
part ner. 
8. 3. 5. 2. E x p os ure D uri n g Bre astfee di n g 
A n e x p os ure d uri n g breastfee di n g occ urs if: 
A fe male partici pa nt is f o u n d t o be breastfee di n g w hile recei vi n g or after 
di sc o nti n ui n g st u d y  i nter ve nti o n .
A fe male is f o u n d t o be breastfee di n g w hile bei n g e x p ose d or ha vi n g bee n e x p ose d t o 
st u d y  i nter ve nti o n (ie, e n vir o n me ntal e x p os ure). A n e xa m ple of e n vir o n me ntal 
e x p os ure d uri n g breastfee di n g is a fe male fa mil y me m ber or heal t hcare pr o vi der w h o 
re p orts t hat s he is breastfee di n g after ha vi n g bee n e x p ose d t o t he st u d y  i nter ve nti o n 
b y i n gesti o n or s ki n c o ntact .  
T he i n vesti gat or m ust re p ort e x p os ure d uri n g breastfee di n g t o [COMPANY_007] Safet y  wit hi n 2 4 h o urs 
of t he i n vesti gat or’s a war e ness, irres pecti ve of w het her a n S A E has occ urre d. T he 
i nf or mati o n m ust be re p orte d usi n g t he C T S A E Re p ort F or m. W he n e x p os ure d uri n g 
breastfee di n g occ urs i n t he setti n g of e n vir o n me ntal e x p os ure, t he e x p os ure i nf or mati o n d oes 
n ot pertai n t o t he partici p a nt e nr olle d i n t he st u d y, s o t he i nf or mati o n is n ot rec or de d o n a 
C R F. H o we ver, a c o p y of t he c o m plete d C T S A E Re p ort F or m is mai ntai ne d i n t he 
i n vesti gat or site file. 
A n e x p os ure d uri n g breastfee di n g re p ort is n ot create d w he n a [COMPANY_007] dr u g s pecificall y 
a p pr o ve d f or use i n breastfee di n g w o me n (e g, vita mi ns) is a d mi nistere d i n acc or d wit h 
a ut h orize d use. H o we ver, if t he i nfa nt e x perie nces a n S A E ass ociate d wit h s uc h a dr u g, t he 
S A E is re p orte d t o get her wit h t he e x p os ure d uri n g breastfee di n g. 
8. 3. 5. 3. Occ u p ati o n al E x p os ure 
T he i n vesti gat or m ust re p ort a n y  i nsta nce of occ u pati o nal e x p os ure t o [COMPANY_007] Safet y wit hi n 
2 4 h o urs of t he i n vesti gat or’s a ware ness usi n g t he C T S A E Re p ort F or m , re gar dless of 
w het her t here is a n ass ociate d S A E. Si nce t he i nf or mati o n a b o ut t he occ u pati o nal e x p os ure 
d oes n ot pertai n t o a partici pa nt e nr olle d i n t he st u d y , t he i nf or mati o n is n ot rec or de d o n a 
C R F; h o we ver, a c o p y of t he c o m plete d C T S A E Re p ort F or m m ust be mai ntai ne d i n t he 
i n vesti gat or site file .
8. 3. 6. C ar di o v asc ul ar a n d De at h E ve nts 
Not a p plica ble. 
8. 3. 7. Dise ase -Rel ate d E ve nts a n d/ or Dise ase -Rel ate d O utc o mes N ot Q u alif yi n g as A Es 
or S A Es 
N ot a p plica ble. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82035] re p ort si g ns, s y m pt o ms, a n d/ or cli nical se q uelae res ulti n g fr o m lac k of 
efficac y . Lac k of efficac y  or fail ure of e x pecte d p har mac ol o gical acti o n is re p orta ble t o 
[COMPANY_007] Safet y  o nl y if ass oci ate d wit h a n S A E .  
8. 3. 9. Me dic al De vice Deficie ncies 
N ot a p plica ble .
8. 3. [ADDRESS_82036] u d y m a y  occ ur i n cli nical trial setti n gs, s uc h as 
me dicati o n err ors. 
S afet y E ve nt Rec or de d o n t he C R F Re p orte d o n t he C T S A E Re p ort 
F or m t o [COMPANY_007] S afet y Wit hi n 
2 4 H o urs of A w are ness 
Me dicati o n err ors All (re gar dless of w het her 
ass ociate d wit h a n A E) O nl y  if ass ociate d wit h a n S A E 
Me dicati o n err ors i ncl u de: 
Me dicati o n err ors i n v ol vi n g partici pa nt e x p os ure t o t he st u d y  i nter ve nti o n .
P ote ntial me dicati o n err ors or uses o utsi de of w hat is f oresee n i n t he pr ot oc ol t hat d o 
or d o n ot i n v ol ve t he st u d y partici pa nt .
T he a d mi nistrati o n of a n i nc orrect st u d y i nter ve nti o n. 
T he a d mi nistrati o n of a n i nc orrect d osa ge. 
S uc h me dicati o n err ors occ urri n g t o a st u d y partici pa nt are t o be ca pt ure d o n t he me dicati o n 
err or pa ge of t he C R F, w hic h is a s pecific versi o n of t he A E pa ge. 
I n t he e ve nt of a me dicati o n d osi n g err or, t he s p o ns or s h o ul d be n otifie d wit hi n 2 4 h o urs .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 7 9 W het her or n ot t he me dicati o n err or is acc o m pa nie d b y  a n A E, as deter mi ne d b y  t he 
i n vesti gat or, t he me dicati o n err or is rec or de d o n t he me dicati o n err or pa ge of t he C R F a n d, if 
a p pli ca ble, a n y ass ociate d A E(s), seri o us a n d n o nseri o us, are rec or de d o n t he A E pa ge of t he 
C R F. 
Me dicati o n err ors s h o ul d be re p orte d t o [COMPANY_007] Safet y wit hi n 2 4 h o urs o n a C T S A E Re p ort 
F or m o nl y w he n ass oci ate d wit h a n S A E. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 8 0 8. 5. Ge netics 
8. 5. 1. S pecifie d Ge netics 
Ge netics (s pecifie d a nal yses) are n ot e val uate d i n t his st u d y .
8. 5. 2. Ret ai ne d Rese arc h S a m ples f or Ge netics 
 
Retai ne d Researc h Sa m ples ma y  be use d f or researc h relate d t o t he st u d y  i nter ve nti o n , A D, 
Ps O ,a n d / or relate d i nfla m mat or y  diseases .  
 
.Details o n pr ocesses f or 
c ollecti o n a n d s hi p me nt of t hese sa m ples ca n be f o u n d i n t he la b orat or y ma n ual .
8. 6. Bi o m ar kers 
8. 6. 1. S pecifie d Ge ne E x pressi o n ( R N A) Rese arc h 
S pecifie d ge ne e x pressi o n ( R N A) researc h is n ot i ncl u de d i n t his st u d y .
8. 6. 2. S pecifie d Pr otei n Rese arc h 
S pecifie d pr otei n researc h is i ncl u de d i n t his st u d y. T he sa m ples will be a nal y ze d f or 
e x pl orat or y  researc h. Details o n pr ocesses f or c ollecti o n a n d s hi p me nt of t hese sa m ples ca n 
be f o u n d i n t he la b orat or y  ma n ual .
Sa m ples ma y  be st ore d at a facilit y selecte d b y t he s p o ns or f or a ma xi m u m of 1 0 ye ars ( or 
acc or di n g t o l ocal re g ulati o ns) f oll o wi n g t he last partici pa nt’s last visit f or t he st u d y .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
C CI 
C CI C CI 
C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82037] u d y :
 
A 6 -m L  w h ole bl o o d Pre p B 2. 5 o pti mize d f or ser u m; 
A 6 -m L  w h ole bl o o d Pre p B 1. 5 o pti mize d f or plas ma. 
Retai ne d Researc h Sa m ples will be c ollecte d as l ocal re g ulati o ns a n d IR B/ E Cs all o w 
acc or di n g t o t he S o A .  
Retai ne d Researc h Sa m ples ma y  be use d f or researc h relate d t o t he st u d y  i nter ve nti o n , A D, 
ps oriasis, a n d or relate d i nfla m mat or y diseases .  
 
 Details o n pr ocesses f or 
c ollecti o n a n d s hi p me nt of t hese sa m ples ca n be f o u n d i n la b orat or y  ma n ual . 
8. 7. I m m u n o ge nicit y Assess me nts 
I m m u n o ge nicit y assess me nts are n ot i ncl u de d i n t his st u d y .
8. 8. He alt h Ec o n o mics 
Healt h ec o n o mics/ me dical res o urce utilizati o n a n d healt h ec o n o mics para meters are n ot 
e val uate d i n t his st u d y .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
C CI 
C CI C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82038] u d y I nter ve nti o n Nee d ( Tre at a ble B S A) 
E val uati o n of %B S A f or st u d y  i nter ve nti o n nee d is t he t otal B S A acr oss all b o d y  l ocati o ns 
bei n g treate d wit h t he st u d y  i nter ve nti o n. T he %B S A f or st u d y  i nter ve nti o n nee d e val uati o n 
met h o d will be t he sa me as t he B S A wit h A D or Ps O f or efficac y  assess me nt .
P ost Da y  1, if a n y ne w A D or Ps O areas bec o me eli gi ble f or treat me nt, t h ose s h o ul d be 
i ncl u de d i n t he %B S A f or st u d y  i nter ve nti o n nee d. T he %B S A at s u bse q ue nt visits s h o ul d be 
e q ual t o or greater t ha n t he val ue at Da y  1. 
8. [ADDRESS_82039] u d y 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82040] u d y  
is o utli ne d here a n d f urt her detaile d i n a S A P, w hic h will be mai ntai ne d b y t he s p o ns or. T h e 
S A P ma y  m o dif y  w hat is o utli ne d i n t he pr ot oc ol w here a p pr o priate; h o we ver, a n y  maj or 
m o dificati o ns of t he pri mar y  e n d p oi nt defi niti o ns or t heir a nal ys es will als o be ref lecte d i n a 
pr ot oc ol a me n d me nt. 
9. 1. St atistic al H y p ot heses 
Statistical i nfere nce will b e ma de o n t he pri mar y  e n d p oi nts: I G A /P G A res p o nse at Wee k 1 2. 
T he n ull h y p ot hesis is t hat t here is n o differe nce bet wee n eac h P F - 0 7 0 3 8 1 2 4 d ose le vel a n d 
t he ve hicle ar m f or eac h i n dicati o n. T he alter nati ve h y p ot hesis is t hat t he P F - 0 7 0 3 8 1 2 4 d ose 
le vel is s u peri or t o t he ve hicle ar m f or eac h i n dicati o n. 
9. 1. 1. Esti m a n ds 
9. 1. 1. 1. Pri m ar y Esti m a n d 
T he esti ma n d is defi ne d b y  t he f oll o wi n g attri b utes: 
At o pic Der m atitis: 
Treat me nt c o n diti o n: recei ve d treat me nt: P F -0 7 0 3 8 1 2 4 oi nt me nt 0. 0 1 % , 0. 0 3 % or ve hicle, 
wit h o ut t he be nefit of a d diti o nal pr o hi bite d me dicati o ns a n d re gar dless of treat me nt 
c o m plia nce .
P o p ulati o n: Partici pa nts wit h mil d or m o derate A D as defi ne d b y t he i ncl usi o n a n d e xcl usi o n 
criteria .
Varia bles: Pr o p orti o n of partici pa nts ac hie vi n g I G A sc ore of clear ( 0) or al m ost clear ( 1) a n d 
a re d ucti o n fr o m baseli ne of ≥ 2 p oi nts at Wee k 1 2 a n d ot her bi nar y  e n d p oi nts .
Ps ori asis: 
Treat me nt c o n diti o n: recei ve d treat me nt: P F -0 7 0 3 8 1 2 4 oi nt me nt 0. 0 1 % , 0. 0 3 % , 0. 0 6 % or 
ve hicle , wit h o ut t he be nefit of a d diti o nal pr o hi bite d me dicati o ns a n d re gar dless of treat me nt 
c o m plia nce .
P o p ulati o n : Partici pa nts wit h mil d , m o derate , or se vere Ps O as defi ne d b y t he i ncl usi o n a n d 
e xcl usi o n criteria. 
Varia bles: Pr o p orti o n of partici pa nts wit h P G A sc ore clear ( 0) or al m ost clear ( 1) a n d a 
re d ucti o n fr o m baseli ne of ≥ 2 p oi nts at Wee k 1 2 a n d ot her bi nar y  e n d p oi nts. 
I nter -c urre nt E ve nts: A) Pr o hi bite d me dicati o n –res p o nse will be c o nsi dere d as fail ure f or 
ti me p oi nts after st art date of t he e ve nt f or partici pa nts w h o recei ve pr o hi bite d me dicati o n 
p ost -ra n d o mizati o n. B) Wit h dra wal a n d all ot her e ve nts, e xce pt C O VI D- 1 9 pa n de mic, 
lea di n g t o missi n g data will be treate d si milarl y  ass u mi n g t hat partici pa nts n o l o n ger recei ve 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82041] u d y  i nter ve nti o n a n d he nce will be c o nsi dere d as fail ure. C) C O VI D - 1 9 
pa n de mic: if a partici pa nt misses a visit d ue t o C O VI D -1 9, he/s he will be e xcl u de d fr o m t he 
a nal ys is f or t hat visit; I f a partici pa nt disc o nti n ues treat me nt or wit h dra ws fr o m t he st u d y  d ue 
t o C O VI D- 1 9, he/s he will be e xcl u de d fr o m t he a nal y ses after t he treat me nt disc o nti n uati o n 
visit or st u d y  wit h dra wal visit, res pecti vel y . D) I n a de q uate c o m plia nce – partici pa nts data 
will be use d as r ec or de d. 
P o p ulati o n le vel s u m mar y: T he differe nce i n s uccess rates bet wee n eac h d ose le vel a n d 
ve hicle .
9. 1. 1. 2. Sec o n d ar y Esti m a n d 
All bi nar y  sec o n dar y  e n d p oi nt s esti ma n ds are si milar t o t he pri mar y  e n d p oi nt. 
T he c o nti n u o us e n d p oi nt esti ma n d is defi ne d b y t he f o ll o wi n g attri b utes: 
At o pic Der m atitis: 
Treat me nt c o n diti o n: recei ve d treat me nt: P F- 0 7 0 3 8 1 2 4 oi nt me nt 0. 0 1 %, 0. 0 3 % or ve hicle, 
wit h o ut t he be nefit of a d diti o nal pr o hi bite d me dicati o ns a n d re gar dless of treat me nt 
c o m plia nce. 
P o p ulati o n: Partici pa nts wit h mi l d or m o derate A D as defi ne d b y i ncl usi o n a n d e xcl usi o n 
criteria .
Varia bles: Perce nt c ha n ge fr o m baseli ne i n E A SI  t otal sc ore at all st u d y  visit ti me p oi nts 
s pecifie d i n S o A . 
Ps ori asis: 
Treat me nt c o n diti o n: recei ve d treat me nt: P F- 0 7 0 3 8 1 2 4 oi nt me nt 0. 0 1 %, 0. 0 3 %, 0. 0 6 % or 
ve hicle, wit h o ut t he be nefit of a d diti o nal pr o hi bite d me dicati o ns a n d re gar dless of treat me nt 
c o m plia nce. 
P o p ulati o n: Partici pa nts wit h mil d , m o derate, or se vere Ps O as d efi ne d b y t he i ncl usi o n a n d 
e xcl usi o n criteria. 
Varia bles: Cha n ge fr o m baseli ne i n P A SI  t otal sc ore at all st u d y  visit ti me p oi nts s pecifie d i n 
S o A .
I nterc urre nt e ve nts: A) Pr o hi bite d me dicati o n –all sc ores meas ur e d at ti me p oi nts after start 
date of t he e ve nt f or partici pa nts w h o recei ve pr o hi bite d me dicati o n p ost ra n d o mizati o n will 
be e xcl u de d fr o m t he a nal y sis a n d treate d as missi n g sc ores. Missi n g sc ores will be i m p ute d 
base d o n t he ass u m pti o n t hat partici pa nts d o n ot be nefit fr o m t he I P  treat me nt. 
B) Wit h dra wal a n d all ot her e ve nts lea di n g t o missi n g data, e xce pt C O VI D -1 9 pa n de mic, 
will be treate d si milarl y ass u mi n g partici pa nts ha ve efficac y val ues si milar t o c o ntr ol 
partici pa nts. C) C O VI D -1 9 pa n de mic: if a pa rtici pa nt misses a visit d ue t o C O VI D- 1 9, 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 8 5 he/s he will be e xcl u de d fr o m t he a nal ys is f or t hat visit; If a partici pa nt disc o nti n ues treat me nt 
or wit h dra ws fr o m t he st u d y d ue t o C O VI D - 1 9, he/s he will be e xcl u de d fr o m t he a nal ys es 
after t he treat me nt disc o nti n uati o n visit or st u d y  wit h dra wal visit, res pecti vel y . D) I na de q uate 
c o m plia nce –partici pa nts data will be use d as rec or de d. 
P o p ulati o n -le vel s u m mar y : T he mea n differe nce bet wee n eac h d ose le vel a n d ve hicle .
9. 1. 2. M ulti plicit y A dj ust me nt 
F or eac h i n dicati o n, t he o verall fa mil y wise T y p e I err or rate will be c o ntr olle d at t he 1-si de d 
0. 0 2 5 le vel usi n g t he H oc h ber g ste p u p pr oce d ure. 
9. 2. A n al ysis Sets 
F or p ur p oses of a nal y sis, t he f oll o wi n g a nal ys is sets are defi ne d: 
P artici p a nt A n al ysis Set Descri pti o n 
F ull A nal ysis Set All partici pa nts ra n d o ml y assi g ne d t o st u d y i nter ve nti o n w h o ta ke at least 
[ADDRESS_82042] me nts f or m ulti plicit y  
will be ma de f or t hese e n d p oi nts. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82043] me nts f or m ulti plicit y  will be ma de f or t hese e n d p oi nts. 
9. 3. 4. Pri m ar y E n d p oi nt(s) / Esti m a n d(s) A n al ysis 
A la n d mar k a nal y sis of t he c o m p osite IG A/ PG A s uccess e n d p oi nts at W ee k [ADDRESS_82044] met h o d; t he ris k differe nces a n d t he c orres p o n di n g 
2-si de d u nc o n diti o nal e xact 9 5 % c o nfi de nce i nter vals will be c o m p ute d usi n g C ha n a n d 
Z ha n g ( 1 9 9 9) 1 4 met h o d. T he o verall fa mil y  wise T y pe I err or rate will be c o ntr olle d at t he 
1- si de d 0. 0 25 le vel usi n g t he H oc h ber g ste p u p pr oce d ure. 
I n a d diti o n, E ma x or ot her a p p r o priate m o del sma y  be use d t o c haracterize t he d ose res p o nse 
relati o ns hi p. Details of t he d ose res p o nse m o del will be descri be d i n t he S A P. 
9. 3. 5. Sec o n d ar y E n d p oi nt(s )/ Esti m a n d(s) A n al ysis 
Bi nar y  sec o n dar y  e n d p oi nts will be a nal y ze d si milar ly t o t he pri mar y  e n d p oi nts. 
A la n d mar k a nal y sis of c o nti n u o us e n d p oi nts i ncl u di n g perce nt c ha n ge fr o m baseli ne i n 
EA SI  a n d c ha n ge fr o m baseli ne i n PA SI  at Wee k 1 2, defi ne d i n Secti o n 9. 1. 1. 2 . will be 
perf or me d b y A N C O V A usi n g t he f ull a nal y sis set wit h baseli ne as a c o variate . Missi n g data, 
e xce pt missi n g d ue t o C O VI D -1 9 pa n de mic, will be i m p ute d usi n g a c o ntr ol -base d met h o d, 
ass u mi n g partic i pa nts ha ve efficac y  val ues si milar t o ve hicle partici pa nts ,a n d data are M A R . 
T he i m p utati o n will utilize A N C O V A m o del i ncl u di n g baseli ne as a c o variate .T he a nal y sis 
will c o m bi ne t he res ults fr o m t he m ulti ple i m p utati o ns usi n g R u bi n’s r ule’s as i m ple me nt e d 
i n S A S P R O C MI A N A L Y Z E. M M R M m o dels ma y  als o be use d o n o bser ve d data at all ti me 
p oi nts as se nsiti vit y  a nal y ses . T he fi xe d effects of treat me nt, visit, a n d treat me nt b y  visit 
i nteracti o n will be i ncl u de d. Baseli ne val ue will be i ncl u de d as a c o variate. N o a dj ust me nts 
f or m ulti plicit y  will be ma de. 
9. 3. 6. Terti ar y/ E x pl or at or y E n d p oi nt(s) 
Tertiar y  a n d ex pl orat or y  e n d p oi nts will be a nal y ze d descri pti vel y.  
 
 
9. 3. 7. S afet y A n al yses 
T he safet y data will be s u m marize d i n acc or da nce wit h [COMPANY_007] Data Sta n dar ds. All safet y 
a nal ys es will b e perf or me d o n t he safet y  p o p ulati o n. Safet y e n d p oi nts i ncl u de I nci de nce of 
treat me nt e mer ge nt A Es a n d S A Es, cli nicall y  si g nifica nt c ha n ges i n vital si g ns, E C G, a n d 
la b orat or y  tests. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 8 7 9. 3. 7. 1. Electr oc ar di o gr a m A n al yses 
C ha n ges fr o m baseli ne f or t he E C G para meters Q T i nter val, heart rate, Q Tc i nter val, P R 
i nter val, a n d Q R S c o m ple x will be s u m marize d b y treat me nt a n d ti me. 
T he n u m ber ( %) of partici pa nt s wit h ma xi m u m p ost -d ose Q Tc val ues a n d ma xi m u m 
i ncreases fr o m baseli ne i n t he f oll o wi n g cate g ories will be ta b ulate d b y  treat me nt: 
S afet y Q Tc Assess me nt 
De gree of Pr ol o n g ati o n Mil d ( ms ec ) M o der ate ( ms ec ) Se vere ( m sec )
A bs ol ute val ue >4 5 0 -4 8 0 >4 8 0 -5 0 0 > 5 0 0 
I ncrease fr o m baseli ne 3 0 -6 0 >6 0 
9. 3. 8. Ot her A n al yses 
 data fr o m Retai ne d Researc h Sa m ples ma y be c ollecte d 
d uri n g or after t he trial a n d retai ne d f or f ut ure a nal yses; t he res ults of s uc h a nal ys es are n ot 
pla n ne d t o be i ncl u de d i n t he C S R. 
9. 3. 8. 2. I nteri m A n al yses 
A n i nteri m a nal ys is ma y  be perf or me d t o assess efficac y  a n d safet y  w he n a p pr o xi matel y 
6 0 % of t he pla n ne d partici pa nts, ie, a p pr o xi matel y  [ADDRESS_82045] u d y  bli n d as per [COMPANY_007]’s S O Ps will be 
d oc u me nte d a n d a p pr o ve d i n a nI R C c harter . I n a d diti o n, t he a nal y sis details will be 
d oc u me nte d a n d a p pr o ve d i n t he S A P. 
9. 4. S a m ple Size Deter mi n ati o n 
9. 4. 1. S a m ple Size Deter mi n ati o n f or A D
A s ufficie nt n u m ber of partici pa nts will be scree ne d t o ac hie ve a p pr o xi matel y  
[ADDRESS_82046] u d y  i nter ve nti o n. T he sa m ple size calc ulati o n is 
base d o n t he pri mar y  efficac y  e sti ma n d I G A s uccess at Wee k 1 2. Ass u mi n g 1 5 % I G A 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 8 8 s uccess rate f or t he ve hicle ar m, a sa m ple size of 4 0 per ar m will ha ve 89% p o wer t o detect a 
treat me nt differe nce of 3 5 % u n der a 1- si de d Ty pe [ADDRESS_82047] , wit h a n o verall Ty pe 1 err or 
0. 0 25 1 -si de d. I n a d diti o n, t his sa m ple size will pr o vi de 9 6% p o wer t o detect a 
4 2 % differe nce i n E A SI -7 5 bet wee n a n acti ve ar m (6 2 % E A SI -7 5) a n d ve hicle 
( 2 0 % E A SI -7 5). 
9. 4. 2. S a m ple Size Deter mi n ati o n f or Ps O
A s ufficie nt n u m ber of partici pa nts will be s cree ne d t o ac hie ve a p pr o xi matel y  
[ADDRESS_82048] u d y  i nter ve nti o n. T he sa m ple size calc ulati o n is 
base d o n t he pri mar y  efficac y  esti ma n d P G A s uccess at Wee k 1 2. Ass u mi n g 8 % P G A 
s uccess rate f or t he ve hicle ar m, a sa m ple size of 3 0 p er ar m will ha ve 92% p o wer t o detect a 
treat me nt differe nce of 4 2 % u n der a 1- si de d Ty pe [ADDRESS_82049] , wit h a n o verall Ty pe 1 err or 
0. 0 25 1 -si de d. I n a d diti o n, t his sa m ple size will pr o vi de 9 6% p o wer t o detect a 
4 4 % differe nce i n P A SI -7 5 bet wee n a n acti ve ar m ( 5 0 % P A SI -7 5) a n d ve hicle 
( 6 % P A SI -7 5). 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 8 9 1 0. S U P P O R TI N G D O C U M E N T A TI O N A N D O P E R A TI O N A L C O N SI D E R A TI O N S 
1 0. 1. A p pe n di x 1: Re g ul at or y, Et hic al, a n d St u d y O v ersi g ht C o nsi der ati o ns 
[ADDRESS_82050] u d y  will be c o n d ucte d i n acc or da nce wit h t he pr ot oc ol a n d wit h t he f oll o wi n g: 
C o nse ns us et hical pri nci ples deri ve d fr o m i nter nati o nal g ui deli nes , i ncl u di n g t he 
Declarati o n of Helsi n ki a n d CI O M S I nter nati o nal Et hical G ui deli nes ;
A p plica ble I C H G C P gui deli nes ;
A p plica ble la ws a n d re g ulati o ns , i ncl u di n g a p plica ble pri vac y  la ws .
T he pr ot oc ol, pr ot oc ol a me n d me nts, I C D, S R S D(s) , a n d ot her rele va nt d oc u me nts 
(e g, a d vertise me nts) m ust be re vie we d a n d a p pr o ve d b y  t he s p o ns or ,s u b mitte d t o a n I R B/ E C 
b y  t he i n vesti gat or, a n d re vie we d a n d a p pr o ve d b y  t he I R B/ E C bef ore t he st u d y  is i nitiate d. 
A n y  a me n d me nts t o t he pr ot oc ol will re q uire I R B/ E C a p pr o val bef ore i m ple me ntati o n of 
c ha n ges ma de t o t he st u d y d esi g n, e xce pt f or c ha n ges necessar y  t o eli mi nate a n i m me diate 
hazar d t o st u d y  partici pa nts. 
Pr ot oc ols a n d a n y s u bsta ntial a me n d me nts t o t he pr ot oc ol will re q uire healt h a ut h orit y  
a p pr o val pri or t o i nitiati o n e xce pt f or c ha n ges necessar y  t o eli mi nate a n i m m e diate hazar d t o 
st u d y  partici pa nts. 
T he i n vesti gat or will be res p o nsi ble f or t he f oll o wi n g: 
Pr o vi di n g writte n s u m maries of t he stat us of t he st u d y  t o t he I R B/ E C a n n uall y  or 
m ore fre q ue ntl y  i n acc or da nce wit h t he re q uire me nts, p olicies, a n d pr oce d ures 
esta blis he d b y t he I R B/ E C ;
N otif y i n g t he I R B/ E C of S A Es or ot her si g nifica nt safet y fi n di n gs as re q uire d b y 
I R B/ E C pr oce d ures ;
Pr o vi di n g o versi g ht of t he c o n d uct of t he st u d y at t he site a n d a d here nce t o 
re q uire me nts of 2 1 C F R, I C H G C P g ui deli nes, t he I R B/ E C, E ur o pea n re g ulati o n 
5 3 6/ [ADDRESS_82051] u dies (if a p plica ble), E ur o pea n Me dical De vice Re g ulati o n 
2 0 1 7/ 7 4 5 f or cli nical de vice researc h (if a p plica ble), a n d all ot her a p plica ble l ocal 
re g ulati o ns ;
F or re p orti n g cases of s us pecte d c hil d a b use a n d/ or ne g lect acc or di n g t o l ocal me dical 
ass ociati o n (e g, A A P) or healt h de part me nt g ui deli nes. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 9 0 1 0. 1. 1. 1. Re p orti n g of S afet y Iss ues a n d Seri o us Bre a c hes of t he Pr ot oc ol or I C H G C P 
I n t he e ve nt of a n y pr o hi biti o n or restricti o n i m p ose d (ie, cli nical h ol d) b y a n a p plica ble 
re g ulat or y  a ut h orit y i n a n y area of t he w orl d, or if t he i n vesti gat or is a ware of a n y ne w 
i nf or mati o n t hat mi g ht i nfl ue nce t he e val uati o n of t he be nefits a n d ris ks of t he st u d y  
i nter ve nti o n , [COMPANY_007] s h o ul d be i nf or me d i m me diatel y . 
I n a d diti o n, t he i n vesti gat or will i nf or m [COMPANY_007] i m me diatel y  of a n y  ur ge nt safet y meas ures 
ta ke n b y t he i n vesti gat or t o pr otect t he st u d y  partici pa nt s a gai nst a n y i m me diate hazar d, a n d 
of a n y seri o us breac hes of t his pr ot oc ol or of t he I C H G C P g ui deli nes t hat t he i n vesti gat or 
bec o me s a ware of. 
[ADDRESS_82052] u d y .
1 0. 1. 3. I nf or me d C o nse nt / asse nt Pr ocess 
T he i n vesti gat or or his / her re prese ntati ve will e x plai n t he nat ure of t he st u d y  t o t he 
partici pa nt a n d his/ her pare nt(s)/le gal g uar dia n a n d a ns wer all q uesti o ns re gar di n g t he st u d y . 
T he partici pa nt a n d his/ her pare nt(s)/le gal g uar dia n s h o ul d be gi ve n s ufficie nt ti me a n d 
o p p ort u n it y  t o as k q uesti o ns a n d t o deci de w het her or n ot t o partici pate i n t he trial. 
W he n c o nse nt is o btai ne d fr o m a partici pa nt’s pare nt(s)/le gal g uar dia n, t he partici pa nt’s 
asse nt ( affir mati ve a gree me nt) m ust be s u bse q ue ntl y  o btai ne d w he n t he partici pa nt has t he 
ca pacit y  t o pr o vi de asse nt, as deter mi ne d b y  t he I R B/ E C. If t he i n vesti gat or deter mi nes t hat a 
partici pa nt’s decisi o nal ca pacit y is s o li mite d he/s he ca n n ot reas o na bl y be c o ns ulte d, t he n, as 
per mitte d b y  t he I R B/ E C a n d c o nsiste nt wit h l ocal re g ulat or y  a n d le gal re q uire me nts, t he 
partici pa nt’s asse nt ma y  be wai ve d wit h s o urce d oc u me ntati o n of t he reas o n asse nt was n ot 
o btai ne d. If t he st u d y partici pa nt d oes n ot pr o vi de his or her o w n asse nt, t he s o urce 
d oc u me nts m ust rec or d w h y  t he partici pa nt di d n ot pr o vi de asse nt (f or e xa m ple, mi n or c hil d), 
h o w t he i n vesti gat or deter mi ne d t hat t he pers o n si g ni n g t he c o nse nt was t he partici pa nt’s 
pare nt(s)/le gal g uar dia n, t he c o nse nt si g ner’s relati o ns hi p t o t he st u d y  partici pa nt, a n d t hat 
t he partici pa nt’s asse nt was o btai ne d or wai ve d. If asse nt is o btai ne d ver ball y, it m ust be 
d oc u me nte d i n t he s o urce d oc u me nts. 
If st u d y  partici pa nts are mi n ors w h o reac h t he a ge of maj orit y d uri n g t he st u d y, as rec o g nize d 
u n der l ocal la w, t he y  m ust be rec o nse nte d as a d ults t o re mai n i n t he st u d y . If t he e nr oll me nt 
of e ma nci pate d mi n ors is per mitte d b y  t he I R B/ E C a n d l ocal la w, t he y  m ust pr o vi de 
d oc u me ntati o n of le gal stat us t o gi ve c o nse nt wit h o ut t he per missi o n of a le gall y a ut h orize d 
re prese ntati ve. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 9 1 Partici pa nts a n d t heir pare nt(s)/le gal g uar dia n m ust be i nf or me d t hat t heir partici pati o n is 
v ol u ntar y . Partici pa nt’s pare nt(s)/le gal g uar dia n will be re q uire d t o si g n a state me nt of 
i nf or me d c o nse nt t hat meets t he re q uire me nts of 2 1 C F R 5 0, l ocal re g ulati o ns, I C H 
g ui deli nes, HI P A A re q ui re me nts, w here a p plica ble, a n d t he I R B/ E C or st u d y  ce nter. 
T he i n vesti gat or m ust e ns ure t hat eac h st u d y  partici pa nt’s pare nt(s)/le gal g uar dia n a n d t he 
st u d y  partici pa nt as a p plica ble is f ull y i nf or me d a b o ut t he nat ure a n d o bjecti ves of t he st u d y, 
t he s har i n g of data relate d t o t he st u d y , a n d p ossi ble ris ks ass ociate d wit h partici pati o n, 
i ncl u di n g t he ris ks ass ociate d wit h t he pr ocessi n g of t he partici pa nt’s pers o nal data.  
T he partici pa nt’s pare nt(s)/le gal g uar dia n m ust be i nf or me d t hat t he partici pa nt’s pers o nal 
st u d y -relate d data will be use d b y  t he s p o ns or i n acc or da nce wit h l ocal data pr otecti o n la w. 
T he le vel of discl os ure m ust als o be e x plai ne d t o t he partici pa nt’s pare nt(s)/le gal g uar dia n. 
T he partici pa nt’s pare nt(s)/le gal g uar dia n m ust be i nf or me d t hat t he partici pa nt’s me dical 
rec or ds ma y  be e xa mi ne d b y  Cli nical Q ualit y Ass ura nce a u dit ors or ot her a ut h orize d 
pers o n nel a p p oi nte d b y t he s p o ns or, b y a p pr o priate I R B/ E C me m bers, a n d b y  i ns pect ors 
fr o m re g ulat or y  a ut h orities. 
T he i n vesti gat or f urt her m ust e ns ure t hat eac h st u d y  partici pa nt’s pare nt(s)/le gal g uar dia n is 
f ull y  i nf or me d a b o ut his or her ri g ht t o access a n d c orrect his or her c hil d’s pers o nal data a n d 
t o wit h dra w c o nse nt f or t he pr ocessi n g of his or her c hil d’s pers o nal data kee pi n g i n mi n d t he 
pri vac y  ri g hts t hat ma y  restrict access of ol der a d olesce nts me dical rec or ds b y  t heir 
pare nt(s)/le gal g uar dia n i n certai n re gi o ns .
T he s o urce d oc u me ntati o n m ust i ncl u de a state me nt t hat writte n i nf or me d c o nse nt a n d as 
a p plica ble, asse nt , was o btai ne d bef ore t he partici pa nt was e nr olle d i n t he st u d y  a n d t he date 
t he writte n c o nse nt/asse nt was o btai ne d. T he a ut h orize d pers o n o btai ni n g t he i nf or me d 
c o nse nt m ust als o si g n t he I C D. 
Pare nt(s)/le gal g uar dia n a n d t he partici pa nt m ust be rec o nse nte d t o t he m o st c urre nt versi o n 
of t he I C D(s)/asse nt d uri n g t heir partici pati o n i n t he st u d y . 
A c o p y of t he I C D(s) a n d asse nt, if writte n, m ust be pr o vi de d t o t he pare nt(s)/le gal g uar dia n 
a n d t he partici pa nt. 
Partici pa nts w h o are rescree ne d are re q uire d t o si g n a ne w I C D. 
[ADDRESS_82053] y  wit h all a p plica ble la ws, i ncl u di n g la ws re gar di n g t he i m ple me ntati o n 
of or ga nizati o nal a n d tec h nical meas ures t o e ns ure pr otecti o n of partici pa nt data. 
Partici pa nts’ pers o nal data will be st ore d at t he st u d y  s ite i n e ncr y pte d electr o nic a n d/ or pa per 
f or m a n d will be pass w or d -pr otecte d or sec ure d i n a l oc ke d r o o m t o e ns ure t hat o nl y  
a ut h orize d st u d y  staff ha ve access. T he st u d y  site will i m ple me nt a p pr o priate tec h nical a n d 
or ga nizati o nal meas ures t o e ns ure t hat t he pers o nal data ca n be rec o vere d i n t he e ve nt of 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82054] t he ri g hts a n d free d o ms of partici pa nts wit h re gar d t o t he pr ocessi n g of pers o nal 
data, partici pa nts will be assi g ne d a si n gle, partici pa nt -s pecific n u merical c o de. A n y 
partici pa nt rec or ds or data sets t hat are tra nsferre d t o t he s p o ns or will c o ntai n t he n u merical 
c o de; partici pa nt na mes will n ot be tra nsferre d. All ot her i de ntifia ble data tra nsferre d t o t he 
s p o ns or will be i de ntifie d b y  t his si n gle, partici pa nt -s pecific c o de. T he st u d y  site will 
ma i ntai n a c o nfi de ntial list of partici pa nt s w h o partici pate d i n t he st u d y, li n ki n g eac h 
partici pa nt ’s n u merical c o de t o his or her act ual i de ntit y a n d me dical rec or d I D . I n case of 
data tra nsfer, t he s p o ns or will pr otect t he c o nfi de ntialit y  of partici pa nt s’ pers o nal data 
c o nsiste nt wit h t he cli nical st u d y  a gree me nt a n d a p plica ble pri vac y  la ws. 
[ADDRESS_82055] u dies o n w w w .cli nicaltrials. g o v ( Cli nical T rials. g o v), t he E u dra C T , a n d/ or 
w w w . pfizer .c o m, a n d ot her p u blic re gistries i n acc or da nce wit h a p plica ble l ocal 
la ws/re g ulati o ns. I n a d diti o n, [COMPANY_007] re p orts st u d y  res ults o utsi de of t he re q uire me nts of l ocal 
la ws/re g ulati o ns p urs ua nt t o its S O Ps. 
I n all cases, st u d y res ults are r e p orte d b y [COMPANY_007] i n a n o bjecti ve, acc urate, bala nce d, a n d 
c o m plete ma n ner a n d are re p orte d re gar dless of t he o utc o me of t he st u d y or t he c o u ntr y i n 
w hic h t he st u d y  was c o n d ucte d. 
w w w .cli nicaltrials. g o v 
[COMPANY_007] p osts cli nical trial res ults o n w w w .cli nicaltrials. g o v f or [COMPANY_007] -s p o ns ore d i nter ve nti o nal 
st u dies (c o n d ucte d i n patie nts) t hat e val uate t he safet y  a n d/ or ef ficac y  of a pr o d uct, 
re gar dless of t he ge o gra p hical l ocati o n i n w hic h t he st u d y  is c o n d ucte d. T hese r es ults are 
s u b mitte d f or p osti n g i n acc or da nce wit h t he f or mat a n d ti meli nes set f ort h b y  U S la w. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82056] u dies i n 
acc or da nce wit h t he f or mat a n d ti meli nes set f ort h b y  E U re q uire me nts. 
w w w . pfizer .c o m 
[COMPANY_007] p osts p u blic discl os ure s y n o pses ( C S R s y n o pses i n w hic h a n y data t hat c o ul d be use d 
t o i de ntif y  i n di vi d ual partici pa nts ha ve bee n re m o ve d) o n w w w. pfizer.c o m f or 
[COMPANY_007] -s p o ns ore d i nter ve nti o nal st u dies at t he sa me ti me t he c orres p o n di n g st u d y  res ults are 
p oste d t o w w w.cli nicaltrials. g o v .
D oc u me nts wit hi n mar keti n g a ut h orizati o n pac ka ges/s u b missi o ns 
[COMPANY_007] c o m plies wit h t he E ur o pea n U ni o n P olic y  0 0 7 0, t he pr oacti ve p u blicati o n of cli nical 
data t o t he E M A we bsite. Cli nical data, u n der P hase 1 of t his p o lic y , i ncl u des cli nical 
o ver vie ws, cli nical s u m maries, C S Rs, a n d a p pe n dices c o ntai ni n g t he pr ot oc ol a n d pr ot oc ol 
a me n d me nts, sa m ple C R Fs, a n d statistical met h o ds. Cli nical data, u n der P hase 2 of t his 
p olic y , i ncl u des t he p u blis hi n g of i n di vi d ual partici pa n t data. P olic y  0 0 7 0 a p plies t o ne w 
mar keti n g a ut h orizati o n a p plicati o ns s u b mitte d via t he ce ntralize d pr oce d ure si nce 
0 1 Ja n uar y 2 0 1 5 a n d a p plicati o ns f or li ne e xte nsi o ns a n d f or ne w i n dicati o ns s u b mitte d via 
t he ce ntralize d pr oce d ure si nce 0 1 J ul y  2 0 1 5. 
Data shari n g 
[COMPANY_007] pr o vi des researc hers sec ure access t o patie nt- le vel data or f ull C S Rs f or t he p ur p oses 
of “ b o na -fi de scie ntific researc h” t hat c o ntri b ute st o t he scie ntific u n dersta n di n g of t he 
disease, tar get, or c o m p o u n d class. [COMPANY_007] will ma ke data f r o m t hese trials a vaila ble 
[ADDRESS_82057], i ncl u di n g i n di vi d uals 
re q uesti n g access f or c o m mercial/c o m petiti ve or le gal p ur p oses. 
[ADDRESS_82058] u d y will be rec or de d o n pri nte d or electr o nic C R F u nless 
tra ns mitt e d t o t he s p o ns or or desi g nee electr o nicall y  (e g, la b orat or y  data). T he i n vesti ga t or is 
res p o nsi ble f or verif y i n g t hat data e ntries are acc urate a n d c orrect b y  p h y sicall y  or 
electr o nicall y  si g ni n g t he C R F. 
G ui da nce o n c o m pleti o n of C R Fs will be pr o vi de d i n t he C R F C o m pleti o n Re q uire me nts 
d oc u me nt .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82059] u d y site i n e ncr y pte d 
electr o nic a n d/ or pa per f or m a n d are pass w or d pr otecte d or sec ure d i n a l oc ke d r o o m t o 
pre ve nt access b y u na ut h orize d t hir d parties. 
Q T L s are pre defi ne d para meters t hat are m o nit ore d d uri n g t he st u d y .I m p orta nt de viati o ns 
fr o m t he Q T Ls a n d a n y re me dial acti o ns ta ke n will be s u m marize d i n t he cli nical st u d y  
re p ort. 
T he i n vesti gat or m ust per mit st u d y -relate d m o nit ori n g, a u dits, I R B/ E C re vie w, a n d 
re g ulat or y  a ge nc y  i ns pecti o ns a n d pr o vi de direct access t o s o urce data d oc u me nts. T his 
verificati o n ma y  als o occ ur after st u d y  c o m pleti o n. I t is i m p orta nt t hat t he i n vesti gat or(s) a n d 
t heir rele va nt pers o n nel are a vaila ble d uri n g t he m o nit ori n g visits a n d p ossi ble a u dits or 
i ns pecti o ns a n d t hat s ufficie nt ti me is de v ote d t o t he pr ocess. 
M o nit ori n g details descri bi n g strate g y , i ncl u di n g defi niti o n of st u d y  critical data ite ms a n d 
pr ocesses (e g, -ris k base d i nitiati ves i n o perati o ns a n d q ualit y  s uc h as ris k ma na ge me nt a n d 
miti gati o n strate gies a n d anal yt ical -ris k base d mo nit ori n g), met h o ds, res p o nsi bilities ,a n d 
re q uire me nts, i ncl u di n g ha n dli n g of n o nc o m plia nce iss ues a n d m o nit ori n g tec h ni q ues 
(ce ntral, virt ual , or o n -site m o nit ori n g) , are pr o vi de d i n t he data ma na ge me nt pla n a n d 
mo nit ori n g pla n mai ntai ne d a n d util ize d b y  t he s p o ns or or desi g nee. 
T he s p o ns or or desi g nee is res p o nsi ble f or t he data ma na ge me nt of t his st u d y ,i ncl u di n g 
q ualit y  c hec ki n g of t he data. 
Rec or ds a n d d oc u me nts, i ncl u di n g si g ne d I C Ds, pertai ni n g t o t he c o n d uct of t his st u d y  m ust 
be retai ne d b y t he i n vesti gat or f or [ADDRESS_82060] ore d sec urel y f or as l o n g as t he y  are 
mai n tai ne d. 
W he n partici pa nt data are t o be delete d, t he i n vesti gat or will e ns ure t hat all c o pi[INVESTIGATOR_1309] s uc h 
data are pr o m ptl y  a n d irre v oca bl y delete d fr o m all s yste ms. 
T he i n vesti gat or(s) will n otif y t he s p o ns or or its a ge nts i m me diatel y  of a n y  re g ulat or y  retai n 
n otificati o n i n relati o n t o t he st u d y . F urt her m ore, t he i n vesti gat or will c o o perate wit h t he 
s p o ns or or its a ge nts t o pre pare t he i n vesti gat or site f or t he i ns pecti o n a n d will all o w t he 
s p o ns or or its a ge nt, w he ne ver feasi ble, t o be prese nt d uri n g t he i ns pecti o n. T he i n vesti gat or 
site a n d i n vesti gat or will pr o m ptl y  res ol ve a n y discre pa ncies t hat are i de ntifie d bet wee n t he 
st u d y  data a n d t he partici pa nt's me dical rec or ds. T he i n vesti gat or will pr o m ptl y  pr o vi de 
c o pi[INVESTIGATOR_1309] t he i ns pecti o n fi n di n gs t o t he s p o ns or or its a ge nt. Bef ore res p o nse s u b missi o n t o 
t he re g ulat or y  a ut h orities, t he i n vesti gat or will pr o vi de t he s p o ns or or its a ge nts wit h a n 
o p p ort u nit y  t o re vie w a n d c o m me nt o n res p o nses t o a n y  s uc h fi n di n gs. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82061] mai ntai n acc urate d oc u me ntati o n (s o urce data) t hat s u p p orts t he 
i nf or mati o n e ntere d i n t he C R F. 
St u d y  m o nit ors will perf or m o n g oi n g s o urce data verificati o n t o c o nfir m t hat data e ntere d 
i nt o t he C R F b y  a ut h orize d site pers o n nel are acc urate, c o m plete, a n d verifia ble fr o m s o urce 
d oc u me nts; t hat t he safet y a n d ri g hts of partici pa nts are bei n g pr otecte d; a n d t hat t he st u d y  is 
bei n g c o n d ucte d i n acc or da nce wit h t he c urre ntl y  a p pr o ve d pr ot oc ol a n d a n y  ot her st u d y  
a gree me nts, I C H G C P g ui deli nes , a n d all a p plica bl e re g ulat or y  re q uire me nts. 
[ADDRESS_82062] partici pa nt’s first visit a n d will be t he st u d y  
start date. 
T he s p o ns or desi g nee reser ves t he ri g ht t o cl ose t he st u d y  site or ter mi nate t he st u d y  at a n y  
ti me f or a n y reas o n at t he s ole discreti o n of t he s p o ns or. St u d y  sites will be cl ose d u p o n st u d y  
c o m pleti o n. A st u d y  site is c o nsi dere d c l ose d w he n all re q uire d d oc u me nts a n d st u d y  
s u p plies ha ve bee n c ollecte d a n d a st u d y- site cl os ure visit has bee n perf or me d. 
T he i n vesti gat or ma y  i nitiate st u d y -site cl os ure at a n y  ti me u p o n n otificati o n t o t he s p o ns or 
or desi g nee/ C R O if re q ueste d t o d o s o b y  t he res p o nsi ble I R B/ E C or if s uc h ter mi nati o n is 
re q uire d t o pr otect t he healt h of st u d y  partici pa nts .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82063] u d y site b y t he s p o ns or ma y i ncl u de b ut are n ot li mite d 
t o: 
Fail ure of t he i n vesti gat or t o c o m pl y  wit h t he pr ot oc ol, t he re q uire me nts of t he 
I R B/ E C or l ocal healt h a ut h orities, t he s p o ns or's pr oce d ures, or t he I C H G C P 
g ui deli nes ;
I n a de q uate recr uit me nt of partici pa nts b y  t he i n vesti gat or; 
Disc o nti n uati o n of f urt her st u d y  i nter ve nti o n de vel o p me nt .
If t he st u d y is pre mat urel y  ter mi nate d or s us pe n de d, t he s p o ns or s hall pr o m ptl y  i nf or m t he 
in vesti gat ors, t he E Cs/I R Bs, t he re g ulat or y  a ut h orities, a n d a n y  C R O (s) use d i n t he st u d y  of 
t he reas o n f or ter mi nati o n or s us pe nsi o n, as s pecifie d b y  t he a p plica ble re g ulat or y  
re q uire me nts. T he in vesti gat or s hall pr o m ptl y  i nf or m t he partici pa nt a n d s h o ul d ass ure 
a p pr o priate partici pa nt t hera p y  a n d/ or f oll o w - u p. 
St u d y  ter mi nati o n is als o pr o vi de d f or i n t he cli nical st u d y  a gree me nt. If t here is a n y  c o nflict 
bet wee n t he c o ntract a n d t his pr ot oc ol ,t he c o ntract will c o ntr ol as t o ter mi nati o n ri g hts. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 9 7 1 0. 1. 1 1. S p o ns or’s Q u alifie d Me dic al Pers o n nel 
T he c o ntact i nf or mati o n f or t he s p o ns or's a p pr o priatel y q ualifie d me dical pers o n nel f or t he 
st u d y  is d oc u me nte d i n t he st u d y  c o ntact list l ocate d i n t he st u d y  tea m o n de ma n d s y ste m . 
T o facilitate access t o a p pr o priatel y q ualifie d me dical pers o n nel f or st u d y -relate d me dical 
q uesti o ns or pr o ble ms, partici pa nts are pr o vi de d wit h a n E C C) at t he ti me of i nf or me d 
c o nse nt /asse nt . T he E C C c o ntai ns, at a mi ni m u m, (a) pr ot oc ol a n d st u d y  i nter ve nti o n 
i de nt ifiers, ( b) partici pa nt’s st u d y  i de ntificati o n n u m ber, (c) site e mer ge nc y  p h o ne n u m ber 
acti ve 2 4 h o urs/ da y , 7 da y s per wee k, a n d ( d) [COMPANY_007] Call Ce nter n u m ber. 
T he E C C is i nte n de d t o a u g me nt, n ot re place, t he esta blis he d c o m m u nicati o n pat h wa y s 
bet wee n t he i n vesti gat or, site staff, a n d st u d y  tea m. T he E C C is t o be use d b y  healt hcare 
pr ofessi o nals n ot i n v ol ve d i n t he researc h st u d y o nl y , as a mea ns of reac hi n g t he i n vesti gat or 
or site staff relate d t o t he care of a partici pa nt. T he [COMPANY_007] Call Ce nter n u m ber s h o ul d o nl y  be 
use d w he n t he i n vesti gat or a n d site staff ca n n ot be reac he d. T he [COMPANY_007] Call Ce nter n u m ber is 
n ot i nte n de d f or use b y t he partici pa nt directl y ; if a partici pa nt calls t hat n u m ber directl y, he 
or s he will be directe d bac k t o t he i n vesti gat or s ite. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 9 8 1 0. 2. A p pe n di x 2: Cli nic al L a b or at or y Tests 
T he f oll o wi n g safet y la b orat or y  tests will be perf or me d at ti mes defi ne d i n t he S o A secti o n of 
t his pr ot oc ol. A d diti o nal la b orat or y  res ults ma y be re p orte d o n t hese sa m ples as a res ult of 
t he met h o d of a nal ys is or t he t y pe of a nal yz er use d b y  t he cli nical la b orat or y ,or as deri ve d 
fr o m calc ulate d val ues. T hese a d diti o nal tests w o ul d n ot re q uire a d diti o nal c ollecti o n of 
bl o o d. U nsc he d ule d cli nical la b orat or y  meas ure me nts ma y  be o btai ne d at a n y  ti me d uri n g t he 
st u d y  t o assess a n y percei ve d safet y iss ues. 
T a ble 6. Pr ot oc ol Re q uire d S afet y L a b or at or y Assess me nts 
H e m at ol o g y C he mistr y Uri n al ysis Ot her 
H e m o gl o bi n 
H e m at ocrit 
R B C c o u nt a n d i n dices 
M C V 
M C H 
M C H C 
W B C c o u n t wit h 
differe ntial 
T otal ne utr o p hils ( A bs) 
E osi n o p hils ( A bs) 
M o n oc ytes ( A bs) 
Bas o p hils ( A bs) 
L y m p h oc ytes ( A bs) 
Platelet c o u nt B U N a n d creati ni ne 
Creati ni ne Ki nase 
Gl uc ose 
Ca lci u m 
S o di u m 
P otassi u m 
C hl ori de 
T otal C O 2( b icar b o nate) 
A S T, A L T 
T otal bilir u bi n 
Direct Bilir u bi n a
Al kali ne p h os p hatase 
Uric aci d 
Al b u mi n 
T otal pr otei n Pr otei n ( q ual )
Bl o o d ( q ual) 
Nitrites 
Le u k oc yte esterase 
Micr osc o p y bF S H c
Pre g na nc y test ( β- h C G )d
a. O nl y if t otal bilir u bi n is ele vate d .
b. O nl y if uri ne di pstic k is p ositi ve f or bl o o d, pr otei n, nitrites, or le u k oc yte esterase. 
c. F or c o nfir mati o n of p ost me n o pa usal stat us, i n fe males w h o are a me n orr heic f or at least [ADDRESS_82064] u d y  has bee n u n bli n de d. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 9 9 1 0. 3. A p pe n di x 3: A d verse E ve nts: Defi niti o ns a n d Pr oce d ures f or Rec or di n g, 
E v al u ati n g, F oll o w - U p, a n d Re p orti n g 
1 0. 3. 1. Defi niti o n of A E 
A E Defi niti o n 
A n A E is a n y u nt o war d me dical occ urre nce i n a patie nt or cli nical st u d y  
partici pa nt, te m p orall y ass ociate d wit h t he use of st u d y i nter ve nti o n, w het her or n ot 
c o nsi dere d relate d t o t he st u d y  i nter ve nti o n. 
Note : A n A E ca n t heref ore be a n y u nfa v ora ble a n d u ni nte n de d si g n (i ncl u di n g a n 
a b n or mal la b orat o r y  fi n di n g), s y m pt o m, or disease ( ne w or e xacer bate d) te m p orall y  
ass ociate d wit h t he use of st u d y  i nter ve nti o n. 
E ve nts Meeti n g t he A E Defi niti o n 
A n y  a b n or mal la b orat or y test res ults ( he mat ol o g y , cli nical c he mistr y , or uri nal y sis) 
or ot her safet y assess m e nts (e g, E C G, ra di ol o gical sca ns, vital si g n meas ure me nts), 
i ncl u di n g t h ose t hat w orse n fr o m baseli ne, c o nsi dere d cli nicall y si g nifica nt i n t he 
me dical a n d scie ntific j u d g me nt of t he i n vesti gat or .A n y a b n or mal la b orat or y test 
res ults t hat meet a n y of t he c o n diti o ns bel o w m ust be rec or de d as a n A E: 
Is ass ociate d wit h acc o m pa n y i n g s y m pt o ms .
Re q uires a d diti o nal dia g n ostic testi n g or me dical/s ur gical i nter ve nti o n .
Lea ds t o a c ha n ge i n st u d y  d osi n g ( o utsi de of a n y  pr ot oc ol -s pecifie d d ose 
a dj ust me nts) or disc o nti n uati o n fr o m t he st u d y, si g nifica nt a d diti o nal 
c o nc o mita nt dr u g treat me nt, or ot her t hera p y. 
E xacer bati o n of a c hr o nic or i nter f ull e nt pree xisti n g c o n diti o n ,i ncl u di n g eit her a n 
i ncrease i n fre q ue nc y  a n d/ or i nte nsit y  of t he c o n diti o n. 
Ne w c o n diti o n detecte d or dia g n ose d after st u d y  i nter ve nti o n a d mi nistrati o n, e ve n 
t h o u g h it ma y  ha ve bee n prese nt bef ore t he start of t he st u d y .
Si g ns, s y m pt o ms, or t he cli nical se q uelae of a s us pecte d dr u g -dr u g i nteracti o n. 
Si g ns, s y m pt o ms, or t he cli nical se q uelae of a s us pecte d o ver d ose of eit her st u d y  
i nter ve nti o n or a c o nc o mita nt me dicati o n. O ver d ose per se will n ot be re p orte d as 
a n A E or S A E u nless it is a n i nte nti o nal o ver d ose ta ke n wit h p ossi ble 
s uici dal/self- har mi n g i nte nt. S uc h o ver d oses s h o ul d be re p orte d re gar dless of 
se q uelae. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 0 0 E ve nts N O T Meeti n g t he A E Defi niti o n 
A n y  cli nicall y  si g nifica nt a b n or mal la b orat or y  fi n di n gs or ot her a b n or mal safet y 
assess me nts t hat are ass ociate d wit h t he u n derl yi n g disease, u nless j u d ge d b y  t he 
i n vesti gat or t o be m ore se vere t ha n e x pecte d f or t he partici pa nt’s c o n diti o n. 
T he disease/ dis or der bei n g st u die d or e x pecte d pr o gressi o n, si g ns, or s y m pt o ms of 
t he disease/ dis or der bei n g st u die d, u nless m ore se vere t ha n e x pecte d f or t he 
partici pa nt’s c o n diti o n. 
Me dical or s ur gical pr oce d ure (e g, e n d osc o p y, a p pe n dect o m y): t he c o n diti o n t hat 
lea ds t o t he pr oce d ure is t he A E. 
Sit uati o ns i n w hic h a n u nt o war d me dical occ urre nce di d n ot occ ur (s oci al a n d/ or 
c o n ve nie nce a d missi o n t o a h os pi[INVESTIGATOR_307]). 
A ntici pate d da y -t o -d a y  fl uct uati o ns of pree xisti n g disease(s) or c o n diti o n(s) prese nt 
or detecte d at t he start of t he st u d y t hat d o n ot w orse n. 
1 0. 3. 2. Defi niti o n of a n S A E 
A n S A E is defi ne d as a n y u nt o w ar d me dic al occ urre nce t h at, at a n y d ose , meets o ne 
or m ore of t he criteri a liste d bel o w: 
a. Res ults i n de at h 
b. Is life -t hre ate ni n g 
T he ter m “life -t hreate ni n g ”i n t he defi niti o n of “seri o us ”refers t o a n e ve nt i n w hic h t he 
partici pa nt was at ris k of deat h at t he ti me of t he e ve nt. It  d oes n ot refer t o a n e ve nt t hat 
h y p ot heticall y  mi g ht ha ve ca use d deat h if it were m ore se vere. 
c. Re q uires i n p atie nt h os pit aliz ati o n or pr ol o n g ati o n of e xisti n g h o s pit aliz ati o n 
I n ge neral, h os pi[INVESTIGATOR_1314] o n si g nifies t hat t he partici pa nt has bee n a d mitte d ( us uall y  
i n v ol vi n g at least a n o ver ni g ht sta y ) at t he h os pi[INVESTIGATOR_6879] e mer ge nc y  war d f or o bser vati o n 
a n d/ or treat me nt t hat w o ul d n ot ha ve bee n a p pr o priate i n t he p h ys ici a n’s office or 
o ut patie nt setti n g. C o m plicati o ns t hat occ ur d uri n g h os pi[INVESTIGATOR_1314] o n are A Es. If a 
c o m plicati o n pr ol o n gs h os pi[INVESTIGATOR_1314] o n or f ulfills a n y ot her seri o us criteria, t he e ve nt is 
seri o us. W he n i n d o u bt as t o w het her “ h os pi[INVESTIGATOR_1314] o n” occ urre d or w as necessar y , t he 
A E s h o ul d be c o nsi dere d seri o us. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 0 1 H os pi[INVESTIGATOR_1314] o n f or electi ve treat me nt of a pree xisti n g c o n diti o n t hat di d n ot w orse n 
fr o m baseli ne is n ot c o nsi dere d a n A E. 
d. Res ults i n persiste nt or si g nific a nt dis a bilit y/i nc a p acit y 
T he ter m disa bilit y  mea ns a s u bsta ntial disr u pti o n of a pers o n’s a bilit y  t o c o n d uct 
n or mal life f u ncti o ns. 
T his defi niti o n is n ot i nte n de d t o i ncl u de e x perie nces of relati vel y mi n or me dical 
si g nifica nce , s uc h as u nc o m plicate d hea dac he, na usea, v o miti n g, diarr hea, 
i nfl ue nza, a n d acci de ntal tra u ma (e g, s prai ne d a n kle), t hat m a y  i nterfere wit h or 
pre ve nt e ver y d a y  life f u ncti o ns b ut d o n ot c o nstit ute a s u bsta ntial disr u pti o n. 
e. Is a c o n ge nit al a n o m al y/ birt h defect 
f. Is a s us pecte d tr a ns missi o n vi a a [COMPANY_007] pr o d uct of a n i nfecti o us a ge nt, p at h o ge nic 
or n o n- p at h o ge nic, is c o nsi dere d seri o us 
T he e ve nt ma y  be s us pecte d fr o m cli nical s y m pt o ms or la b orat or y  fi n di n gs i n dicati n g 
a n i nfecti o n i n a partici pa nt e x p ose d t o a Pfi zer pr o d uct. T he ter ms “s us pecte d 
tra ns missi o n ” a n d “tra ns missi o n ” are c o nsi dere d s y n o n y m o us. T hese cases are 
c o nsi dere d u ne x pecte d a n d ha n dle d as seri o us e x pe dite d cases b y p har mac o vi gila nce 
pers o n nel. S uc h cases are als o c o nsi dere d f or re p orti n g as pr o d u ct defects, if 
a p pr o priate. 
g. Ot her sit u ati o ns: 
Me dical or scie ntific j u d g me nt s h o ul d be e xercise d b y  t he i n vesti gat or i n deci di n g 
w het her S A E re p orti n g is a p pr o priate i n ot her sit uati o ns, s uc h as si g nifica nt 
me dical e ve nts t hat ma y je o par dize t he partici pa nt or ma y  re q uire me dical or 
s ur gical i nter ve nti o n t o pre ve nt o ne of t he ot her o utc o mes liste d i n t he a b o ve 
defi niti o n. T hese e ve nts s h o ul d us uall y  be c o nsi dere d seri o us. 
E xa m ples of s uc h e ve nts i ncl u de i n vasi ve or mali g na nt ca ncers, i nte nsi ve treat me nt 
i n a n e mer ge nc y  r o o m or at h o me f or aller gic br o nc h os pas m, bl o o d d y scrasias or 
c o n v ulsi o ns t hat d o n ot res ult i n h os pi[INVESTIGATOR_1314] o n , or de vel o p me nt of dr u g 
de pe n de nc y  or dr u g a b use. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 0 2 1 0. 3. 3. Rec or di n g / Re p orti n g a n d F oll o w - U p of A E sa n d/ or S A E sD uri n g t he Acti ve 
C ollecti o n Peri o d 
A E a n d S A E Rec or di n g / Re p orti n g 
T he ta ble bel o w s u m marizes t he re q uire me nts f or rec or di n g A Es o n t he C R F a n d f or 
re p orti n g S A E so n t he C T S A E Re p ort F or m t o [COMPANY_007] Safet yt hr o u g h o ut t he acti ve 
c ollecti o n peri o d . T hese re q uire me nts are deli neate d f or 3 t y pes of e ve nts: ( 1) S A Es; 
( 2) n o nseri o us A Es ; a n d ( 3) e x p os ure t o t he st u d y  i nter ve nti o n u n der st u d y d uri n g 
pre g na nc y  or breastfee di n g, a n d occ u pati o nal e x p os ure. 
It s h o ul d be n ote d t hat t he C T S A E Re p ort F or m f or re p orti n g of S A E i nf or m ati o n is n ot 
t he sa me as t he A E pa ge of t he C R F. W he n t he sa me data are c ollecte d, t he f or ms m ust be 
c o m plete d i n a c o nsiste nt ma n ner. A Es s h o ul d be rec or de d usi n g c o ncise me dical 
ter mi n ol o g y  a n d t he sa me A E ter m s h o ul d be use d o n b ot h t he C R F a n d t he C T S A E 
Re p ort F or m f or re p orti n g of S A E i nf or mati o n. 
S afet y E ve nt Rec or de d o n t he C R F Re p orte d o n t he C T S A E 
Re p ort F or m t o [COMPANY_007] 
S afet y Wit hi n [ADDRESS_82065] u d y 
d uri n g pre g na nc y  or 
breastfee di n g, All A Es or S A Es ass ociate d 
wit h e x p os ure d uri n g 
pre g na nc y  or breastfee di n g 
N ote: I nsta nces of E D P or 
E D B n ot ass ociate d wit h a n 
A E or S A E are n ot ca pt ure d 
i n t he C R F. All i nsta nces of E D P are 
re p orte d ( w het her or n ot 
t here is a n ass ociate d 
S A E) * 
All i nsta nces of E D B are 
re p orte d ( w het her or n ot 
t here is a n ass ociate d 
S A E). * * 
E n vir o n me ntal or 
occ u pati o nal e x p os ure t o 
t he pr o d uct u n der st u d y t o 
a n o n -partici pa nt ( n ot 
i n v ol vi n g E D P or E D B). N o ne. E x p os ure t o a st u d y  
n o n- partici pa nt is n ot 
c ollecte d o n t he C R F. T he e x p os ure ( w het her or 
n ot t here is a n ass ociate d 
A E or S A E) m ust be 
re p orte d. * * * 
*E D P ( w it h or wit h o ut a n ass ociate d A E or S A E): a n y pre g na nc y i nf or mati o n is re p orte d t o [COMPANY_007] 
Safet y usi n g C T S A E Re p ort F or m a n d E D P S u p ple me ntal F or m; if t he E D P is ass ociate d w it h a n 
S A E, t he n t he S A E is re p orte d t o [COMPANY_007] Safet y usi n g t he C T S A E Re p ort F or m . 
* * E D B is re p orte d t o [COMPANY_007] Safet y usi n g t he C T S A E Re p ort F or m w hic h w o ul d als o i ncl u de details of 
a n y S A E t hat mi g ht be ass ociate d w it h t he E D B. 
* * * E n vir o n me nt al or Occ u p ati o n al e x p os ure: A E s or S A Es ass ociate d wit h occ u pati o nal e x p os ure are 
re p orte d t o [COMPANY_007] Safet y usi n g t he C T S A E Re p ort F or m. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 0 3 W he n a n A E or S A E occ urs, it is t he res p o nsi bilit y  of t he i n vesti gat or t o re vie w all 
d oc u me ntati o n (e g, h os pi[INVESTIGATOR_75512] o gress n otes, la b orat or y  re p orts, a n d dia g n ostic 
re p orts) relate d t o t he e ve nt. 
T he i n vesti gat or will t he n rec or d all rele va nt A E or S A E i nf or mati o n i n t he C R F. 
It is n ot acce pta ble f or t he i n vesti gat or t o se n d p h ot oc o pi[INVESTIGATOR_1309] t he partici pa nt’s 
me dical rec or ds t o [COMPANY_007] Safet y  i n lie u of c o m pleti o n of t he C T S A E Re p ort 
F or m / A E or S A E C R F p a ge. 
T here ma y  be i nsta nces w he n c o pi[INVESTIGATOR_75513] f or certai n cases are 
re q ueste d b y [COMPANY_007] Safet y .I n t his case, all partici pa nt i de ntifiers, wit h t he 
e xce pti o n of t he partici pa nt n u m ber, will be re dacte d o n t he c o pi[INVESTIGATOR_1309] t he me dical 
rec or ds bef o re s u b missi o n t o [COMPANY_007] Safet y .
T he i n vesti gat or will atte m pt t o esta blis h a dia g n osis of t he e ve nt base d o n si g ns, 
s y m pt o ms, a n d/ or ot her cli nical i nf or mati o n. W he ne ver p ossi ble, t he dia g n osis ( n ot 
t he i n di vi d ual si g ns/s y m pt o ms) will be d oc u me nte d as t he A E or S A E. 
Assess me nt of I nte nsit y 
T he i n vesti gat or will ma ke a n assess me nt of i nte nsit y f or eac h A E a n d S A E re p orte d 
d uri n g t he st u d y a n d assi g n it t o 1 of t he f oll o wi n g cate g ories: 
Mil d: As y m pt o matic or mil d s y m pt o ms; cli nical or dia g n ostic o bser vati o ns o nl y ; 
i nter ve nti o n n ot i n dicate d. 
M o derate: Mi ni mal, l ocal or n o ni n vasi ve i nter ve nti o n i n dicate d; li miti n g a ge -
a p pr o priate i nstr u me ntal A D L. I nstr u me ntal A D L refers t o pre pari n g meals, 
s h o p pi n g f or gr oceries or cl ot hes, usi n g t he tele p h o ne, ma na gi n g m o ne y , etc.  
Se vere: Se vere or me dicall y  si g nifica nt b ut n ot i m me diatel y  life -t hreate ni n g; 
h os pi[INVESTIGATOR_1314] o n or pr ol o n gati o n of h os pi[INVESTIGATOR_1314] o n i n dicate d; disa bli n g, li miti n g self 
care A D L. Self care A D L refers t o bat hi n g, dressi n g a n d u n dressi n g, fe e di n g self, 
usi n g t he t oilet, ta ki n g me dicati o ns, a n d n ot be dri d de n. 
A n e ve nt is defi ne d as “seri o us ”w he n it meets at least 1 of t he pre defi ne d o utc o mes as 
descri be d i n t he defi niti o n of a n S A E, N O T w he n it is rate d as se vere. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 0 4 Assess me nt of C a us alit y 
T he i n vesti gat or is o bli gate d t o assess t he relati o ns hi p bet wee n st u d y i nter ve nti o n 
a n d eac h occ urre nce of eac h A E or S A E. T he i n vesti gat or will use cli nical 
j u d g me nt t o deter mi ne t he relati o ns hi p. 
A “reas o na ble p ossi bilit y” of a relati o ns hi p c o n ve ys t hat t here are facts, e vi de nce, 
a n d/ or ar g u me nts t o s u g gest a ca usal relati o ns hi p, rat her t ha n a relati o ns hi p ca n n ot 
be r ule d o ut. 
Alter nati ve ca uses, s uc h as u n derl yi n g disease(s), c o nc o mita nt t hera p y, a n d ot her 
ris k fact ors, as well as t he te m p oral relati o ns h i p of t he e ve nt t o st u d y i nter ve nti o n 
a d mi nistrati o n ,will be c o nsi dere d a n d i n vesti gate d. 
T he i n vesti gat or will als o c o ns ult t he I B a n d/ or pr o d uct inf or mati o n, f or mar kete d 
pr o d ucts, i n his/ her assess me nt. 
F or eac h A E or S A E, t he i n vesti gat or m ust d oc u me nt i n t he me dical n otes t hat 
he/s he has re vie we d t he A E or S A E a n d has pr o vi de d a n assess me nt of ca usalit y .
T here ma y  be sit uati o ns i n w hic h a n S A E has occ urre d a n d t he i n vesti gat or has 
mi ni mal i nf or mati o n t o i ncl u de i n t he i nitial re p ort t o t he s p o ns or . H o we ver, it is 
ver y i m p ort a nt t h at t he i n vesti g at or al w a ys m a ke a n assess me nt of c a us alit y 
f or e ver y e ve nt bef ore t he i niti al tr a ns missi o n of t he S A E d at a t o t he s p o ns or .
T he i n vesti gat or ma y  c ha n ge his/ her o pi [INVESTIGATOR_9384] o n of ca usalit y  i n li g ht of f oll o w - u p 
i nf or mati o n a n d se n d a nS A E f oll o w -u p re p ort wit h t he u p date d ca usalit y  
assess me nt. 
T he ca usalit y  assess me nt is o ne of t he criteria use d w he n deter mi ni n g re g ulat or y  
re p orti n g re q uire me nts. 
If t he i n vesti gat or d oes n ot k n o w w het her or n ot t he st u d y  i nter ve n ti o n ca use d t he 
e ve nt, t he n t he e ve nt will be ha n dle d as “relate d t o st u d y  i nter ve nti o n ” f or re p orti n g 
p ur p oses, as defi ne d b y t he s p o ns or . I n a d diti o n, if t he i n vesti gat or deter mi nes t hat 
a n S A E is ass ociate d wit h st u d y  pr oce d ures, t he i n vesti gat or m ust r ec or d t his 
ca usal relati o ns hi p i n t he s o urce d oc u me nts a n d C R F, a n d re p ort s uc h a n 
assess me nt i n t he de dicate d secti o n of t he C T S A E Re p ort F or m a n d i n acc or da nce 
wit h t he S A E re p orti n g re q uire me nts. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 0 5 F oll o w - U p of A Es a n d S A Es 
T he i n vesti gat or is o bli gat e d t o perf or m or arra n ge f or t he c o n d uct of s u p ple me ntal 
meas ure me nts a n d/ or e val uati o ns, as me dicall y  i n dicate d or as re q ueste d b y  t he 
s p o ns or ,t o el uci date t he nat ure a n d/ or ca usalit y of t he A E or S A E as f ull y as 
p ossi ble. T his ma y  i ncl u de a d diti o nal la b orat or y  tests or i n vesti gati o ns, 
hist o pat h ol o gical e xa mi nati o ns, or c o ns ultati o n wit h ot her healt hcare pr o vi ders .
If a partici pa nt dies d uri n g partici pati o n i n t he st u d y or d uri n g a rec o g nize d 
f oll o w - u p peri o d, t he i n vesti gat or will pr o vi de [COMPANY_007] Safet y wit h a c o p y of a n y 
p ost m orte m fi n di n gs ,i ncl u di n g hist o pat h ol o g y .
Ne w or u p date d i nf or mati o n will be rec or de d i n t he ori gi nall y  s u b mitte d 
d oc u me nts .
T he i n vesti gat or will s u b mit a n y  u p date d S A E data t o t he s p o ns or wit hi n 2 4 h o urs 
of recei pt of t he i nf or mati o n. 
1 0. 3. 4. Re p orti n g of S A Es 
S A E Re p orti n g t o [COMPANY_007] S afet y vi a a n Electr o nic D at a C ollecti o n T o ol 
T he pri mar y  mec ha nis m f or re p orti n g a n S A E t o [COMPANY_007] Safet y will be t he 
electr o nic data c ollecti o n t o ol. 
If t he electr o nic s ys te m is u na vaila ble, t he n t he site will use t he pa per S A E data 
c ollecti o n t o ol (see ne xt secti o n) t o re p ort t he e ve nt wit hi n 2 4 h o urs. 
T he site will e nter t he S A E data i nt o t he electr o nic s y ste m as s o o n as t he data 
bec o me a vaila ble. 
After t he st u d y is c o m plete d at a gi ve n site, t he electr o nic data c ollecti o n t o ol will 
be ta ke n off -li ne t o pre ve nt t he e ntr y  of ne w data or c ha n ges t o e xisti n g data. 
If a site recei ves a re p ort of a ne w S A E fr o m a st u d y  partici pa nt or recei ves u p date d 
dat a o n a pre vi o usl y  re p orte d S A E after t he electr o nic data c ollecti o n t o ol has bee n 
ta ke n off -li ne, t he n t he site ca n re p ort t his i nf or mati o n o n a pa per S A E f or m (see 
ne xt secti o n) or t o [COMPANY_007] Safet y  b y  tele p h o ne. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 0 6 S A E Re p orti n g t o [COMPANY_007] S afet y vi a C T S A E Re p ort F or m 
Facsi mile tra ns missi o n of t he C T S A E Re p ort F or m is t he preferre d met h o d t o 
tra ns mit t his i nf or mati o n t o [COMPANY_007] Safet y .
I n circ u msta nces w he n t he fac si mile is n ot w or ki n g , n otificati o n b y  tele p h o ne is 
acce pta ble wit h a c o p y of t he C T S A E Re p ort F or m se nt b y  o ver ni g ht mail or 
c o urier ser vice. 
I nitial n otificati o n via tele p h o ne d oes n ot re place t he nee d f or t he i n vesti gat or t o 
c o m plete a n d si g n t he C T S A E Re p ort F or m pa ges wit hi n t he desi g nate d re p orti n g 
ti me fra mes. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 0 7 1 0. 4. A p pe n di x 4: C o ntr ace pti ve a n d B arrier G ui d a nce 
[ADDRESS_82066] u d y  
i nter ve nti o n(s): 
Refrai n fr o m d o nati n g s per m .
P L U S eit her: 
Be a bsti ne nt fr o m heter ose x ual or h o m ose x ual i nterc o urse as t heir preferre d a n d us ual 
lifest y le (a bsti ne nt o n a l o n g -ter m a n d persiste nt basis) a n d a gree t o re mai n a bsti ne nt .
O R 
M ust a gree t o use c o ntrace pti o n/ barrier as detaile d bel o w .
A gree t o use a male c o n d o m w he n e n ga gi n g i n a n y  acti vit y  t hat all o ws f or 
passa ge of ejac ulate t o a n ot her pers o n .
[ADDRESS_82067] 1of t he f oll o wi n g c o n diti o ns a p plies: 
Is n ot a W O C B P (see defi niti o ns bel o w i n Secti o n 1 0. 4. 3 ). 
O R 
Is a W O C B P a n d a grees t o use a hi g hl y effecti ve c o ntrace pti ve met h o d (fail ure rate 
< 1 % per ye ar) d uri n g t he i nt er ve nti o n peri o d a n d f or a mi ni m u m of [ADDRESS_82068] u d y  partici pa nt’s pare nt/ g uar dia n if t he partici pa nt’s a ge is [ADDRESS_82069] or y , a n d rece nt 
se x ual acti vit y  t o decrease t he ris k f or i ncl usi o n of a w o ma n wit h a n earl y u n detecte d 
pre g na nc y . 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82070] me n o pa usal 
u nless per ma ne ntl y sterile (see bel o w). 
If fertilit y  is u nclear (e g, a me n orr hea i n a d olesce nts or at hletes) a n d a me nstr ual c y cle ca n n ot 
be c o nfir me d bef ore t he first d ose of st u d y  i nter ve nti o n, a d diti o nal e val uati o n s h o ul d be 
c o nsi dere d. 
W o me n i n t he f oll o wi n g cate g ories are n ot c o nsi dere d W O C B P: 
1. Pre me narc hal .
2. Pre me n o pa usal fe male wit h 1 of t he f oll o wi n g: 
D oc u me nte d h ys terect o m y ;
D oc u me nte d bilateral sal pi n gect o m y ;
D oc u me nte d bilateral o o p h orect o m y. 
F or i n di vi d uals wit h per ma ne nt i nfertilit y  d ue t o a n alter nate me dical ca use ot her t ha n t he 
a b o ve, (e g, m ulleria n a ge nesis, a n dr o ge n i nse nsiti vit y ), i n vesti gat or discreti o n s h o ul d be 
a p plie d t o deter mi ni n g st u d y  e ntr y .
N ote: D oc u me ntati o n f or a n y of t he a b o ve cate g ories ca n c o me fr o m t he site pers o n nel’s 
re vie w of t he partici pa nt’s me dical rec or ds, me dical e xa mi nati o n, or me dical hist or y  
i nter vie w. T he met h o d of d oc u me ntati o n s h o ul d be rec or de d i n t he partic i pa nt’s me dical 
rec or d f or t he st u d y. 
3. P ost me n o pa usal fe male :
A p ost me n o pa usal state is defi ne d as n o me nses f or 1 2 m o nt hs wit h o ut a n 
alter nati ve me dical ca use. I n  a d diti o n :
A hi g h F S H le vel i n t he p ost me n o pa usal ra n ge m ust be use d t o c o nfir m a 
p ost me n o pa us al state i n w o me n u n der 6 0 ye ars of a ge a n d n ot usi n g h or m o nal 
c o ntrace pti o n or H R T. 
N ote: F or w o me n o ver 6 0 y ears of a ge, F S H ma y  still be teste d, b ut is left t o 
t he discreti o n of t he PI. 
A f e male o n H R T a n d w h ose me n o pa usal stat us is i n d o u bt will be re q uire d t o 
use o ne of t he n o n -estr o ge n h or m o nal hi g hl y effecti ve c o ntrace pti o n met h o ds 
if t he y  wis h t o c o nti n ue t heir H R T d uri n g t he st u d y .Ot her wise, t he y  m ust 
disc o nti n ue H R T t o all o w c o nfir mati o n of p ost me n o pa usal stat us bef ore st u d y  
e nr oll me nt. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 0 9 1 0. 4. 4. C o ntr ace pti o n Met h o ds 
C o ntrace pti ve use b y me n or w o me n s h o ul d be c o nsiste nt wit h l ocal a vaila bilit y /re g ulati o ns 
re gar di n g t he use of c o ntrace pti ve met h o ds f or t h ose partici pati n g i n cli nical trials. 
T he f oll o wi n g c o ntrace pti ve met h o ds are a p pr o priate f or t his st u d y :
1. I m pla nta ble pr o gest o ge n -o nl y  h or m o ne c o ntrace pti o n ass ociate d wit h i n hi biti o n of 
o v ulati o n .
2. I ntra uteri ne de vice .
3. I ntra uteri ne h or m o ne -releasi n g s ys te m .
4. Bilateral t u bal occl usi o n (e g, bilateral t u bal li gati o n). 
5. Vasect o mize d part ner :
A v asect o mize d part ner is a hi g hl y effecti ve c o ntrace pti ve met h o d pr o vi de d t hat 
t he part ner is t he s ole se x ual part ner of t he w o ma n of c hil d beari n g p ote ntial a n d 
t he a bse nce of s per m has bee n c o nfir me d. If n ot, a n a d diti o nal hi g hl y effecti ve 
met h o d of c o ntrac e pti o n s h o ul d be use d. T he s per mat o ge nesis c y cle is 
a p pr o xi matel y  9 0 da y s. 
6. C o m bi ne d (estr o ge n -a n d pr o gest o ge n - c o ntai ni n g) h or m o nal c o ntrace pti o n ass ociate d 
wit h i n hi biti o n of o v ulati o n :
Oral + barrier * ;
I ntra va gi nal + barrier * ;
Tra ns der mal + barrier * .
7. Pr o gest o ge n - o nl y h or m o ne c o ntrace pti o n ass ociate d wit h i n hi biti o n of o v ulati o n :
Oral + barrier * ;
Injecta ble + barrier * .
*I n  a d diti o n, o ne of t he f oll o wi n g effecti ve barrier met h o ds m ust als o be use d  w he n 
o pti o ns 6 or 7 are c h ose n a b o ve : 
Male or fe male c o n d o m, wit h or wit h o ut s per mici de; 
Cer vical ca p, dia p hra g m, or s p o n ge wit h s per mici de; 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 1 0 A c o m bi nati o n of male c o n d o m wit h eit her cer vical ca p, dia p hra g m, or s p o n ge 
wit h s per mici de ( d o u ble -barrier met h o ds). 
8. Se x ual a bsti ne nce :
Se x ual a bsti ne nce is c o nsi dere d a hi g hl y effecti ve met h o d o nl y  if defi ne d as 
refrai ni n g fr o m heter ose x ual i nterc o urse d uri n g t he e ntire peri o d of ris k ass ociate d 
wit h t he st u d y  i nter ve nti o n. T he relia bilit y  of se x ual a bsti ne nce nee ds t o be 
e val uate d i n relati o n t o t he d urati o n of t he st u d y  a n d t he preferre d a n d us ual 
lifest y le of t he partici pa nt .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 1 1 1 0. 5. A p pe n di x 5: Ge netics 
Use/ A n al ysis of D N A 
Ge netic variati o n ma y  i m pact a partici pa nt’s res p o nse t o st u d y  i nter ve nti o n, 
s usce pti bilit y  t o, a n d se verit y  a n d pr o gressi o n of disease. T heref ore, w here l ocal 
re g ulati o ns a n d I R B s/ E C sall o w, a bl o o d sa m ple will be c ollecte d f or D N A a nal ys is. 
T he sc o pe of t he g e netic researc h ma y  be narr o w (e g , 1 or m ore ca n di date ge nes )or 
br oa d (e g ,t he e ntire ge n o me ), as a p pr o priate t o t he scie ntific q uesti o n u n der 
i n ve sti gati o n .
T he sa m ples ma y  be a nal y ze d as part of a m ulti st u d y  assess me nt of ge netic fact ors 
i n v ol ve d i n t he res p o nse t o P F - [ADDRESS_82071] u d y  i nter ve nti o ns of t his class t o 
u n dersta n d treat me nts f or t he disease(s) u n der st u d y  or t he disease(s) t he msel ves. 
T he res ults of ge netic a nal y ses ma y  be re p orte d i n C S R or i n a se parate st u d y  
s u m mar y , or ma y  be use d f or i nter nal decisi o n ma ki n g wit h o ut bei n g i ncl u de d i n a 
st u d y  re p ort. 
T he s p o ns or will st ore t he D N A sa m ples i n a sec ure st ora ge s pace wit h a de q uate 
mea s ures t o pr otect c o nfi de ntialit y . 
T he sa m ples will be retai ne d as i n dicate d: 
Retai ne d s a m ples will be st ore d i n defi nitel y  or f or a n ot her peri o d as per l ocal 
re q uire me nts. 
Partici pa nt s ma y  wit h dra w t heir c o nse nt f or t he st ora ge a n d/ or use of t heir Retai ne d 
Researc h Sa m ples at a n y ti me b y  ma ki n g a re q uest t o t he i n vesti gat or; i n t his case, 
a n y  re mai ni n g material will be destr o y e d. Data alrea d y  ge nerate d fr o m t he sa m ples 
will be retai ne d t o pr otect t he i nte grit y of e xisti n g a nal ys es. 
Sa m ples f or ge netic res earc h will be la bele d wit h a c o de. T he ke y  bet wee n t he c o de 
a n d t he partici pa nt ’s pers o nall y  i de ntif y i n g i nf or mati o n (e g ,na me, a d dress) will be 
hel d sec urel y  at t he st u d y site. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 1 2 1 0. 6. A p pe n di x 6: Li ver S afet y: S u g geste d Acti o ns a n d F oll o w - U p Assess me nts 
P ote nti al C ases of Dr u g -I n d uce d Li ver I nj ur y 
H u ma ns e x p ose d t o a dr u g w h o s h o w n o si g n of li ver i nj ur y  (as deter mi ne d b y  ele vati o ns i n 
tra nsa mi nases) are ter me d “t olerat ors,” w hile t h ose w h o s h o w tra nsie nt li ver i nj ur y  b ut a da pt 
are ter me d “a da pt ors.” I n  s o me partici pa nt s, tra nsa mi nase ele vati o ns are a har bi n ger of a 
m ore seri o us p ote ntial o utc o me. T hese partici pa nt s fail t o a da pt a n d t heref ore are 
"s usce pti ble" t o pr o gressi ve a n d seri o us li ver i nj ur y, c o m m o nl y referre d t o as DI LI. 
Partici pa nt s w h o e x perie n ce a tra nsa mi nase ele vati o n a b o ve 3 × U L N s h o ul d be m o nit ore d 
m ore fre q ue ntl y  t o deter mi ne if t he y  are “a da pt or s” or are “s usce pti ble.” 
I n t he maj orit y  of DI LI cases, ele vati o ns i n A S T a n d/ or A L T prece de T Bili ele vati o ns 
( > 2 ×U L N) b y  se veral da y s or wee ks. T he i ncrease i n T Bili t y pi[INVESTIGATOR_1306] y  occ urs w hile 
A S T/ A L T is/are still ele vate d a b o ve 3 × U L N (ie, A S T/ A L T a n d T Bili val ues will be 
ele vate d wit hi n t he sa me la b orat or y sa m ple). I n rare i nsta nces, b y  t he ti me T Bili ele vati o ns 
are detecte d, A S T/ A L T val ues mi g ht ha ve decrease d. T his occ urre nce is still re gar de d as a 
p ote ntial DI LI. T heref ore, a b n or mal ele vati o ns i n eit her A S T O R A L T i n a d diti o n t o T Bili 
t hat meet t he criteria o utli ne d bel o w are c o nsi dere d p ote ntial DI LI (assesse d per H y ’s la w 
criteria) cases a n d s h o ul d al wa y s be c o nsi dere d i m p orta nt me dical e ve nts, e ve n bef ore all 
ot her p ossi ble ca uses of li ver i nj ur y  ha ve bee n e xcl u de d. 
T he t hres h ol d of la b orat or y  a b n or malities f or a p ote ntial DI LI case de pe n ds o n t he 
partici pa nt ’s i n di vi d ual baseli ne val ues a n d u n derl y i n g  c o n diti o ns. Partici pa nt s w h o prese nt 
wit h t he f oll o wi n g la b orat or y  a b n or malities s h o ul d be e val uate d f urt her as p ote ntial DI LI 
( H y’s la w) cases t o defi niti vel y  deter mi ne t he eti ol o g y  of t he a b n or mal la b orat or y  val ues: 
Partici pa nt s wit h A S T/ A L T a n d T Bili baseli ne val ues wit hi n t he n or mal ra n ge w h o 
s u bse q ue ntl y  prese nt wit h A S T O R A L T val ues > 3 × U L N A N D a T Bili val ue 
> 2 × U L N wit h n o e vi de nce of he m ol ys is a n d a n al kali ne p h os p hatase val ue 
< 2 ×U L N or n ot a vaila ble. 
F or partici pa nt s wit h basel i ne A S T O R A L T O R T Bili val ues a b o ve t he U L N, t he 
f oll o wi n g t hres h ol d val ues are use d i n t he defi niti o n me nti o ne d a b o ve, as nee de d, 
de pe n di n g o n w hic h val ues are a b o ve t he U L N at baseli ne: 
Pree xisti n g A S T or A L T baseli ne val ues a b o ve t he n or mal ra n ge: A S T or A L T 
val ues > 2 ti mes t he baseli ne val ues A N D > 3 × U L N; or > 8 × U L N ( w hic he ver is 
s maller). 
Pree xisti n g val ues of T Bili a b o ve t he n or mal ra n ge: T Bili le vel i ncrease d fr o m 
baseli ne val ue b y a n a m o u nt of at least 1 × U L N or if t he val ue reac hes 
> 3 × U L N ( w h ic he ver is s maller). 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 1 3 Rises i n A S T/ A L T a n d T Bili se parate d b y m ore t ha n a fe w wee ks s h o ul d be assesse d 
i n di vi d uall y  base d o n cli nical j u d g me nt; a n y  case w here u ncertai nt y  re mai ns as t o w het her it 
re prese nts a p ote ntial H y’s la w case s h o ul d be re vie we d wit h t he s p o ns or. 
T he partici pa nt s h o ul d ret ur n t o t he i n vesti gat or site a n d be e val uate d as s o o n as p ossi ble, 
prefera bl y wit hi n [ADDRESS_82072] or y , a n d p h ysical as sess me nt. 
I n a d diti o n t o re peati n g meas ure me nts of A S T a n d A L T a n d T Bili f or s us pecte d H y ’s la w 
cases , a d diti o nal la b orat or y  tests s h o ul d i ncl u de al b u mi n, C K, direct a n d i n direct bilir u bi n, 
G G T, P T/I N R, t otal bile aci ds, a n d al kali ne p h os p hatase. C o nsi der ati o n s h o ul d als o be gi ve n 
t o dra wi n g a se parate t u be of cl otte d bl o o d a n d a n a ntic oa g ulate d t u be of bl o o d f or f urt her 
testi n g, as nee de d, f or f urt her c o nte m p ora ne o us a nal y ses at t he ti me of t he rec o g nize d i nitial 
a b n or malities t o deter mi ne eti ol o g y . A det aile d hist or y , i ncl u di n g rele va nt i nf or mati o n, s uc h 
as re vie w of et ha n ol, aceta mi n o p he n / paraceta m ol (eit her b y  itself or as a c o -f or m ulate d 
pr o d uct i n prescri pti o n or o ver -t he -c o u nter me dicati o ns), recreati o nal dr u g, or s u p ple me nt 
( her bal) use a n d c o ns u m pt i o n, fa mil y  hist or y , se x ual hist or y , tra vel hist or y, hist or y  of c o ntact 
wit h a ja u n dice d pers o n, s ur ger y , bl o o d tra nsf usi o n, hist or y  of li ver or aller gic disease, a n d 
p ote ntial occ u pati o nal e x p os ure t o c he micals, s h o ul d be c ollecte d. F urt her testi n g f or ac ute 
he patitis A, B, C, D, a n d E i nfecti o n ,li ver i ma gi n g (e g, biliar y  tract) ,a n d c ollecti o n of ser u m 
sa m ple s f or aceta mi n o p he n / paraceta m ol dr u g a n d/ or pr otei n a d d uct le vels ma y  be warra nte d. 
All cases de m o nstrate d o n re peat testi n g as meeti n g t he la b orat or y  criteria of A S T/ A L T a n d 
T Bili ele vati o n defi ne d a b o ve s h o ul d be c o nsi dere d p ote ntial DI LI ( H y ’s la w) cases if n o 
ot her reas o n f or t he L F T a b n or malities has yet bee n f o u n d. S uc h p ote nti al DI LI ( H y’s l a w) 
c ases are t o be re p orte d as S A Es, irres pecti ve of a v ail a bilit y of all t he res ults of t he 
i n vesti g ati o ns perf or me d t o deter mi ne eti ol o g y of t he L F T a b n or m alities. 
A p ote ntial DI LI ( H y ’s la w) case bec o mes a c o nfir me d case o nl y after all res ults of 
reas o na ble i n vesti gati o ns ha ve bee n recei ve d a n d ha ve e xcl u de d a n alter nati ve eti ol o g y .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 1 4 1 0. 7. A p pe n di x 7: E C G Fi n di n gs of P ote nti al Cli nic al C o ncer n 
E C G Fi n di n gs Th at M a y Q u alif y as A Es 
Mar ke d si n us bra d yc ar dia (rate < 4 0 b p m) lasti n g mi n utes .
Ne w P R i nter val pr ol o n gati o n > 2 8 0 ms ec .
Ne w pr ol o n gati o n of Q Tc F t o > 4 8 0 ms ec (a bs ol ute) or b y ≥6 0 ms ec fr o m baseli ne .
Ne w - o nset atrial fl utter or fi brillati o n, wit h c o ntr olle d ve ntric ular res p o nse rate: 
ie, rate < 1 2 0 b p m .
Ne w - o nset ty pe I sec o n d - d e gree ( We nc ke bac h) A V bl oc k of > 3 0 sec o n ds ’
d urati o n .
Fre q ue nt P V Cs, tri plets, or s h ort i nter vals ( < 3 0 sec o n ds) of c o nsec uti ve ve ntric ular 
c o m ple xes .
E C G Fi n di n gs Th at M a y Q u alif y as S A Es 
Q Tc F pr ol o n gati o n > 5 0 0 ms ec .
Ne w S T -T c ha n ges s u g gesti ve of m y ocar dial isc he mia .
Ne w - o nset left bu n dle bra nc h bl oc k ( Q R S > 1 2 0 ms ec ). 
Ne w - o nset ri g ht bu n dle bra nc h bl oc k ( Q R S > 1 2 0 ms ec ). 
S y m pt o matic bra d yc ar dia .
As y st ole: 
I n a wa ke, s y m pt o m -free patie nts i n si n us r h y t h m, wit h d oc u me nte d peri o ds of 
as y st ole ≥3. 0 sec o n ds or a n y  esca pe rate < 4 0 b p m, or wit h a n esca pe r h y t h m 
t hat is bel o w t he A V n o de ; 
I n a wa ke, s y m pt o m -free patie nts wit h atrial fi brillati o n a n d bra d yc ar dia wit h 
[ADDRESS_82073] 5 sec o n ds or l o n ger ; 
Atrial fl utter or fi brillati o n, wit h ra pi d ve ntric ular res p o nse rate: ra pi d = rate 
> 1 2 0 b p m. 
S ustai ne d su pra ve ntric ular tac h yc ar dia (rate > 1 2 0 b p m) ( “s ustai ne d ”= s h ort 
d urati o n wit h rele va nt s y m pt o ms or lasti n g > 1 mi n ute) .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 1 5 Ve ntric ular r h y t h ms > 3 0 sec o n ds ’d urati o n, i ncl u di n g i di o ve ntric ular r h y t h m ( heart 
rate < 4 0 b p m), accelerate d i di o ve ntric ular r h yt h m ( H R 4 0 b p m t o < 1 0 0 b p m), a n d 
m o n o m or p hic/ p ol y m or p hic ve ntric ular tac h ycar dia ( H R > 1 0 0 b p m (s uc h as 
torsa des de p oi ntes) ). 
T y pe II sec o n d - d e gree ( M o bitz II) A V bl oc k .
C o m plete (t hir d- de gree) heart bl oc k .
E C G Fi n di n gs Th at Qu alif y as S A Es 
C ha n ge i n patter n s u g gesti ve of ne w m y ocar dial i nfarcti o n .
S ustai ne d ve ntric ular ta c h y arr h y t h mias ( > 3 0 sec o n ds ’d urati o n) .
Sec o n d -or t hir d - de gree A V bl oc k re q uiri n g pace ma ker place me nt. 
As y st olic pa uses re q uiri n g pace ma ker place me nt .
Atrial fl utter or fi brillati o n wit h ra pi d ve ntric ular res p o nse re q uiri n g car di o versi o n .
Ve ntric ular fi brillati o n/ fl utter .
At t he discreti o n of t he i n vesti gat or, a n y arr h yt h mia classifie d as a n a d verse 
e x perie nce .
The e n u merate d list of maj or e ve nts of p ote ntial cli nical c o ncer n are rec o m me n de d as “alerts ”or 
n otificati o ns fr o m t he c ore E C G la b orat or y t o t he i n vesti gat or a n d [COMPANY_007] st u d y tea m ,a n d n ot t o be 
c o nsi dere d as all i ncl usi ve of w hat t o be re p orte d as A Es/ S A Es. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 1 6 1 0. 8. A p pe n di x 8: Pr o hi bite d Pri or a n d C o nc o mit a nt Me dic ati o ns 
[ADDRESS_82074] u gs ( E x a m ples bel o w) Re q uire d W as h o ut Peri o d 
Re q uire me nt Pri or t o 
D a y 1/ R a n d o m iz ati o n 
A n y cell de pleti n g 
a ge nts rit u xi ma b or ot her selecti ve 
B- l y m p h oc yte de pleti n g a ge nts 
(i ncl u di n g e x peri me ntal a ge nts), 
ale mt uz u ma b ( Le mtra da ®or 
Ca m Pat h ®), al k ylati n g a ge nts 
(e g, c y cl o p h os p ha mi de or 
c hl ora m b ucil), t otal l y m p h oi d 
irra diati o n, etc. 6 m o nt hs or 5 half -li ves (if k n o w n), 
w hic he ver is l o n ger, or u ntil l y m p h oc yte 
c o u nt ret ur ns t o n or mal, w hic he ver is 
l o n ger. 
I L -1 7 i n hi bit or, 
I L -1 2/ 2 3 i n hi bit or, or 
I L -2 3 i n hi bit or sec u ki n u ma b ( C ose nt y x ®), 
i xe kiz u ma b ( Taltz ®), uste ki n u ma b 
( Stelara ®), br o dal u ma b ( Sili q ®), 
g usel k u ma b ( Tre mf ya ®), 
risa n kiz u ma b ( S k yrizi ®), 
til dra kiz u ma b (Il u m ya ®), a n d 
bi m e kiz u ma b, 1 2 w ee ks. 
T N F i n hi bit or a dali m u ma b ( H u mira ®or bi osi milars), 
cert oliz u ma b ( Ci mzia ®), g oli m u ma b 
( Si m p o ni ®a n d Si m p o ni Aria ®). 1 0 w ee ks or 5 half -li ves ( w hic he ver is 
l o n ger) ( N ote: I nfli xi ma b ( Re mica de ®or 
bi osi milars) 8 wee ks, Eta nerce pt 
( E n brel ®or bi osi milars) 4 we e ks). 
Ot her bi ol o gics d u pil u ma b ( D u pi [INVESTIGATOR_75514] ®), efaliz u ma b 
( Ra pti va ®), a batace pt ( Ore ncia ®). 1 2 w ee ks u nless ot her wise s pecifie d i n 
t his ta ble. 
T o pic al P D E 4 
i n hi bit ors ( a n y w here 
o n t he b o d y), or al 
P D E 4 i n hi bit ors crisa b or ole ( E ucrisa ®), r ofl u milast 
( Dalires p ®, A R Q -1 5 1), a pre milast 
( Otezla ®), difa milast .2we e ks. 
S yste mic 
c ortic oster oi ds ( or al, 
p are nter al) 4 w ee ks 
(sta ble use /re g ular re gi me n of 
i ntra nasal/i n hale d/ o p ht hal mic 
c ortic oster oi ds w it h ≥ 1 4 da ys of 
c o nsiste nt use pri or t o 
D a y 1/ Ra n d o mizati o n are per mitte d t o 
c o nti n ue b ut m ust n ot alter or st o p 
re gi me n d uri n g t he st u d y). 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82075] u gs ( E x a m ples bel o w) Re q uire d W as h o ut Peri o d 
Re q uire me nt Pri or t o 
D a y 1/ R a n d o m iz ati o n 
S yste mic 
i m m u n os u p pressi ve 
a ge nts a n d ot her or al 
n o n bi ol o gic tre at m e nts met h otre xate, lefl u n o mi de, 
s ulfasalazi ne, h y dr o x yc hl or o q ui ne, 
azat hi o pri ne, c ycl os p ori ne, 
miz ori bi ne, tacr oli m us, M M F, 
h y dr o x ycar ba mi de ( h y dr o x y urea), 
f u maric aci d deri vati ves, acitreti n. 4 w ee ks. 
Or al J A K i n hi bit ors t ofaciti ni b ( Xelja nz ®), bariciti ni b 
( Ol u mia nt ®), u pa daciti ni b, peficiti ni b, 
fil g oti ni b , a br ociti ni b ( Ci bi n q o ®). 4 w ee ks. 
I nterfer o n g a m m a i nterfer o n ga m ma -1 b ( Acti m m u ne ®). 4 we e ks. 
Li g ht t her a p y etc. s u n bat hi n g, ta n ni n g be d use, or li g ht 
t hera p y (U V, U V -B, P U V A), e xci mer 
laser ( 3 0 8 n m). 4 w ee ks. 
T o pic al reti n oi ds, 
Vit a m i n D a n al o g ues, 
B P O, a nt hr ali n 
( dit hr a n ol), 
ker at ol ytics (s alic ylic 
aci d), t ars, o n st u d y 
tre at a ble lesi o ns tazar ote ne, calci p otrie ne. 2 w ee ks (sta ble re gi me n wit h ≥ 1 4 da ys 
of c o nsiste nt use pri or t o 
D a y 1/ Ra n d o mizati o n a n d n ot o n t he 
st u d y treata ble lesi o ns are per mitte d t o 
c o nti n ue b ut m ust n ot alter or st o p t heir 
re gi me n d uri n g t he st u d y. 
S yste mic a nti bi otics 2 w ee ks ( S h ort c o urses ( ≤ 1 4 da ys) of 
s yste mic a nti bi otics ma y be gi ve n 
d uri n g t he st u d y if cli nicall y necessar y 
f or t he treat me nt of ne w o nset 
i nfecti o ns). 
T C S, Cl ass I t o V, 
a n y w here o n t he b o d y beta met has o ne, cl o betas ol, 
difl oras o ne, hal o bet as ol, a mci n o ni de, 
des o xi metas o ne, fl u oci n o ni de, 
halci n o ni de, m o metas o ne, 
tria mci n ol o ne, cl oc ort ol o ne, 
fl ura n dre n oli de, fl uticas o ne, 
fl u oci n ol o ne, pre d nicar bate, 
h y dr oc ortis o ne b ut yrate, 
h y dr oc ortis o ne pr o b utate, 
h y dr oc ortis o ne valerate. 2 w ee ks. 
T CI or J A K i n hi bit or , 
a n y w here o n t he b o d y t o pi[INVESTIGATOR_75515] m us ( Pr ot o pic ®), t o pi[INVESTIGATOR_75516] m ecr oli m us ( Eli del ®), del g ociti ni b .[ADDRESS_82076] a mi nes 
a n y w here o n t he b o d y d o xe pi n. 2 w ee ks (t o pi[INVESTIGATOR_2855] a nti hista mi nes f or 
seas o nal aller gies are all o we d pr o vi de d 
sta ble d oses wit hi n 7 d a y s of 
D a y 1/ Ra n d o mizati o n). 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82077] u gs ( E x a m ples bel o w) Re q uire d W as h o ut Peri o d 
Re q uire me nt Pri or t o 
D a y 1/ R a n d o m iz ati o n 
T o pic al a nti b acteri al 
me dic ati o ns or 
pr o d ucts, i ncl u di n g 
s o a ps, ble ac h b at hs, or 
t o pic al s o di u m 
h y p oc hl orite - b ase d 
pr o d ucts a n y w here o n 
t he b o d y [ADDRESS_82078] a ble 
(e g, esc al ati n g, 
decre asi n g, or P R N) 
re gi m e n cetirizi ne, 7 da ys (sta ble n o n -se dati n g s yste mic 
a nti hista mi ne re gi me n wit h ≥ 7 da ys of 
c o nsiste nt use pri or t o 
D a y 1/ Ra n d o mizati o n are per mitte d t o 
c o nti n ue b ut m ust n ot alter or st o p t heir 
re gi me n d uri n g t he st u d y). 
Use of bl a n d 
( n o n -me dic ate d , ure a -
a n d l actic aci d -free ) 
e m ollie nts o n tre at a ble 
lesi o ns 2 4 h o urs ( After t he 
D a y 1/ Ra n d o mizati o n Visit, use of 
bla n d ( n o n -me dicate d) e m ollie nt(s) is 
per mitte d d uri n g t he st u d y t o ma na ge 
dr y s ki n i n areas s urr o u n di n g b ut n ot o n 
or o verla p pi n g t he treata ble lesi o ns ). 
A n y ot her bi ol o gic 
i n vesti g ati o n al t h er a p y 
f or A D, ps ori asis or 
ps ori atic art hritis [ADDRESS_82079] u g i nter acti o n See Secti o n 1 0. 8. 2 bel o w . 7 da ys or 5 half -li ves ( w hic h e ver is 
l o n ger). 
1 0. 8. 2. Pr o hi bite d C o nc o mit a nt Me dic ati o ns w hic h m a y R es ult i n D DI 
U p o n t o pi[INVESTIGATOR_2855] a p plicati o n of P F - 0 7 0 3 8 1 2 4, s ys te mic e x p os ure t o date has bee n l o w. 
Ma xi m u m plas ma c o nce ntrati o n has n ot e xcee de d 1 n M; w hic h is a p pr o xi matel y  [ADDRESS_82080] u g i nteracti o n. F or m ore details, please 
refer t o t he I n vesti gat or’s Br oc h ure. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 1 9 1 0. 9. A p pe n di x 9: Alter n ati ve Me as ures D uri n g P u bli c E mer ge ncies 
T he alter nati ve st u d y  meas ures descri be d i n t his secti o n are t o be f oll o we d d uri n g p u blic 
e mer ge ncies, i ncl u di n g t he C O VI D -[ADDRESS_82081] u d y  meas ures are e x pecte d t o cease u p o n t he ret ur n of b usi ness as 
us ual circ u msta nces (i ncl u di n g t he lifti n g of a n y q uara nti nes a n d tra vel ba ns/a d vis ories). 
[ADDRESS_82082] data p oi nts. Tele healt h i ncl u des t he e xc ha n ge of healt hcare i nf or mati o n a n d 
ser vices via telec o m m u nicati o n tec h n ol o gies (e g, a u di o, vi de o, vi de o -c o nfere nci n g s oft ware) 
re m otel y , all o wi n g t he partici pa nt a n d t he i n vesti gat or t o c o m m u nicate o n as pects of cli nical 
care, i ncl u di n g me dical a d vice, re mi n ders, e d ucati o n, a n d safet y m o nit ori n g. T he f oll o wi n g 
assess me nts m ust be perf or me d d uri n g a tele healt h visit :
Re vie w a n d rec or d st u d y i nter ve nti o n(s) ,i ncl u di n g c o m plia nce a n d misse d d oses .
Re vie w a n d rec or d a n y  A Es a n d S A Es si nce t he last c o ntact. Refer t o Secti o n 8. 3 .
Re vie w a n d rec or d a n y ne w c o nc o mita nt me dicati o ns or c ha n ges i n c o nc o mita nt 
me dicati o ns si nce t he last c o ntact .
Re vie w a n d rec or d c o ntrace pti ve met h o d a n d res ults of pre g na nc y testi n g. C o nfir m 
t hat t he partici pa nt is a d heri n g t o t he c o ntrace pti o n met h o d(s) re q uire d i n t he 
pr ot oc ol. Re fer t o A p pe n di x 4 a n d Secti o n 1 0. 9. 2. 1 of t his a p pe n di x re gar di n g 
pre g na nc y  tests .
C o nfir mati o n t hat I P is a p plie d t o all treat me nt -eli gi ble areas re g ularl y . 
A d mi nis tr ati o n of P R Os , if a p plica ble f or t hat visit. 
If a d mi nistere d, P R O assess me nt s h o ul d occ ur at t he be gi n ni n g of t he visit a n d t o 
be c o n d ucte d i n a q uiet, pri vate area (ie , n o o ne else ar o u n d a n d/ or a ble t o pr o vi de 
i n p ut or i nfl ue nce t heir res p o nses). 
D oc u me nt r es p o nses t o  
T he site staff s h o ul d rea d t he i nstr ucti o ns a n d q uesti o ns t o t he partici pa nt a n d 
rec or d t he p artici pa nt’s res p o nses i n s o urce d oc u me nts .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 2 0 Q uesti o ns s h o ul d be rea d ver bati m at clear a n d c o mf orta ble pace (re -rea d, if 
nee de d) wit h N O i n p ut fr o m site staff or p h y sicia ns .
D o n ot i nter pret a n y part of t he q uesti o n naire f or t he partici pa nt. If t he partici pa nt 
d oes n ot u n dersta n d, please re peat t he q uesti o n a n d res p o nse c h oices ver bati m a n d 
as k t he m t o select t he res p o nse t hat t he y  feel best re prese nts his/ her e x perie nce. 
C o nfir m t he patie nt’s res p o nse selecti o n bef ore y o u rec or d t he a ns wer (e g ,y o u 
w o ul d li ke me t o select “ m o derate pai n”, is t hat ri g ht?). 
O bser vati o n of a p plicati o n of st u d y  i nter ve nti o n o n treata ble area (s) (if feasi ble ). 
Assess me nt of l ocal t olera bilit y , p ost a p plicati o n of I P o n n o n -lesi o nal areas. 
Assess me nt of efficac y  o utc o me meas ures as descri be d i n Secti o n [ADDRESS_82083] u d y partici pa nt is u na ble t o visit t he site f or pr ot oc ol -s pecifie d safet y  la b orat or y  
e val uati o ns, testi n g m a y  be c o n d ucte d at a l ocal la b orat or y  if per mitte d b y  l ocal re g ulati o ns. 
T he l ocal la b orat or y  ma y be a sta n dal o ne i nstit uti o n or wit hi n a h os pi[INVESTIGATOR_307]. T he f oll o wi n g 
safet y la b orat or y  e val uati o ns ma y  be perf or me d at a l ocal la b orat or y : 
La b orat or y  Safet y e val uati o ns, i ncl u di n g pre g na nc y  testi n g (Ta ble 6). 
If a l ocal la b orat or y  is use d, q ualifie d st u d y site pers o n nel m ust or der, recei ve, a n d re vie w 
res ults. Site staff m ust c ollect t he l ocal la b orat or y  refere nce ra n ges a n d certificati o ns/ 
accre ditati o ns f or fili n g at t he site. La b orat or y test res ults are t o b e pr o vi de d t o t he site staff 
as s o o n as p ossi ble. T he l ocal la b orat or y  re p orts s h o ul d be  file d i n t he partici pa nt’s s o urce 
d oc u me nts/ me dical rec or ds. Rele va nt data fr o m t he l ocal la b orat or y  re p ort s h o ul d 
be  rec or de d o n t he C R F. 
If a partici pa nt re q uiri n g pre g na nc y testi n g ca n n ot visit a l ocal la b orat or y  f or pre g na nc y  
testi n g, a h o me uri ne pre g na nc y  testi n g kit wit h a se nsiti vit y  of at least 2 5 mI U/ m L ma y  be 
use d b y  t he partici pa nt t o perf or m t he test at h o me, if c o m plia nt wit h l ocal re g ulat or y  
re q uire me nts . T he pre g na nc y  test o utc o me s h o ul d be d oc u me nte d i n t he partici pa nt’s s o urce 
d oc u me nts/ me dical rec or ds a n d rele va nt data rec or de d o n t he C R F. C o nfir m t hat t he 
partici pa nt is a d heri n g t o t he c o ntrace pti o n met h o d(s) re q uire d i n t he pr ot oc ol. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82084] be ke pt i n t he 
partici pa nt’s s o urce d oc u me nts/ me dical rec or ds. 
[ADDRESS_82085] u d y  
visit at t he partici pa nt’s l ocati o n, rat her t ha n a n i n -pers o n st u d y visit at t he site. T he 
f oll o wi n g ma y  be perf or me d d uri n g a h o me healt h visit: 
Re vie w a n d rec or d st u d y i nter ve nti o n(s), i ncl u di n g c o m plia nce a n d misse d d oses ;
Re vie w a n d rec or d a n y  A Es a n d S A Es si nce t he last c o ntact. Refer t o Secti o n 8. 3; 
Re vie w a n d rec or d a n y ne w c o nc o mita nt me dicati o ns or c ha n ges i n c o nc o mita nt 
me dicati o ns si nce t he last c o ntact ;
Re vie w a n d rec or d c o ntrace pti ve met h o d a n d res ults of pre g na nc y  testi n g. C o nf ir m 
t hat t he partici pa nt is a d heri n g t o t he c o ntrace pti o n met h o d(s) re q uire d i n t he 
pr ot oc ol. Refer t o A p pe n di x 4 a n d Secti o n 1 0. 9. 2. 1 _ H o me _ Healt h _ Visits of t his 
a p pe n di x re gar di n g pre g na nc y  tests ;
E C G ;
Vital si g ns ;
P h y sical assess me nt; 
La b orat or y  sa m ple s, 
C ollect a n d wei g h pre vi o us st u d y  i nter ve nti o n t u bes ;
Dis pe nsi n g of st u d y  i nter ve nti o n ;0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 2 2 St u d y  i nter ve nti o n a p plicati o n a n d o bser vati o n ;
L ocal T olera bilit y  assess me nts ;
Ot her, as deter mi ne d b y t he I n vesti gat or a n d/ or s p o ns or .
[ADDRESS_82086] u d y  visits ca n n ot be c o n d ucte d, t he f oll o wi n g pr oce d ures a n d 
assess me nts ma y  be c o nsi dere d: 
Efficac y  Assess me nts f or A D, i ncl u di n g I G A, E A SI , B S A , a n d se vere lesi o n T S S (if 
a p plica ble). 
Efficac y  Assess me nts f or Ps O , i ncl u di n g P G A, P A SI , a n d B S A. 
O nl y  q ualifie d raters will be all o we d t o e val uate partici pa nts re m otel y. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 2 3 1 0. 1 0. A p pe n di x 10:Di a g n osis Criteri a f or A D
Per A D -s pecific I n cl usi o n Criteria as i n Secti o n 5. 1. 2. 1 , a partici pa nt is t o ha ve a cli nical 
dia g n osis of A D acc or di n g t o t he criteria of Ha nifi n a n d Raj ka. 7
H a nifi n a n d R aj k a’s Di a g n ostic Criteri a f or A D 
M aj or Criteri a ( m ust h a ve at le ast t hree) 
Pr urit us 
T y pi[INVESTIGATOR_2855] m or p h ol o g y a n d distri b uti o n: 
Fle x ural lic he nificati o n i n a d ults 
Facial a n d e xte ns or er u pti o ns i n i nfa nts a n d c hil dre n 
C hr o nic or c hr o nicall y -rela psi n g der matitis 
Pers o nal or fa mil y hist or y of at o p y (ast h ma, aller gic r hi nitis, A D) 
Mi n or Criteri a ( m ust h a ve at le ast t hree) 
Xer osis 
Ic ht h y osis/ kerat osis pi[INVESTIGATOR_22785]/ pal mar h y perli nearit y 
I m me diate (t y pe 1) s ki n test reacti o n 
Ele vate d ser u m I g E 
Earl y a ge of o nset 
Te n de nc y t o w ar d c uta ne o us i nfecti o ns (es p. sta p h. a ure us a n d her pes si m ple x), i m paire d cell -me diate d 
i m m u nit y 
Te n de nc y t o w ar d n o n -s pecific ha n d or f o ot der matitis 
Ni p ple ecze ma 
C heilitis 
Rec urre nt c o nj u ncti vitis 
De n nie -M or ga n i nfra or bital f ol d 
Kerat oc o n us 
A nteri or s u bca ps ular cataracts 
Or bital dar ke ni n g 
Facial pall or, facial er yt he ma 
Pit yriasis al ba 
A nteri or nec k f ol ds 
Itc h w he n s weati n g 
I nt olera nce t o w o ol a n d li pi d s ol ve nts 
Peri of ollic ular acce nt uati o n 
F o o d i nt olera nce 
C o urse i nfl ue nce d b y e n vir o n me ntal a n d e m oti o nal fact ors 
W hite d er m o gra p his m, dela ye d bla nc h 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 2 4 1 0. 1 1. A p pe n di x 11: C- S S R S 
Partici pa nt s s h o ul d be e val uate d f or a n y  ps yc hiatric c o n diti o n i ncl u di n g rece nt or acti ve 
s uici dal i deati o n or be ha vi or a n d e xcl u de d fr o m t he st u d y  w h o meets a n y  of t he f oll o wi n g 
criteria at Scree ni n g: 
a. S uici dal i deati o n ass ociate d wit h act ual i nte nt a n d a met h o d or pla n i n t he past y ear: 
“ Yes” a ns wers o n ite ms 4 or 5 of t he C -S S R S; 
b. Pre vi o us hist or y  of s uici dal be ha vi ors i n t he past 5 y ears: “ Yes” a ns wer (f or e ve nts 
t hat occ urre d i n t he past 5 y ears) t o a n y  of t he s uici dal be ha vi or ite ms of t he C -S S R S; 
c. A n y  lifeti me hist or y  of seri o us or rec urre nt s uici dal be ha vi or; 
d. T he prese nce of a n y c urre nt maj or ps yc hiatric dis or der t hat is n ot e x plicitl y per mitte d 
i n t he i ncl usi o n/e xcl usi o n criteria; 
e. I n t he o pi [INVESTIGATOR_9384] o n of t he i n vesti gat or or [COMPANY_007] ( or desi g nee) e xcl usi o n is re q uire d. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 2 5 1 0. 1 2. A p pe n di x 12: Dise ase - S pecific Assess me nts 
1 0. 1 2. 1. A D -s pecific assess me nts 
1 0. 1 2. 1. 1. I G A 
T he I G A of A D is sc ore d o n a 5 -p oi nt scale ra n gi n g fr o m 0 (clear) t o 4 (se vere), reflecti n g a 
gl o bal c o nsi derati o n of t he er yt he ma, i n d urati o n a n d scali n g . T he cli nical e val uat or of A D 
will perf or m a n assess me nt of t he o verall se verit y of A D a n d assi g n a n I G A sc ore a n d 
cate g or y  as descri be d bel o w. 
T a ble 7. I n vesti g at or's Gl o b al Assess me nt f or A D 
Sc ore C ate g or y Descri pti o n *
0 Clear A D is cleare d, e xce pt f or a n y resi d ual disc ol orati o n ( p ost -i nfla m mat or y 
h y per pi g me ntati o n a n d/ or h y p o pi g me ntati o n). 
1Al m ost 
Clear O verall, t he A D is n ot e ntirel y cleare d a n d re mai ni n g lesi o ns are li g ht pi n k ( n ot 
i ncl u di n g p ost i nfla m mat or y h y per pi g me ntati o n) a n d/ or; ha ve barel y pal pa ble 
har d t hic ke ne d s ki n a n d/ or pa p ules a n d/ or; ha ve barel y perce pti ble 
lic he nificati o n; e xc oriati o n a n d o ozi n g/cr usti n g are a bse nt. 
2 Mil d O verall, t he A D c o nsists of lesi o ns t hat are li g ht re d ; wit h sli g ht, b ut defi nite 
har d t hic ke ne d s ki n a n d/ or pa p ules; wit h sli g ht, b ut defi nite li near or pic ke d 
scratc h mar ks or pe netrati n g s urface i nj ur y; wit h sli g ht, b ut defi nite t hic ke ne d 
s ki n, fi ne s ki n mar ki n gs, a n d lic he n oi d scale; o ozi n g/cr usti n g is a b se nt. 
3 M o derate O verall, t he A D c o nsists of lesi o ns t hat are re d; w it h easil y pal pa ble m o derate 
har d t hic ke ne d s ki n a n d/ or pa p ules; wit h m o derate li near or pic ke d scratc h 
mar ks or pe netrati n g s urface i nj ur y; wit h m o derate t hic ke ne d s ki n, c oarse s ki n 
mar k i n gs, a n d c oarse lic he n oi d scale; w it h sli g ht o ozi n g/cr usti n g. 
4 Se vere O verall, t he A D c o nsists of lesi o ns t hat are dee p, dar k re d; wit h se vere har d 
t hic ke ne d s ki n a n d/ or pa p ules; w it h se vere li near or pic ke d scratc h mar ks or 
pe netrati n g s urface i nj ur y; wit h se vere t hic ke ne d s ki n wit h ver y c oarse s ki n 
mar ki n gs a n d lic he n oi d scale; wit h m o derate t o se vere o ozi n g/cr usti n g. 
* T he I G A will e xcl u de hai r-beari n g scal p fr o m t he assess me nt/sc ori n g. 
1 0. 1 2. 1. 2. E A SI 
T he E A SI q ua ntifies t he se verit y of a partici pa nt’s A D base d o n b ot h se verit y  of lesi o n b y 
cli nical si g ns a n d t he perce nt of B S A affecte d. E A SI  is a c o m p osite sc ori n g of t he de gree of 
er yt he ma, i n d urati o n/ pa p ulati o n, e xc oriati o n, a n d lic he nificati o n (eac h sc ore d se paratel y) f or 
eac h of f o ur b o d y re gi o ns, wit h a dj ust me nt f or t he perce nt of B S A i n v ol ve d f or eac h b o d y 
re gi o n a n d f or t he pr o p orti o n of t he b o d y  re gi o n t o t he w h ole b o d y .8T he cli nical e val uat or o f 
A D will perf or m a n assess me nt of se verit y a n d area i n v ol ve d as descri be d bel o w. 
Lesi o n Se verit y  b y  Cli nical Si g ns 
T he basic c haracteristics of A D lesi o ns (er y t he ma, i n d urati o n/ pa p ulati o n, e xc oriati o n, a n d 
lic he nificati o n) pr o vi de a mea ns f or assessi n g t he se verit y of lesi o ns. Assess me nt of t hese 
f o ur mai n cli nical si g ns is perf or me d se paratel y f or 4b o d y  re gi o ns: hea d a n d nec k, u p per 
li m bs, tr u n k (i ncl u di n g a xillae a n d gr oi n) a n d l o wer li m bs (i ncl u di n g b utt oc ks). A vera ge 
er yt he ma, i n d urati o n/ pa p ulati o n, e xc oriati o n, a n d lic he nificati o n are sc ore d f or eac h b o d y 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 2 6 re gi o n acc or di n g t o a 4 -p oi nt scale: 0 =a bse nt; 1 =mil d; 2 =m o derate; 3 =se vere. 
M or p h ol o gic descri pt ors f or eac h cli nical si g n se verit y  sc ore are s h o w n i n Ta ble 8bel o w. 
T a ble 8. Cli nic al Si g n Se verit y Sc ori n g Criteri a f or E A SI 
Sc ore Descri pti o n 
Er yt he ma ( E) 
0 A bse nt N o ne; ma y ha ve resi d ual disc ol orati o n ( p ost -i nfla m mat or y h y per pi g me ntati o n a n d/ or 
h y p o pi g me ntati o n) 
1 Mil d Li g ht pi n k t o li g ht re d 
2 M o derate Re d 
3 Se vere Dee p, dar k re d 
I n d urati o n/ Pa p ulati o n (I) 
0 A bse nt N o ne 
1 Mil d Barel y pal pa ble t o sli g ht, b ut defi nite har d t hic ke ne d s ki n a n d/ or pa p ules 
2 M o derate Easil y pal pa ble m o derate har d t hic ke ne d s ki n a n d/ or pa p ules 
3 Se vere Se vere har d t hic ke ne d s ki n a n d/ or pa p ules 
E xc oriati o n ( E x) 
0 A bse nt N o ne 
1 Mil d Sli g ht, b ut defi nite li near or pic ke d scratc h mar ks or pe netrati n g s urface i nj ur y 
2 M o derate M o derate li near or pic ke d scratc h mar ks or pe netrati n g s urface i nj ur y 
3 Se vere Se vere li near or pic ke d scratc h mar ks or pe netrati n g s urface i nj ur y 
Lic he nificati o n ( L) 
0 A bse nt N o ne 
1 Mil d Barel y perce pti ble t o sli g ht, b ut defi nite t hic ke ne d s ki n, fi ne s ki n mar ki n gs, a n d 
lic he n oi d scale 
2 M o derate M o derate t hic ke ne d s ki n, c oarse s ki n mar ki n gs, a n d c oarse lic he n oi d scale 
3 Se vere Se vere t hic ke ne d s ki n wit h ver y c oarse s ki n mar ki n gs a n d lic he n oi d scale 
*T he E A SI will e xcl u de hair -beari n g scal p fr o m t h e assess me nt/sc ori n g. 
Area Sc ore 
T he e xte nt ( % B S A ) t o w hic h eac h of t he f o ur b o d y  re gi o ns ie hea d a n d nec k, u p per li m bs, 
tr u n k a n d l o wer li m bs is i n v ol ve d wit h A D is cate g orize d usi n g a n o n -li near scali n g met h o d 
t o a n u merical area sc ore acc or di n g t o t he f oll o wi n g B S A sc ori n g criteria ( Ta ble 9). T he 
% B S A is calc ulate d as descri be d i n Secti o n 1 0. 1 2. 1. 3 .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 2 7 T a ble 9. E A SI Are a Sc ore Criteri a 
Perce nt B S A *wit h A D i n a 
B o d y Re gi o n Are a Sc ore 
0 % 0
0t o < 1 0 % 1
1 0 t o < 3 0 % 2
3 0 t o < 5 0 % 3
5 0 t o < 7 0 % 4
7 0 t o < 9 0 % 5
9 0 t o 1 0 0 % 6
* b ase d o n h a n d pri nt met h o d 
B o d y Re gi o n Wei g hti n g 
Eac h b o d y re gi o n is wei g hte d acc or di n g t o its a p pr o xi mate perce nta ge of t he w h ole b o d y 
(Ta ble 1 0 ). 
T a ble 1 0 .B o d y Re gi o n Wei g hti n g 
B o d y Re gi o n T ot al N u m ber of 
H a n d pri nts i n 
B o d y Re gi o n S urf ace Are a of B o d y 
Re gi o n E q ui v ale nt of 
O ne H a n d pr int B o d y Re gi o n 
Wei g hti n g 
He a d a n d Nec k 1 0 1 0 % 0. 1 
U p per Li m bs 2 0 5 % 0. 2 
Tr u n k (i ncl u di n g a xill ae a n d gr oi n) 3 0 3. 3 3 % 0. 3 
L o wer Li m bs (i ncl u di n g b utt oc ks) 4 0 2. 5 % 0. 4 
Calc ulati o n of E A SI Sc ore 
I n e ac h b o d y re gi o n , t he s u m of t he Cli nical Si g ns Se verit y  Sc ores f or er y t he ma, 
i n d urati o n/ pa p ulati o n, e xc oriati o n, a n d lic he nificati o n is m ulti plie d b y  t he Area Sc ore a n d b y  
t he B o d y Re gi o n Wei g hti n g t o pr o vi de a b o d y re gi o n val ue, w hic h is t he n s u m me d acr oss all 
f o ur b o d y re gi o ns res ulti n g i n a n E A SI  sc ore as descri be d i n t he f oll o wi n g e q uati o n. 
E A SI = 0. 1 A h( E h+I h+ E x h+ L h) + 0. 2 A u( E u+I u+ E x u+ L u) + 0. 3 At( E t+I t+ E x t+ L t) + 
0. 4 Al( E l+I l+ E x l+ L l)
A = Area Sc ore; E = er yt he ma; I =i n d urati o n/ pa p ulati o n; E x = e xc oriati o n; L =lic he nificati o n; 
h = hea d a n d nec k; u =u p per li m bs; t = tr u n k; l = l o wer li m bs. 
T he E A SI sc ore ca n var y i n i ncre me nts of 0. [ADDRESS_82087] u d y , t he ma xi m u m p ossi ble sc ore will be less t ha n 7 2. 0. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 2 8 1 0. 1 2. 1. 3. B S A 
Ide ntif y  t he s urface area e q ui vale nt of 1 ha n d pri nt i n eac h res pecti ve b o d y re gi o n. 
B o d y re gi o n val ue is t he n s u m me d acr oss all f o ur b o d y re gi o ns res ulti n g i n a t otal B S A wit h 
A D as descri be d i n t he f oll o wi n g e q uati o n: 
B S A ( %) = 0. 1 S h + 0. 2 S u + 0. 3 St + 0. 4 Sl 
w here S = b o d y re gi o n s urface area w it h A D; h = hea d & nec k; u = u p per li m bs; t =tr u n k; l =l o w er li m bs. 
1 0. 1 2. 1. 4. Se vere Lesi o n T S S 
T he se vere l esi o n T S S is a n assess me nt of t he I n vesti gat or -i de ntifie d /selecte d se vere lesi o n i n 
eac h of t he f oll o wi n g: er y t he ma, i n d urati o n / pa p ulati o n, e xc oriati o n, a n d lic he nificati o n. Eac h 
of t hese are rate d usi n g t he 4 -p oi nt se verit y scale descri be d i n Ta ble 1 1 . T hese rati n gs are 
t he n a d de d t o create a t otal sc ore ( 1 2 -p oi nt scale; ra n gi n g fr o m 0 t o 1 2 p oi nts). 
T a ble 1 1. Se vere Lesi o n T S S 
Sc ore Descri pti o n 
Er yt he ma ( E ; Re d ness )
0 A bse nt N o re d ness 
1 Mil d Mil dl y detecta ble er y t he m a; pi n k 
2 M o derate D ull re d; clearl y disti n g uis ha ble 
3 Se vere Dee p, dar k re d ; mar ke d a n d e xte nsi ve 
I n d urati o n/ Pa p ulati o n (I) 
0 A bse nt N o ne 
1 Mil d Sli g htl y per ce pti ble ele vati o n 
2 M o derate Clearl y perce pti ble ele vati o n b ut n ot e xte nsi ve 
3 Se vere Mar ke d a n d e xte nsi ve ele vati o n 
E xc oriati o n ( E x ; E vi de nce of Scratc hi n g )
0 A bse nt N o e vi de nce of e xc oriati o n 
1 Mil d Mil d e xc oriati o n prese nt 
2 M o derate Defi nite e xc oriati o n prese nt 
3 Se vere Mar ke d, dee p, or e xte nsi ve e xc oriati o n prese nt 
Lic he nificati o n ( L ; E pi [INVESTIGATOR_71772] T hic ke ni n g )
0 A bse nt N o e pi [INVESTIGATOR_71772] t hic ke ni n g 
1 Mil d Mi n or e pi [INVESTIGATOR_71772] t hic ke ni n g 
2 M o derate M o derate e pi [INVESTIGATOR_71772] t hic ke ni n g; acce nt uate d s ki n li nes 
3 Se vere Se vere e pi [INVESTIGATOR_71772] t hic ke ni n g; dee pl y acce nt uate d s ki n li nes 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 2 9 1 0. 1 2. 2. Ps ori asis -s pecific assess me nts 
1 0. 1 2. 2. 1. P G A 
T he P G A of ps oriasis is sc ore d o n a descri pti ve 5- p oi nt scale. 9T he 5 -p oi nt scale f or P G A is: 
0, “clear”; 1, “al m ost clear ”; 2, “ mil d”; 3, “ m o derate”; 4 “se vere” .T he assess me nt will be a 
static e val uati o n wit h o ut re gar d t o t he sc ore at a pre vi o us visit. T he cli nical e val uat or of 
ps oriasis will perf or m a n assess me nt of t he o verall se verit y a n d assi g n a n P G A sc ore a n d 
cate g or y  as descri be d bel o w. 
T a ble 1 2. P h ysici a n Gl o b al Assess me nt ( P G A) Sc ore 
P h ysici a n’s Gl o b al 
Assess me nt Descri pti o n 
0 Clear N o si g ns of ps oriasis; p ost -i nfla m mat or y h y per pi g me ntati o n ma y be prese nt 
[ADDRESS_82088] Clear N o t hic ke ni n g; n or mal t o pi n k c ol orati o n; n o t o mi ni mal f ocal scali n g 
[ADDRESS_82089] detecta ble t o mil d t hic ke ni n g; pi n k t o li g ht re d c ol orati o n; pre d o mi na ntl y fi ne 
scali n g 
3 M o derate Clearl y disti n g uis ha ble t o m o derate t hic ke ni n g; d ull t o bri g ht re d, clearl y 
disti n g uis ha ble t o m o derate t hic ke ni n g; m o derate scali n g 
4 Se vere Se vere t hic ke ni n g wit h har d e d ges; bri g ht t o dee p dar k re d c ol orati o n; 
se vere/c oarse scali n g c o veri n g al m ost all or all lesi o ns 
*T he P G A will e xcl u de hair -beari n g scal p, pal ms , s oles , a n d fi n ger a n d t oe nails fr o m t he 
assess me nt/sc ori n g 
1 0. 1 2. 2. 2. P A SI 
Lesi o n Se verit y  Sc ore 
T he basic c haracteristics of ps oriatic lesi o ns (er yt he ma, i n d urati o n a n d scali n g) pr o vi de a 
mea ns f or assessi n g t he se verit y of lesi o ns. Assess me nt of t hese t hree mai n si g ns is 
perf or me d se paratel y f or f o ur areas of t he b o d y:  hea d, u p per li m bs, tr u n k, a n d l o wer li m bs. 
A vera ge er y t he ma, i n d urati o n a n d s cali n g are rate d f or eac h b o d y  area acc or di n g t o a 5 -p oi nt 
scale: 0, n o i n v ol ve me nt; 1, sli g ht; 2, m o derate; 3, mar ke d; 4, ver y  mar ke d. A p pr o priate 
m or p h ol o gic descri pt ors f or eac h se verit y  sc ore are s h o w n i n Ta ble 1 3 .0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 3 0 T a ble 1 3. C o m p o ne nt Sc ori n g Criteri a f or P A SI 
C o m p o ne nt Sc ore Descri pti o n 
Er yt he ma ( E) 
0 N o i n v ol ve me nt N o ne; ma y ha ve resi d ual h y per pi g me ntati o n 
1 Sli g ht Pi n k or li g ht re d 
2 M o derate Dar ker pi n k -re d 
3 Mar ke d Re d 
4 Ver y  Mar ke d E xtre mel y re d, “ beef y” re d 
I n d urati o n (I) 
0 N o i n v ol ve me nt N o ne 
1 Sli g ht Mi ni mal ele vati o n relati ve t o n or mal s urr o u n di n g s ki n 
2 M o derate Easil y pal pa ble wit h r o u n de d e d ges 
3 Mar ke d Ele vate d wit h har d, s har p b or ders 
4 Ver y  Mar ke d Ver y  ele vate d wit h ver y har d, s har p b or ders 
Scali n g ( S) 
[ADDRESS_82090] lesi o ns partiall y c o vere d 
3 Mar ke d C oarser t hic k scale, nearl y all lesi o ns c o vere d, r o u g h 
4 Ver y  Mar ke d Ver y  t hic k scale, all lesi o ns c o vere d, ver y r o u g h 
*T he P A SI will e xcl u de hair -beari n g scal p, pal ms , s oles , a n d fi n ger a n d t oe nails fr o m t he 
assess me nt/sc ori n g 
Area Sc ore 
T he e xte nt ( % B S A) t o w hic h eac h of t he f o ur b o d y  re gi o ns (ie hea d a n d nec k, u p per li m bs, 
tr u n k , a n d l o wer li m bs )is i n v ol ve d wit h ps oriasis is cate g orize d usi n g a n o n -li near scali n g 
met h o d t o a n u merical area sc ore acc or di n g t o t he f oll o wi n g B S A sc ori n g criteria ( Ta ble 1 4 ). 
T he % B S A is calc ulate d as descri be d i n Secti o n 8. 1. 2. 1. 3 .
T a ble 1 4. P A SI Are a Sc ore Criteri a 
Perce nt B S A *wit h 
Ps ori asis i n a B o d y Re gi o n Are a Sc ore 
0 % 0
0t o < 1 0 % 1
1 0 t o < 3 0 % 2
3 0 t o < 5 0 % 3
5 0 t o < 7 0 % 4
7 0 t o < 9 0 % 5
9 0 t o 1 0 0 % 6
* b ase d o n h a n d pri nt met h o d 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 3 1 B o d y Re gi o n Wei g hti n g 
Eac h b o d y re gi o n is wei g hte d acc or di n g t o its a p pr o xi mate perce nta ge of t he w h ole b o d y 
(Ta ble 1 5 ). 
T a ble 1 5 .B o d y Re gi o n Wei g hti n g 
B o d y Re gi o n T ot al N u m ber of 
H a n d pri nts i n 
B o d y Re gi o n S urf ace Are a of B o d y 
Re gi o n E q ui v ale nt of 
O ne H a n d pr int B o d y Re gi o n 
Wei g hti n g 
He a d a n d Nec k 1 0 1 0 % 0. 1 
U p per Li m bs 2 0 5 % 0. 2 
Tr u n k (i ncl u di n g a xill ae a n d gr oi n) 3 0 3. 3 3 % 0. 3 
L o wer Li m bs (i ncl u di n g b utt oc ks) 4 0 2. 5 % 0. 4 
Calc ulati n g of P A SI sc ore 
I n eac h b o d y re gi o n, t he s u m of t he Se verit y  Sc ores f or er y t he ma, i n d urati o n a n d scali n g is 
m ulti plie d b y  t he Area Sc ore a n d b y t he B o d y Re gi o n Wei g hti n g t o pr o vi de a b o d y re gi o n 
val ue, w hic h is t he n s u m me d acr oss all f o ur b o d y  re gi o ns res ulti n g i n a P A SI  sc ore as 
descri be d i n t he f oll o wi n g e q uati o n: 
PA SI = 0. 1 A h( E h+I h+ S h) + 0. 2 A u( E u+I u+ S u) + 0. 3 At( E t+I t+ S t) + 0. 4 Al( E l+I l+ S l)
A = Area Sc ore; E = er yt he ma; I =i n d urati o n/ pa p ulati o n; S =scali n g; h = hea d a n d nec k; u =u p per li m bs; 
t = tr u n k; l = l o wer li m bs. 
T he P A SI  sc ore ca n var y i n i ncre me nts of 0. 1 a n d ra n ge fr o m 0. 0 t o 7 2. 0 *, wit h hi g her sc ores 
re prese nti n g greater se verit y  of ps oriasis.  
*Si nce t he hair -beari n g scal p, pal ms, s oles a n d nails will be e xcl u de d fr o m t he P A SI  
assess me nt i n t his st u d y , t he ma xi m u m p ossi ble sc ore will be less t ha n 7 2. 0. 
1 0. 1 2. 2. 3. B S A 
I d e ntif y  t he s urface area e q ui vale nt of 1 ha n d pri nt i n eac h res pecti ve b o d y  re gi o n. 
B o d y re gi o n val ue is t he n s u m me d acr oss all f o ur b o d y re gi o ns res ulti n g i n a t otal B S A wit h 
ps oriasis as descri be d i n t he f oll o wi n g e q uati o n: 
B S A ( %) = 0. 1 S h + 0. 2 S u + 0. 3 St + 0. 4 Sl 
w here S = b o d y re gi o n s urface area w it h Ps O ; h = hea d & nec k; u = u p per li m bs; t =tr u n k; l =l o w er li m bs. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 3 2 1 0. 1 3. A p pe n di x 1 3 : A b bre vi ati o ns 
T he f oll o wi n g is a list of a b bre viati o ns t hat ma y  be use d i n t he pr ot oc ol. 
A b bre vi ati o n Ter m 
A A P A merica n Aca de m y  of Pe di atrics 
A bs a bs ol ute 
A D at o pic der matitis 
A D L acti vities of dail y  li vi n g 
A E a d verse e ve nt 
A L T ala ni ne a mi n otra nsferase 
A N C O V A a nal ys is of c o varia nce 
A S T as partate a mi n otra nsferase 
A U C area u n der t he c ur ve 
A V atri o ve ntric ular 
-h C G beta -h u ma n c h ori o nic g o na d otr o pi n 
B A P bi o mar ker a nal ys is pla n 
B P O be nz o y l per o xi de 
BI D t wice dail y
B L Q bel o w t he li mit of q ua ntificati o n 
b p m beats per mi n ute 
B S A b o d y  s urface area 
B U N bl o o d urea nitr o ge n 
c A M P c y clic a de n osi ne m o n o p h os p hate 
Ca v a vera ge c o nce ntrati o ns 
C F B c ha n ge fr o m baseli ne 
C F R c o de of fe deral re g ulati o ns 
c G M P c y clic g ua n osi ne m o n o p h os p hate 
CI O M S C o u ncil f or I nter nati o nal Or ga nizati o ns of Me dical Scie nces 
C K creati ne ki nase 
C K D -E PI C hr o nic Ki d ne y  Disease -E pi [INVESTIGATOR_32450] o g y  C olla b orati o n 
Cma x ma xi m u m o bser ve d c o nce ntrati o n 
C O 2 car b o n di o xi de ( bicar b o nate) 
C O N S O R T C o ns oli date d Sta n dar ds of Re p orti n g Trials 
C O VI D -[ADDRESS_82091] u g i nteracti o n 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82092] u g Re g ulati n g A ut h orities Cli nical Trials 
( E ur o pea n Cli nical Trials Data base) 
F A S f ull a nal y sis set 
F D A F o o d a n d Dr u g A d mi nistrati o n 
FI H first -i n -h u ma n 
F S H f ollicle -sti m ulati n g h or m o ne 
f u p fracti o n u n b o u n d plas ma 
G C P G o o d Cli nical Practice 
G G T ga m ma -gl uta m y l tra nsferase 
H E E N T hea d, e y es, ears, n ose a n d t hr oat 
H R Q o L healt h -relate d q ualit y  of life 
H R heart rate 
H R T h or m o ne re place me nt t hera p y
I B I n vesti gat or’s Br oc h ure 
I C 5 0 50 % i n hi biti ve c o nce ntrati o n 
I C D i nf or me d c o nse nt d oc u me nt 
I C H I nter nati o nal C o u ncil f or Har m o nisati o n of Tec h nical Re q uire me nts 
f or P har mace uticals f or H u ma n Use 
I D i de ntificati o n 
I G A I n vesti gat or’s Gl o bal Assess me nt 
I g E i m m u n o gl o b uli n e 
I L i nterle u ki n 
I M P i n vesti gati o nal me dici nal pr o d uct 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82093] le vel 
P A SI Ps oriasis Area a n d Se verit y  I n de x 
P B M C peri p heral bl o o d m o n o n uclear cell 
P C P pri mar y  care pr o vi der 
P D p har mac o d y n a mic(s) 
P D E p h os p h o diesterase 
P D E 4 p h os p h o diesterase 4 
P G A P h y sicia n Gl o bal Assess me nt 
PI [INVESTIGATOR_32449] i n vesti gat or 
P K p har mac o ki netic(s) 
P P -N R S Pea k Pr urit us N u merical Rati n g Scale 
P R N as nee de d 
P R O patie nt re p orte d o utc o mes 
Ps O pla q ue ps oriasis 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI C CI 
C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 3 5 A b bre vi ati o n Ter m 
P T pr ot hr o m bi n ti me 
P U V A ps orale n –ultra vi olet a 
P V C pre mat ure ve ntric ular c o ntracti o n/c o m ple x 
Q D o nce dail y
Q o L q ualit y  of life 
Q Tc c orrecte d Q T i nter val 
Q Tc F Q T C c orrecte d usi n g Fri dericia’s f or m ula 
R A r he u mat oi d art hritis 
R B C re d bl o o d cell 
R N A ri b o n ucleic aci d 
S A E seri o us a d verse e ve nt 
S A P Statistical A nal y sis Pla n 
S A R S -C o V -[ADDRESS_82094] or 
T S S T otal Si g n Sc ore 
u Ca v u n b o u n d a vera ge c o nce ntrati o ns 
U G T uri di ne gl uc ur o n yl  tra nsferases 
U L N u p per li mit of n or mal 
U S U nite d States 
U V ultra vi olet 
U V A ultra vi olet A 
U V B ultra vi olet B 
W B C w hite bl o o d cell 
W O C B P w o ma n/ w o me n of c hil d beari n g p ote ntial 
W O N C B P w o ma n/ w o me n of n o n -c hil d beari n g p ote ntial 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) C CI 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge 1 3 6 1 1. R E F E R E N C E S 
1. Wei di n ger S, N o va k N. At o pic der matitis. La ncet. 2 0 1 6; 3 8 7( 1 0 0 2 3): 1 1 0 9 - 2 2. 
2. Y osi p o vitc h G, Rea ne y  M, Maste y  V, et al. Pea k Pr urit us N u merical Rati n g Scale: 
ps y c h o metric vali dati o n a n d res p o n der defi niti o n f or assessi n g itc h i n m o derate -t o -
se vere at o pic der matitis. Br J Der mat ol. 2 0 1 9; 1 8 1( 4): 7 6 1- 6 9. 
3. Nestle F O, Ka pla n D H, Bar ker J. Ps oriasis. N E n gl J Me d. 2 0 0 9; 3 6 1( 5): 4 9 6 - 5 0 9. 
4. S bi dia n E, C hai ma ni A, Afac h S, et al. S ys te mic p har mac ol o gical treat me nts f or c hr o nic 
pla q ue ps oriasis: a net w or k meta -a nal ys is. C oc hra ne Data base S ys t Re v. 
2 0 2 0; 1: C D 0 1 1 5 3 5. 
5. Paller A S, T o m W L , L e b w o hl M G, et al. Efficac y  a n d safet y of crisa b or ole oi nt me nt, a 
n o vel, n o nster oi dal p h os p h o diesterase 4 ( P D E 4) i n hi bit or f or t he t o pi[INVESTIGATOR_75517] o pic der matitis ( A D) i n c hil dre n a n d a d ults. J A m Aca d Der mat ol. 2 0 1 6; 7 5( 3): [ADDRESS_82095] Crea m f or C hr o nic 
Pla q ue Ps oriasis. N E n gl J Me d. 2 0 2 0; 3 8 3( 3): 2 2 9 - 3 9. 
7.  Ha nifi n J M. Dia g n ostic feat ures of at o pic der matitis. Acta Der m Ve nere ol. 
1 9 8 0; 9 2: 4 4 - 4 7. 
8. T ofte S, Grae ber M, C herill R, et al. E cze ma area a n d se verit y i n de x ( E A SI): a ne w t o ol 
t o e val uate at o pic der matitis. J o ur nal of t he E ur o pea n Aca de m y of Der mat ol o g y a n d 
Ve nere ol o g y . 1 9 9 8; 1 1( 2): S 1 9 7. 
9. La n gle y  R G, Fel d ma n S R, N y ira d y J , et al. T he 5 -p oi nt I n vesti gat or's Gl o bal 
Assess me nt (I G A) Scale: A m o difie d t o ol f or e val uati n g pla q ue ps oriasis se verit y i n 
cli nical trials. J Der mat ol o g Treat. 2 0 1 5; 2 6( 1): 2 3 - 3 1. 
1 0. Fre dri kss o n T, Petterss o n U. Se vere ps oriasis -- oral t hera p y wit h a ne w reti n oi d. 
Der mat ol o gica. 1 9 7 8; 1 5 7( 4): 2 3 8 - 4 4. 
1 1. B us h nell D M, Marti n M L, Mc Carrier K, et al. Vali dati o n of t he Ps oriasis S y m pt o m 
I n ve nt or y  ( P SI), a patie nt- re p orte d o utc o me meas ure t o assess ps oriasis s y m pt o m 
se verit y. J Der mat ol o g Treat. 2 0 1 3; 2 4( 5): 3 5 6 - 6 0. 
1 2. P os ner K, Br o w n G K, Sta nle y  B, et al. T he C ol u m bia -S uici de Se veri t y  Rati n g Scale: 
i nitial vali dit y  a n d i nter nal c o nsiste nc y  fi n di n gs fr o m t hree m ultisite st u dies wit h 
a d olesce nts a n d a d ults. A m J Ps y c hiatr y . 2 0 1 1; 1 6 8( 1 2): [ADDRESS_82096] osis. J E ur Aca d Der mat ol 
Ve nere ol. 2 0 1 8; 3 2( 1): 1 4 5 - 5 1. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 
P F -0 7 0 3 8 1 2 4 
Pr ot oc ol C 3 9 4 1 0 0 5 
Fi nal Pr ot oc ol A me n d me nt 1 , 0 2 N o ve m ber 2 0 2 2 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 Marc h 2 0 2 1) 
Pa ge [ADDRESS_82097] c o nfi de nce i nter vals f or t he differe nce of t w o 
bi n o mial pr o p orti o ns. Bi o metrics. 1 9 9 9 Dec; 5 5( 4): 1 2 0 2 - 9. 0 9 0 1 7 7 e 1 9 b b 9 c 5f d\ A p pr o v e d\ A p pr o v e d O n: 0 3- N o v- 2 0 2 2 1 1: 4 8 ( G M T) 